1 00:00:04,821 --> 00:00:07,457 I THINK WE HAVE EVERYBODY 2 00:00:07,457 --> 00:00:09,693 ASSEMBLED HERE AND OUR KEY 3 00:00:09,693 --> 00:00:10,327 MEMBERS PARTICIPATING REMOTELY 4 00:00:10,327 --> 00:00:10,994 ARE ON THE SCREEN. 5 00:00:10,994 --> 00:00:13,630 I WILL GET STARTED. 6 00:00:13,630 --> 00:00:15,465 I WILL GIVE A BRIEF REPORT TO 7 00:00:15,465 --> 00:00:16,666 OUR SUBCOMMITTEE HERE IN THE 8 00:00:16,666 --> 00:00:17,601 PUBLIC SESSION EMPLOY NEXT 9 00:00:17,601 --> 00:00:18,068 SLIDE, PLEASE. 10 00:00:18,068 --> 00:00:20,337 ON THIS SLIDE YOU WILL SEE THE 11 00:00:20,337 --> 00:00:21,271 AGENDA FOR THIS AFTERNOON, I 12 00:00:21,271 --> 00:00:26,543 WILL START WITH A PERSONNEL 13 00:00:26,543 --> 00:00:28,779 UPDATE I WILL TALK AND HIT 14 00:00:28,779 --> 00:00:29,312 HIGHLIGHTS OF OUR RECENT 15 00:00:29,312 --> 00:00:30,413 RESEARCH NEWS AND THEN YOU WILL 16 00:00:30,413 --> 00:00:34,417 HEAR AN UPDATE ON THE SEER 17 00:00:34,417 --> 00:00:37,187 RESPONSE TO THE NH51 N1 18 00:00:37,187 --> 00:00:41,091 INFLUENZA OUTBREAK BY LAUREN 19 00:00:41,091 --> 00:00:43,727 BERG LEOTIS, AND THEN WE WILL 20 00:00:43,727 --> 00:00:46,763 MOVE ON FOR PRESENTING OUR 21 00:00:46,763 --> 00:00:47,631 CONCEPT CLEARANCE FOR YOUR 22 00:00:47,631 --> 00:00:48,799 CONSIDERATION AND THE 5 CONCEPTS 23 00:00:48,799 --> 00:00:51,234 WE WILL THINK ABOUT ARE 24 00:00:51,234 --> 00:00:59,776 PRESENTED ON THIS AGENDA SLIDE. 25 00:00:59,776 --> 00:01:05,816 SO INCOME SLIDE, PLEASE IT'S 26 00:01:05,816 --> 00:01:06,750 SOMETIMES HARD TO HIRE PEOPLE 27 00:01:06,750 --> 00:01:08,285 AND WE'VE HAD A LOT OF SUCCESS 28 00:01:08,285 --> 00:01:11,021 SINCE THE LAST TIME WE MET IN 29 00:01:11,021 --> 00:01:11,855 BRINGING NEW PEOPLE ONBOARD SO 30 00:01:11,855 --> 00:01:16,092 I'LL GIVE YOU BITS ABOUT EACH OF 31 00:01:16,092 --> 00:01:23,834 THE NEW DMID STAFF, CYNDA HALL 32 00:01:23,834 --> 00:01:25,502 IS A NURSE OFFICER WHO JOINED 33 00:01:25,502 --> 00:01:26,903 THE OCRREFRESH YOUR 34 00:01:26,903 --> 00:01:28,471 RECOLLECTION TEAM AS A NURSE 35 00:01:28,471 --> 00:01:29,272 CONSULTANT AND PROGRAM OFFICER. 36 00:01:29,272 --> 00:01:31,441 SHE COMES TO US FROM THE OFFICE 37 00:01:31,441 --> 00:01:35,045 OF THE ASSISTANT SECRETARY FOR 38 00:01:35,045 --> 00:01:35,946 HEALTH. 39 00:01:35,946 --> 00:01:38,515 ALSO KNOWN AS OASH, AND THE 40 00:01:38,515 --> 00:01:40,383 POPULATION OF AFFAIRS WHERE SHE 41 00:01:40,383 --> 00:01:43,286 WAS A PROJECT OFFICER FOR FAMILY 42 00:01:43,286 --> 00:01:44,354 BLANKING GRANTS ACROSS MULTIPLE 43 00:01:44,354 --> 00:01:48,225 REGIONS IN THE UNITED STATES. 44 00:01:48,225 --> 00:01:51,194 AND THEN TOM DIMAGGIO IS ANOTHER 45 00:01:51,194 --> 00:01:53,296 NURSE FROM THE INTRAMURAL 46 00:01:53,296 --> 00:01:55,098 PROGRAM, IN THE LAB OF CLINICAL 47 00:01:55,098 --> 00:01:57,500 AND MICROBIOLOGY WHERE HE WAS A 48 00:01:57,500 --> 00:01:58,301 CLINICAL RESEARCH SPECIALIST. 49 00:01:58,301 --> 00:02:00,570 HE HAS MORE THAN 20 YEARS OF 50 00:02:00,570 --> 00:02:01,538 EXPERIENCE IN CLINICAL RESEARCH, 51 00:02:01,538 --> 00:02:07,110 HE'S GOING TO BE SUPPORTING 52 00:02:07,110 --> 00:02:11,448 PHASE 1 AND 2 CLINICAL TRIALS 53 00:02:11,448 --> 00:02:12,682 THROUGH OBRTRTR, THROUGH 54 00:02:12,682 --> 00:02:16,219 CONTRACTS AND DR. LISA CAZARES 55 00:02:16,219 --> 00:02:17,487 AS JOINED OBRRTR AS A PROGRAM 56 00:02:17,487 --> 00:02:19,256 OFFICER IN THE DRUG DEVELOPMENT 57 00:02:19,256 --> 00:02:21,524 SECTION, SHE RECENTLY, HER MOST 58 00:02:21,524 --> 00:02:26,396 RECENT POSITION WAS AT AFT 59 00:02:26,396 --> 00:02:26,997 RAZENECCA BIOPHARMACEUTICAL 60 00:02:26,997 --> 00:02:31,434 WHERE SHE HAD A DIVERSE 61 00:02:31,434 --> 00:02:34,170 PORTFOLIO INVOLVING RESPIRAT ORY 62 00:02:34,170 --> 00:02:35,705 CARDIOVASCULAR DISEASES WELCOME 63 00:02:35,705 --> 00:02:40,744 TO CYNETWORK DA, TOM, AND LISA, 64 00:02:40,744 --> 00:02:41,544 NEXT SLIDE, PLEASE. 65 00:02:41,544 --> 00:02:45,215 AND I MENTIONED THAT LEOTUS WILL 66 00:02:45,215 --> 00:02:51,755 TALK FOLLOWING MY PRESENTATION 67 00:02:51,755 --> 00:02:54,090 AND AND SHE IS NOW IN THE CENTER 68 00:02:54,090 --> 00:03:04,634 FOR EXCELLENCE AND INFLUENZA AND 69 00:03:08,471 --> 00:03:09,673 RESEARCH AND RESPONSE--A LITTLE 70 00:03:09,673 --> 00:03:11,207 BIT OF BAPTISM BY FIRE, SO THAT 71 00:03:11,207 --> 00:03:11,474 WAS GREAT. 72 00:03:11,474 --> 00:03:14,544 SHE CAME TO US FROM NHLBI WHERE 73 00:03:14,544 --> 00:03:19,883 SHE WAS A PROGRAM OFFICER IN THE 74 00:03:19,883 --> 00:03:20,784 LUNG PULMONARY INFECTIONS 75 00:03:20,784 --> 00:03:23,086 PROGRAM WHERE SHE HAD THOSE TO 76 00:03:23,086 --> 00:03:24,254 THE MICROBIOME AND HIV/AIDS. 77 00:03:24,254 --> 00:03:26,890 BEFORE THAT SHE WAS A WRITER AND 78 00:03:26,890 --> 00:03:29,025 EDITOR IN THE SPECIAL PATHOGENS 79 00:03:29,025 --> 00:03:31,394 BRANCH AT THE CDC, BUT ALSO 80 00:03:31,394 --> 00:03:34,831 MAURI OSHEROFF ICE EDWARDS HAS 81 00:03:34,831 --> 00:03:35,999 JOINED THE PARASITOLOGY AND 82 00:03:35,999 --> 00:03:37,067 INTERNATIONAL PROGRAMS BRANCH AS 83 00:03:37,067 --> 00:03:40,537 A PROJECT MANAGER, HE COMES FROM 84 00:03:40,537 --> 00:03:41,705 NIEHS, THE ENVIRONMENTAL HEALTH 85 00:03:41,705 --> 00:03:44,140 INSTITUTE WHERE HE SERVED AS A 86 00:03:44,140 --> 00:03:52,082 GRANT SPECIALIST AND ASSISTED IN 87 00:03:52,082 --> 00:03:53,883 AS A POST DOC SPECIALIST. 88 00:03:53,883 --> 00:03:57,721 BEFORE THAT HE WORKED AS A GRANT 89 00:03:57,721 --> 00:03:58,555 SPECIALIST, THEIR REVIEW PROGRAM 90 00:03:58,555 --> 00:04:02,058 AND ALSO WORKED WITH RCDC AND 91 00:04:02,058 --> 00:04:02,292 NIH OD. 92 00:04:02,292 --> 00:04:05,528 AND DR. RICKY SONG HAS JOINED 93 00:04:05,528 --> 00:04:06,930 OBRRTR, RECENTLY, HE WILL 94 00:04:06,930 --> 00:04:08,231 SUPPORT ADVANCE PRODUCT 95 00:04:08,231 --> 00:04:09,966 DEVELOPMENT AND PRECLINICAL 96 00:04:09,966 --> 00:04:11,034 SERVICES IN THE DIAGNOSTIC AREA 97 00:04:11,034 --> 00:04:13,937 WHICH WE'RE FRYING TO EXPAND. 98 00:04:13,937 --> 00:04:15,572 YOU PREVIOUSLY WORKED AT MRI 99 00:04:15,572 --> 00:04:19,809 GLOBAL WHERE HE LED PROGECS AND 100 00:04:19,809 --> 00:04:21,311 INVITRO DIAGNOSTICS FOR BOTH 101 00:04:21,311 --> 00:04:23,046 CHEMICAL AND INFECTIOUS DISEASE 102 00:04:23,046 --> 00:04:25,015 APPLICATIONS TO BE PART OF THE 103 00:04:25,015 --> 00:04:26,783 REGULATORY PACKAGES SUBMITTED TO 104 00:04:26,783 --> 00:04:28,985 THE FDA. 105 00:04:28,985 --> 00:04:34,457 NEXT SLIDE, PLEASE. 106 00:04:34,457 --> 00:04:36,659 EVEN MORE DR. [INDISCERNIBLE] 107 00:04:36,659 --> 00:04:37,927 JOINED DMID IN THE PAST WEEK 108 00:04:37,927 --> 00:04:39,829 WHERE SHE WILL SERVE AS THE 109 00:04:39,829 --> 00:04:40,864 PROGRAM OFFICER FOR PRECLINICAL 110 00:04:40,864 --> 00:04:42,866 DESIGN AND CLINICAL TRANSLATION 111 00:04:42,866 --> 00:04:45,168 OF TB REGIMENS, THIS IS A NEW 112 00:04:45,168 --> 00:04:49,239 CONSORTIUM THAT WE'RE FUNDING IN 113 00:04:49,239 --> 00:04:52,242 ADDITION TO A FEW OTHER 114 00:04:52,242 --> 00:04:55,078 SPRBILITYS IN THE MICROBACTERIAL 115 00:04:55,078 --> 00:04:56,713 EXPRESSION, SHE COMES TO US FROM 116 00:04:56,713 --> 00:04:57,881 THE UNIVERSITY OF GEORGIA WHERE 117 00:04:57,881 --> 00:05:00,083 SHE WAS AN ASIFT ANT PROFESSOR 118 00:05:00,083 --> 00:05:02,952 FOR INFECT YOWZ DISEASES AND 119 00:05:02,952 --> 00:05:06,456 WORKED ON IMMUNOLOGIC 120 00:05:06,456 --> 00:05:07,057 DYSFUNCTION AND CLINICALLY 121 00:05:07,057 --> 00:05:09,125 RECOVERED HPV AND IN SARS-COV-2 122 00:05:09,125 --> 00:05:14,798 INDIVIDUALS AND AS WELLsA 123 00:05:14,798 --> 00:05:17,100 FOCUSING ON MICROBACTERIUM 124 00:05:17,100 --> 00:05:17,367 INFECTION. 125 00:05:17,367 --> 00:05:19,269 JEREMY WARNER HAS JOINED THE 126 00:05:19,269 --> 00:05:20,470 OFFICE OF CLINICAL RESEARCH 127 00:05:20,470 --> 00:05:22,372 RESOURCES, AS A PROGRAM ANALYST, 128 00:05:22,372 --> 00:05:23,540 HE COMES FROM SAN DIEGO WHERE HE 129 00:05:23,540 --> 00:05:25,408 WORKED FOR A RESEARCH 130 00:05:25,408 --> 00:05:27,277 ORGANIZATION FOCUSED ON 131 00:05:27,277 --> 00:05:28,344 ARTIFICIAL INTELIENCE POWERED 132 00:05:28,344 --> 00:05:30,613 PATHOLOGY, HE LED THEIR 133 00:05:30,613 --> 00:05:32,715 SCIENTIFIC MARKETING EFFORTS AND 134 00:05:32,715 --> 00:05:34,317 MANAGED PRECLINICAL PATHOLOGY 135 00:05:34,317 --> 00:05:36,619 STUDIES FOR ACADEMIC LABS AND 136 00:05:36,619 --> 00:05:37,020 PHARMA COMPANIES. 137 00:05:37,020 --> 00:05:38,254 AND CATH LYNN LUKE HAS BEEN WITH 138 00:05:38,254 --> 00:05:42,492 US FOR A NUMBER OF YEARS BUT 139 00:05:42,492 --> 00:05:45,161 SHE'S TRANSITIONING FROM 140 00:05:45,161 --> 00:05:45,829 DMID WITHIN THE RESPIRATORY 141 00:05:45,829 --> 00:05:47,130 DISEASE BRARCH WHERE SHE SERVED 142 00:05:47,130 --> 00:05:49,466 AS A SCIENTIST ON MANY OF THE 143 00:05:49,466 --> 00:05:50,200 INFLUENZA CLINICAL TRIALS AND 144 00:05:50,200 --> 00:05:52,469 MOVED TO THE OFFICE OF 145 00:05:52,469 --> 00:05:53,536 REGULATORY AFFAIRS, AND SHOULD 146 00:05:53,536 --> 00:05:55,672 BE A REGULATORY AFFAIRS MANAGER, 147 00:05:55,672 --> 00:05:57,507 AND SHE HAS 20 YEARS EXPERIENCE 148 00:05:57,507 --> 00:06:01,578 IN MICROBIOLOGY AND VACCINE 149 00:06:01,578 --> 00:06:06,382 DEVELOPMENT INCLUDING ACADEMIA, 150 00:06:06,382 --> 00:06:07,650 BIOTECH, INDUSTRY, AS WELL AS 151 00:06:07,650 --> 00:06:12,155 GOVERNMENT. 152 00:06:12,155 --> 00:06:13,623 NEXT SLIDE, PLEASE. 153 00:06:13,623 --> 00:06:16,526 AND THEN 3 NEW DMID STAFF IN THE 154 00:06:16,526 --> 00:06:17,927 OFFICE OF COORDINATION, KNOWN AS 155 00:06:17,927 --> 00:06:19,262 BUGS, THEY'VE BEEN WITH US FOR A 156 00:06:19,262 --> 00:06:20,997 NUMBER OF YEARS BUT THEY'VE 157 00:06:20,997 --> 00:06:26,536 MOVED INTO NEW ROLES. 158 00:06:26,536 --> 00:06:27,604 TRISH STRIKLER [INDISCERNIBLE] 159 00:06:27,604 --> 00:06:29,205 JUST ASSUMED THE ROLE OF THE THE 160 00:06:29,205 --> 00:06:30,073 GRANT OPERATIONS TEAM LEAD, 161 00:06:30,073 --> 00:06:32,408 SHE'S BEEN A PART OF THE OFFICE 162 00:06:32,408 --> 00:06:35,145 SINCE 2007 WHEN SHE CAME TO US 163 00:06:35,145 --> 00:06:37,147 AS A TRIP AAS FELLOW AND WORKED 164 00:06:37,147 --> 00:06:38,581 FOR A NUMBER OF YEARS IN A 165 00:06:38,581 --> 00:06:39,983 FEDERAL POSITION AND THEN MOVED 166 00:06:39,983 --> 00:06:43,086 AWAY, SWITCHED TO A CONTRACTOR 167 00:06:43,086 --> 00:06:46,189 BUT NOW SHE'S COMING BACK 168 00:06:46,189 --> 00:06:47,891 WORKING REMOTELY AS A FEDERAL 169 00:06:47,891 --> 00:06:49,292 ROLE AS TEAM LEAD. 170 00:06:49,292 --> 00:06:51,928 AND ALEX CLARK CAME ON BOARD AS 171 00:06:51,928 --> 00:06:54,597 A CONTRACTOR LAST YEAR BUT NOW 172 00:06:54,597 --> 00:06:55,999 HE'S TRANITIONING TO A FEDERAL 173 00:06:55,999 --> 00:06:58,768 POSITION, HE'S A PROJECT MANAGER 174 00:06:58,768 --> 00:07:00,303 FOR THE CONTRACK, PLANNING AND 175 00:07:00,303 --> 00:07:01,804 EXECUTION TOOL WHICH IS HOW WE 176 00:07:01,804 --> 00:07:06,476 TRACK OUR PRECLINICAL SERVICES 177 00:07:06,476 --> 00:07:08,077 AND OUR PRECLINICAL SERVICE AND 178 00:07:08,077 --> 00:07:11,047 ACTIONS, SO HE'S WORKING WITH 179 00:07:11,047 --> 00:07:13,983 THOSE INFORMATION TECHNOLOGY 180 00:07:13,983 --> 00:07:14,784 SYSTEMS. 181 00:07:14,784 --> 00:07:17,020 AND AMANDA, AS BEEN IN DMID FOR 182 00:07:17,020 --> 00:07:21,057 15 YEARS, SHE'S COMING BACK TO 183 00:07:21,057 --> 00:07:22,492 US AS A HEALTH COMMUNICATIONS 184 00:07:22,492 --> 00:07:22,725 TEAM. 185 00:07:22,725 --> 00:07:24,594 SHE MAKES MOST OF MY SLIDES FOR 186 00:07:24,594 --> 00:07:26,329 ME SO SHE'S VERY EXPERIENCED AND 187 00:07:26,329 --> 00:07:33,770 HAS MOVED ON TO A FEDERAL ROLE. 188 00:07:33,770 --> 00:07:37,674 ONE SLIDE, 1 MORE, DR. ERIC 189 00:07:37,674 --> 00:07:39,175 STEMI, IS THE DIRECT OF THE 190 00:07:39,175 --> 00:07:41,077 BRARCH, HE WILL CONTINUE IN HIS 191 00:07:41,077 --> 00:07:43,780 ROLE FOR INFLUENZA WERE AND 192 00:07:43,780 --> 00:07:46,649 RESPONSE HE'S BEEN A PROGRAM 193 00:07:46,649 --> 00:07:48,084 OFFICER IN RDB FOR A NUMBER OF 194 00:07:48,084 --> 00:07:49,886 YEARS WHERE HE HAD THE CORONA 195 00:07:49,886 --> 00:07:52,755 VIRUS PORTFOLIO AND THEN HE 196 00:07:52,755 --> 00:07:56,359 MOVED INTO THE SEER NETWORK AND 197 00:07:56,359 --> 00:07:59,128 HE NOW WILL BE THE DEPUTY BRANCH 198 00:07:59,128 --> 00:08:00,096 CHIEF IN RDD. 199 00:08:00,096 --> 00:08:00,863 NEXT SLIDE, PLEASE. 200 00:08:00,863 --> 00:08:02,632 SO JUST MOVING ON TO A LITTLE 201 00:08:02,632 --> 00:08:04,133 BIT OF RESEARCH NEWS, SOME 202 00:08:04,133 --> 00:08:06,536 HIGHLIGHTS OF WHAT WE'VE 203 00:08:06,536 --> 00:08:08,972 ACCOMPLISHED AND HAS HIT 204 00:08:08,972 --> 00:08:11,007 THE--EITHER THE PUBLIC, PRESS OR 205 00:08:11,007 --> 00:08:16,079 THE SCIENTIFIC PRESS RECENTLY. 206 00:08:16,079 --> 00:08:18,448 THIS IS JUST TALKING ABOUT HOW 207 00:08:18,448 --> 00:08:19,983 IN THE PAST SEVERAL MONTHS WE'VE 208 00:08:19,983 --> 00:08:30,493 BEEN VERY INVOLVED IN THE HIGH 209 00:08:31,694 --> 00:08:33,062 PATH OUTBREAK IN DAIRY KALGT. 210 00:08:33,062 --> 00:08:35,531 WE KNOW THIS HAS BEEN A VIRUS 211 00:08:35,531 --> 00:08:37,834 THAT'S BEEN CIRCULATING IN BIRDS 212 00:08:37,834 --> 00:08:39,836 AND HAS IMPACTED SOME MAMMALIAN 213 00:08:39,836 --> 00:08:43,906 POPULATIONS OVER THE PAST 214 00:08:43,906 --> 00:08:45,508 SEVERAL YEARS WITH 1 CASE 215 00:08:45,508 --> 00:08:53,583 DETECTED IN A POULTRY WORKER IN 216 00:08:53,583 --> 00:08:56,119 2022, BUT THEN THE DAIRY KALGT 217 00:08:56,119 --> 00:08:58,254 OUTBREAK THAT WAS ANNOUNCED IN 218 00:08:58,254 --> 00:08:59,722 MARCH 2024, IN THE TEXAS 219 00:08:59,722 --> 00:09:01,357 PANHANDLE CAUGHT A LOT OF US 220 00:09:01,357 --> 00:09:03,059 OFFGUARD BECAUSE WE DEPARTMENT 221 00:09:03,059 --> 00:09:04,494 THINK THIS I HAVE WOULD REALLY 222 00:09:04,494 --> 00:09:08,765 DO ANYTHING IN CATTLE, NEXT 223 00:09:08,765 --> 00:09:09,966 SLIDE, YOU WILL HEAR MORE 224 00:09:09,966 --> 00:09:12,568 DETAILS IN THIS IN LAWRENCE 225 00:09:12,568 --> 00:09:14,504 PRESENTATION BUT THE SLIDE JUST 226 00:09:14,504 --> 00:09:17,940 SUMMARIZES SOME OF THE HIGH 227 00:09:17,940 --> 00:09:19,375 LEVEL EVENTS THAT WE HEARD ON 228 00:09:19,375 --> 00:09:20,543 MULTIPLE CONFERENCE CALLS OVER 229 00:09:20,543 --> 00:09:27,250 THE PAST SEVERAL MONTHS, THERE 230 00:09:27,250 --> 00:09:29,152 HAVE BEEN 3 WITH THE CURRENT 231 00:09:29,152 --> 00:09:30,420 DAIRY KALGT OUTBREAK IN PEOPLE 232 00:09:30,420 --> 00:09:31,954 WHO HAVE PROBABLY HAD CLOSE 233 00:09:31,954 --> 00:09:33,222 EXPOSURE TO DAIRY CATTLE, BUT 234 00:09:33,222 --> 00:09:35,091 NOT A LOT OF TESTING BEING DONE 235 00:09:35,091 --> 00:09:43,533 ON SOME OF THESE FARMS JUST 236 00:09:43,533 --> 00:09:45,368 BECAUSE OF THE FARMERS AND MANY 237 00:09:45,368 --> 00:09:46,669 WORKERS REGARD THE GOVERNMENT 238 00:09:46,669 --> 00:09:49,305 AND THEY'RE NOT INVITED ON TO 239 00:09:49,305 --> 00:09:51,607 THE FARMS TO TEST SO EVEN 240 00:09:51,607 --> 00:09:56,012 SYMPTOMATIC CASES FOR EXAMPLE, 241 00:09:56,012 --> 00:10:01,050 THERE IS A LOT OF WORK AT BARTA, 242 00:10:01,050 --> 00:10:02,885 THAT ARE THOUGHT TO BE 243 00:10:02,885 --> 00:10:03,753 PROTECTIVE THAT HAVE ALREADY, 244 00:10:03,753 --> 00:10:08,024 THE CASE OF SOME OF THESE 245 00:10:08,024 --> 00:10:08,758 COMPANIES BEEN LICENSED FOR USE 246 00:10:08,758 --> 00:10:11,494 SO THIS WILL BE A STRAINCHL 247 00:10:11,494 --> 00:10:14,597 CHANGE COMPARED TO PREPANDEMIC 248 00:10:14,597 --> 00:10:16,099 H5 N1 STRAINS THAT HAD 249 00:10:16,099 --> 00:10:18,601 PREVIOUSLY BEEN TESTED IN HUMANS 250 00:10:18,601 --> 00:10:19,836 SO BARTA IS WORKING WITH 251 00:10:19,836 --> 00:10:21,204 COMPANIES TO MANUFACTURE AND 252 00:10:21,204 --> 00:10:23,773 TEST SOME OF THESE HHIV N1 253 00:10:23,773 --> 00:10:25,608 CANDIDATES AND THE INVITRO 254 00:10:25,608 --> 00:10:29,645 TESTING THUS FAR INDICATES THAT 255 00:10:29,645 --> 00:10:31,180 THESE ARE VERY CLOSELY RELATED 256 00:10:31,180 --> 00:10:32,482 TO THE VIRUS CIRCULATION AND 257 00:10:32,482 --> 00:10:34,083 SHOULD PROTECT INDIVIDUAL WHO IS 258 00:10:34,083 --> 00:10:37,720 GET VACCINATED SHOULD THAT TYPE 259 00:10:37,720 --> 00:10:40,256 OF OF RESPONSE BE REQUIRED TO 260 00:10:40,256 --> 00:10:40,890 PUBLIC HEGHT. 261 00:10:40,890 --> 00:10:42,125 RIGHT NOW THERE'S PROBABLY 262 00:10:42,125 --> 00:10:47,964 ENOUGH BEING MANUFACTURED FOR 263 00:10:47,964 --> 00:10:49,298 ABOUT--ABOUT 10,000,001st 264 00:10:49,298 --> 00:10:51,768 REPONDERS BUT ONCE THE SEASONAL 265 00:10:51,768 --> 00:10:53,836 PRODUCTION FOR INFLUENZA VACCINE 266 00:10:53,836 --> 00:10:55,705 IS CONCLUDED, THERE IS THE 267 00:10:55,705 --> 00:11:02,345 CAPACITY TO RAMP UPLARGE SCALE 268 00:11:02,345 --> 00:11:03,112 PRODECLARATION IF NOTHING. 269 00:11:03,112 --> 00:11:09,786 SO NEXT SLIDE EMPLOY SO JUST A 270 00:11:09,786 --> 00:11:12,622 FEW HIGHLIGHTS FROM CLINICAL 271 00:11:12,622 --> 00:11:13,823 TRIALS THAT DMID SUPPORTED SINCE 272 00:11:13,823 --> 00:11:15,691 THE LAST TIME WE MET IN JANUARY. 273 00:11:15,691 --> 00:11:23,366 THERE WERE INTERIM RESULTS 274 00:11:23,366 --> 00:11:26,469 ANNOUNCED, AND AN ONGOING OR THE 275 00:11:26,469 --> 00:11:31,707 CONSORTIUM OR THE IDRCD, THIS 276 00:11:31,707 --> 00:11:35,311 COMPARED TO THE 277 00:11:35,311 --> 00:11:37,146 PENTAVALENTINEDDENT CONJUGATE 278 00:11:37,146 --> 00:11:41,451 VACCINE AND IT INOCULATED 279 00:11:41,451 --> 00:11:43,419 CHILDREN IN AFRICA WITH THE 280 00:11:43,419 --> 00:11:47,790 VACCINE AND INDICATED IN THE 281 00:11:47,790 --> 00:11:50,326 NINTH MONTH IT WAS SAFE AND 282 00:11:50,326 --> 00:11:52,662 EFFECTIVE SO THE W. H. O. GROUP 283 00:11:52,662 --> 00:11:53,729 THAT MAKES RECOMMENDATIONS FOR 284 00:11:53,729 --> 00:11:56,265 THE WORLD ACTUALLY IN 285 00:11:56,265 --> 00:11:56,933 VACCINATION, RECOMMENDED THIS 286 00:11:56,933 --> 00:11:59,502 ROLL OUT IN THE MENIGE JIETIS 287 00:11:59,502 --> 00:12:10,012 BELT OF AFFRIC ASO IT'S BASED 288 00:12:24,494 --> 00:12:26,095 UPON THOSE RESULTS. 289 00:12:26,095 --> 00:12:29,565 AND THEN THE MOMMY VX STUDY 290 00:12:29,565 --> 00:12:31,334 FOUND THAT WHEN PREGNANT WOMEN 291 00:12:31,334 --> 00:12:37,073 RECEIVED A COVID VACCINE THEIR 292 00:12:37,073 --> 00:12:41,878 INVANTS HAD MUCH PROTECTION 293 00:12:41,878 --> 00:12:43,579 AFTER BIRKT SO THIS IS THE STUDY 294 00:12:43,579 --> 00:12:46,749 ENROLLED A NUMBER OF MATERNAL 295 00:12:46,749 --> 00:12:54,624 INFANT DIADS AND OVER 475 296 00:12:54,624 --> 00:13:04,166 INFANTS THAT WERE BORN--SORRY 297 00:13:04,166 --> 00:13:05,835 EITHER DO DOSES DURING PREGNANCY 298 00:13:05,835 --> 00:13:08,938 OR A BOOST DURING PREGNANCY THE 299 00:13:08,938 --> 00:13:12,241 DATA INDICATE THAD DURING THE 300 00:13:12,241 --> 00:13:14,310 INFANTS THAT WERE IN THE FOLLOW 301 00:13:14,310 --> 00:13:19,682 UP VISIT WERE BETTER PROTECTED 302 00:13:19,682 --> 00:13:22,051 WHEN THERE WAS A BOOST DURING 303 00:13:22,051 --> 00:13:25,755 PREGNANCY. 304 00:13:25,755 --> 00:13:26,422 NEXT SLIDE, PLEASE. 305 00:13:26,422 --> 00:13:29,525 YOU HEARD FROM DR. MIKE ISON THE 306 00:13:29,525 --> 00:13:31,060 LAST TIME WE MET ON HIS TB 307 00:13:31,060 --> 00:13:34,630 UPDATE THAT WE WERE WORKING ON A 308 00:13:34,630 --> 00:13:36,832 STRATEGIC PLAN FOR TUBERCULOSIS 309 00:13:36,832 --> 00:13:39,035 RESEARCH, SO THIS WAS AN NIH 310 00:13:39,035 --> 00:13:41,470 WIDE PLAN, THAT PLAN WAS 311 00:13:41,470 --> 00:13:43,205 RELEASED ON WORLD TB DAY WHICH 312 00:13:43,205 --> 00:13:44,140 WAS MARCH 24th SO PLEASE TAKE 313 00:13:44,140 --> 00:13:48,578 A LOOK AT THAT AND LEARN WHAT WE 314 00:13:48,578 --> 00:13:50,246 PROPOSED TO DO OVER THE NEXT 5 315 00:13:50,246 --> 00:13:55,251 YEARS IN ORDER TO TACKLE THE 316 00:13:55,251 --> 00:14:02,758 NUMBER 1 GLOBAL KILLER IN INFECT 317 00:14:02,758 --> 00:14:05,027 YOWSES DISEASES AND THEN JUST A 318 00:14:05,027 --> 00:14:06,762 LITTLE BIT INFORMATION ON OUR 319 00:14:06,762 --> 00:14:11,634 EFFORTS TO DEVELOP A MORE 320 00:14:11,634 --> 00:14:14,503 BROADLY PROTECTIVE, BROADLY AND 321 00:14:14,503 --> 00:14:15,271 DURANNABLILY PROTECTIVE 322 00:14:15,271 --> 00:14:17,039 INFLUENZA VACCINE, RESEARCH THAT 323 00:14:17,039 --> 00:14:19,508 WAS SUPPORTED BY THE 324 00:14:19,508 --> 00:14:20,643 COLLABORATIVE INFLUENCA VACCINE 325 00:14:20,643 --> 00:14:22,745 INNOVATION CENTER IS KNOWN AS 326 00:14:22,745 --> 00:14:23,579 THE CIVICS HAD PRECLINICAL 327 00:14:23,579 --> 00:14:32,021 STUDIES ON A NEW VACCINE THAT 328 00:14:32,021 --> 00:14:33,089 OUR CIVICS INVESTIGATORS 329 00:14:33,089 --> 00:14:37,293 DESIGNED USED TO TARGET THE 330 00:14:37,293 --> 00:14:45,368 HHSTOCK AND FOUND THIS 331 00:14:45,368 --> 00:14:46,569 EXPERIMENTAL VACCINE PRODUCED A 332 00:14:46,569 --> 00:14:48,104 STRONGER RESPONSE, AND IT WAS IN 333 00:14:48,104 --> 00:14:49,171 TRANSLATIONAL MEDICINE JUST A 334 00:14:49,171 --> 00:14:55,344 FEW WEEKS AGO, NEXT SLIDE, 335 00:14:55,344 --> 00:14:55,611 PLEASE. 336 00:14:55,611 --> 00:14:57,413 SO, SO I THINK IN A PAST MEETING 337 00:14:57,413 --> 00:15:02,084 I ASKED FOR APPROVAL FOR FISCAL 338 00:15:02,084 --> 00:15:03,686 YEAR 25, SBIR CONTRACT TOPIC AND 339 00:15:03,686 --> 00:15:05,388 WE HAVE 1 ADDITIONAL CONTRACT 340 00:15:05,388 --> 00:15:07,156 TOPIC TO ASK FOR YOUR 341 00:15:07,156 --> 00:15:08,424 CONSIDERATION AND APPROVAL, SO I 342 00:15:08,424 --> 00:15:09,859 WILL DISCUSS THAT NOW. 343 00:15:09,859 --> 00:15:11,127 NEXT SLIDE, PLEASE. 344 00:15:11,127 --> 00:15:13,095 THIS WOULD BE A SOLICITATION TO 345 00:15:13,095 --> 00:15:15,498 CALL FOR DISCOVERY AND 346 00:15:15,498 --> 00:15:17,867 DEVELOPMENT OF ORAL, SMALL 347 00:15:17,867 --> 00:15:19,068 MOLECULE DIRECT ACTING 348 00:15:19,068 --> 00:15:21,737 ANTIVIRALS THAT TARGET VIRUSES 349 00:15:21,737 --> 00:15:22,538 OF PANDEMIC POTENTIAL, THIS 350 00:15:22,538 --> 00:15:29,679 ADDRESSES A PROGRAM THAT WE HAVE 351 00:15:29,679 --> 00:15:35,317 CALLED THE ANTIVIRALS FOR 352 00:15:35,317 --> 00:15:37,286 PANDEMIC PROGRAM, THIS IS THIS 353 00:15:37,286 --> 00:15:39,822 IS--WE RECOGNIZE IT WAS VERY, WE 354 00:15:39,822 --> 00:15:43,025 WERE SLOW TO DEVELOP NEW SMALL 355 00:15:43,025 --> 00:15:46,662 MOLECULE THERAPEUTICS DURING THE 356 00:15:46,662 --> 00:15:48,164 COVID RESPONSE, THE 1S THAT MADE 357 00:15:48,164 --> 00:15:49,832 IT TO AUTHORIZATION AND 358 00:15:49,832 --> 00:15:51,767 LICENSURE REALLY WERE, WERE 359 00:15:51,767 --> 00:15:55,604 REPURPOSED DRUGS SUCH AS 360 00:15:55,604 --> 00:15:59,308 REMDESAVIR AND [INDISCERNIBLE] 361 00:15:59,308 --> 00:16:05,948 AND ALSO THE PROTEASE INHIBITOR 362 00:16:05,948 --> 00:16:06,982 PLAXWELL, OVID, BUT LEADING 363 00:16:06,982 --> 00:16:08,651 THROUGH LEAD OPTICAL IMAGES 364 00:16:08,651 --> 00:16:10,252 MIDDATION, THROUGH PRECLINICAL 365 00:16:10,252 --> 00:16:10,886 TESTS AND PRECLINICAL TRIALS, 366 00:16:10,886 --> 00:16:13,489 THAT ALWAYS JUST TAKES LONGER 367 00:16:13,489 --> 00:16:15,291 THAN WAS THE TIME AVAILABLE FOR 368 00:16:15,291 --> 00:16:16,058 AN EFFECTIVE PANDEMIC RESPONSE, 369 00:16:16,058 --> 00:16:17,560 SO WE'RE TRYING TO MAKE MORE 370 00:16:17,560 --> 00:16:23,399 INVESTMENTS IN IN AREA, WE HAVE 371 00:16:23,399 --> 00:16:24,967 A NUMBER OF DRUG DISCOVERY 372 00:16:24,967 --> 00:16:25,668 CENTERS WHICH ARE WORKING ON 373 00:16:25,668 --> 00:16:28,003 THIS BUT WE NEED TO FILL IN 374 00:16:28,003 --> 00:16:30,639 OTHER GAPS AS WELL AND WE HOPE 375 00:16:30,639 --> 00:16:32,041 THAT THIS SOLICITATION SUCH AS 376 00:16:32,041 --> 00:16:34,376 THIS WILL GET SMALLER GROUPS AND 377 00:16:34,376 --> 00:16:40,316 BOY BIOTECH TO COME IN WITH 378 00:16:40,316 --> 00:16:41,283 THEIR DISCOVERIES. 379 00:16:41,283 --> 00:16:44,987 THE FOCUS IS TO FOCUSED ON 380 00:16:44,987 --> 00:16:47,089 ANTIVIRAL DISCOVERY, ANTIVIRALS 381 00:16:47,089 --> 00:16:50,326 ADMINITTERRED IN THE OUTPATIENT 382 00:16:50,326 --> 00:16:52,161 SETTING, ORALLY OR OTHER 383 00:16:52,161 --> 00:16:53,429 NON-CUTANEOUS ROOTS THAT WOULD 384 00:16:53,429 --> 00:16:57,666 FOCUS ON 1 OR MORE OF THE VIRAL 385 00:16:57,666 --> 00:17:00,035 PATHOGENS WITH FAMILIES AND THIS 386 00:17:00,035 --> 00:17:01,337 WOULD INCLUDE INFLUENZA IN 387 00:17:01,337 --> 00:17:02,872 ADDITION AND CORONA VIRUSES IN 388 00:17:02,872 --> 00:17:05,074 ADDITION TO OTHER VIRUS FAMILIES 389 00:17:05,074 --> 00:17:11,147 THAT WE'VE IDENTIFIED WITH 390 00:17:11,147 --> 00:17:14,450 PANDEMIC POTENTIAL. 391 00:17:14,450 --> 00:17:16,218 SO I WOULD ASK YOU TO VOTE ON 392 00:17:16,218 --> 00:17:17,753 THIS IN YOUR ELECTRONIC COUNCIL 393 00:17:17,753 --> 00:17:19,355 RECORD AND HAPPY TO TAKE ANY 394 00:17:19,355 --> 00:17:21,557 QUESTIONS BEFORE I HAND THE 395 00:17:21,557 --> 00:17:32,001 MICROPHONE OFF TO LAUREN. 396 00:17:51,720 --> 00:17:55,024 OKAY, GOOD EMPLOY. 397 00:17:55,024 --> 00:17:55,624 >> OKAY. 398 00:17:55,624 --> 00:17:57,593 IMRAIT. 399 00:17:57,593 --> 00:18:00,629 OKAY, SO I AM LAUREN, AND I AS 400 00:18:00,629 --> 00:18:03,299 WAS JUST MENTIONED RECENTLY 401 00:18:03,299 --> 00:18:06,368 JOINED NIAID FOR THE PROGRAM 402 00:18:06,368 --> 00:18:07,436 OFFICER FOR CEIRR, SO I WILL 403 00:18:07,436 --> 00:18:08,604 GIVE AN INTRODUCTION INTO THE 404 00:18:08,604 --> 00:18:10,506 PROGRAM AND TALK ABOUT OUR 405 00:18:10,506 --> 00:18:12,908 ACTIVITIES AND RESPONSE TO THE 406 00:18:12,908 --> 00:18:14,577 REENLT HIGHLY PATHOGENIC 407 00:18:14,577 --> 00:18:15,778 INFLUENZA OUTBREAK FROM DAIRY 408 00:18:15,778 --> 00:18:16,212 KALGT. 409 00:18:16,212 --> 00:18:21,150 SO WHEN I SAY CEIRR, IT STANDS 410 00:18:21,150 --> 00:18:24,320 FOR THE CENTERS OF EXCELLENCE 411 00:18:24,320 --> 00:18:26,689 AND INFECT WERE AND RESPONSE. 412 00:18:26,689 --> 00:18:29,391 THIS WAS INITIATED IN 2000 413 00:18:29,391 --> 00:18:32,161 SERVE, AT THE TIME IT HAD AN SOT 414 00:18:32,161 --> 00:18:34,496 END STANDING FOR SURVEILLANCE. 415 00:18:34,496 --> 00:18:37,533 IT WAS ESTABLISHED FOR THE HHS 416 00:18:37,533 --> 00:18:39,468 PANDEMIC INFLUENZA PLAN AND THE 417 00:18:39,468 --> 00:18:41,136 GOAL WAS TO LEVERAGE THE 418 00:18:41,136 --> 00:18:42,238 EXPERTISE OF OUR EXTRAMURAL 419 00:18:42,238 --> 00:18:43,606 INVESTIGATORS TO UNDERSTAND THE 420 00:18:43,606 --> 00:18:45,374 IMPACT OF EPIDEMIC INFLUENZA AND 421 00:18:45,374 --> 00:18:47,610 REDUCE THE THREAT OF PANDEMIC 422 00:18:47,610 --> 00:18:47,877 INFLUENZA. 423 00:18:47,877 --> 00:18:49,879 SO AS I MENTIONED IT WAS 424 00:18:49,879 --> 00:18:51,413 ESTABLISHED IN 2007, THEY ARE 7 425 00:18:51,413 --> 00:18:54,350 YEAR CONTRACKS AND WE'RE IN OUR 426 00:18:54,350 --> 00:18:57,553 THIRD ITERATION NOW WITH SEER. 427 00:18:57,553 --> 00:19:00,289 THE PROGRAM OR THE NETWORK 428 00:19:00,289 --> 00:19:01,390 RATHER IS COMPRISED OF 7 429 00:19:01,390 --> 00:19:03,859 CENTERS, 6 OF THOSE ARE HOUSED 430 00:19:03,859 --> 00:19:05,494 IN ACADEMIC INSTITUTIONS 431 00:19:05,494 --> 00:19:06,595 INCLUDING THE UNIVERSITY OF IMA 432 00:19:06,595 --> 00:19:08,130 GATE KEEPER, IKAN--KANA SCHOOL 433 00:19:08,130 --> 00:19:11,667 OF MEDICINE AT MT. SINAI, EMORY 434 00:19:11,667 --> 00:19:12,534 UNIVERSITY, JOHNS HOPKINS, 435 00:19:12,534 --> 00:19:14,536 UNIVERSITY, UNIVERSITY OF 436 00:19:14,536 --> 00:19:16,138 PENNSYLVANIA AND THE ST. JUDE'S 437 00:19:16,138 --> 00:19:17,640 RESEARCH HOSPITAL. 438 00:19:17,640 --> 00:19:19,608 WE HAVE A SEVENTH CENTER 439 00:19:19,608 --> 00:19:21,543 RESPONSIBLE FOR PROCESSING DATA 440 00:19:21,543 --> 00:19:22,144 APPROXIMATE COMMUNICATION AND 441 00:19:22,144 --> 00:19:23,879 THIS TO HELP WITH DIGITAL 442 00:19:23,879 --> 00:19:24,146 CONFUSION. 443 00:19:24,146 --> 00:19:26,448 SO AS I MENTIONED, THESE ARE 444 00:19:26,448 --> 00:19:27,816 CONTRACT MECHANISMS AND THE 445 00:19:27,816 --> 00:19:29,685 DIFFERENCE HERE INSTEAD OF GRANT 446 00:19:29,685 --> 00:19:32,922 SUPPORT FOR OUR EXTRAMURAL 447 00:19:32,922 --> 00:19:34,723 INVESTIGATORS IS THIS LENDS US A 448 00:19:34,723 --> 00:19:36,492 LEVEL OF AGILITY AND FLEXIBILITY 449 00:19:36,492 --> 00:19:39,261 WHEN WE ARE FACED WITH AN 450 00:19:39,261 --> 00:19:39,862 OUTBREAK SITUATION. 451 00:19:39,862 --> 00:19:42,197 SO WE ARE ABLE TO RAPIDLY 452 00:19:42,197 --> 00:19:50,272 REDIRECT THE EFFORTS OF OUR 453 00:19:50,272 --> 00:19:51,006 SOCIETIES BECAUSE BECAUSE THIS 454 00:19:51,006 --> 00:19:53,242 IS THE FIRST DETECTION OF 455 00:19:53,242 --> 00:19:55,044 INFLUENZA VIRUS IN CATTLE, 456 00:19:55,044 --> 00:19:56,011 NOBODY WAS STUDYING THIS SPACE 457 00:19:56,011 --> 00:19:57,513 BEFORE, SO WITH A REDIRECTION 458 00:19:57,513 --> 00:19:59,381 AND A CHANGE IN A STATEMENT OF 459 00:19:59,381 --> 00:20:00,816 WORK, WE WERE ABLE TO MOVE OUR 460 00:20:00,816 --> 00:20:02,117 SCIENTISTS INTO THIS AREA AND 461 00:20:02,117 --> 00:20:03,519 REALLY GET STARTED ANSWERING 462 00:20:03,519 --> 00:20:10,626 THESE RELEVANT QUESTIONS EARLY 463 00:20:10,626 --> 00:20:10,793 ON. 464 00:20:10,793 --> 00:20:13,862 SO 1 OF THE OTHER ITERATIONS OF 465 00:20:13,862 --> 00:20:15,431 THE CEIRREFRESH YOUR 466 00:20:15,431 --> 00:20:16,966 RECOLLECTION NETWORK IS THE RISK 467 00:20:16,966 --> 00:20:18,968 ASSESSMENT FOCUS, AND WE SET UP 468 00:20:18,968 --> 00:20:20,569 THE RISK ASSESSMENT PIPELINE 469 00:20:20,569 --> 00:20:22,838 KNOWN AS RAP, AND SO THIS IS 470 00:20:22,838 --> 00:20:24,206 DESIGNED OF 4 DIFFERENT FOCUS 471 00:20:24,206 --> 00:20:26,008 AREAS, WHILE IN SURVEILLANCE, 472 00:20:26,008 --> 00:20:28,777 SURVEILLANCE AT THE HUMAN 473 00:20:28,777 --> 00:20:32,481 INTERFACE, COMPUTATIONAL AND N 474 00:20:32,481 --> 00:20:33,082 MODELING AND REGENERATION, AND 475 00:20:33,082 --> 00:20:34,950 THE IDEA IS THAT WE'RE 476 00:20:34,950 --> 00:20:36,151 DECENTRALIZING OUR RISK ARK 477 00:20:36,151 --> 00:20:37,753 ASSESSESMENT EFFORTS SO IT'S NOT 478 00:20:37,753 --> 00:20:38,520 HOUSED IN ANYONE PARTICULAR 479 00:20:38,520 --> 00:20:41,623 CENTER BUT WE HAVE, WOOING 480 00:20:41,623 --> 00:20:43,158 GROUPS WITHIN EACH OF THESE 481 00:20:43,158 --> 00:20:45,527 FOCUS AREAS THAT ARE COMPRISED 482 00:20:45,527 --> 00:20:46,595 OF INVESTIGATORS FROM ALL 7 483 00:20:46,595 --> 00:20:49,365 CENTERS AND THIS IS AN EFFORT TO 484 00:20:49,365 --> 00:20:50,799 REALLY BE MOST EFFICIENT IN 485 00:20:50,799 --> 00:20:53,435 USING OUR RESOURCES AND OUR 486 00:20:53,435 --> 00:20:55,604 EXPERTISE SPREAD ACROSS THE 487 00:20:55,604 --> 00:20:57,539 ENTIRE NETWORK, SO THE 488 00:20:57,539 --> 00:20:58,240 DELIVERABLE, THE ULTIMATE 489 00:20:58,240 --> 00:20:59,908 DELIVERABLE OF THE RISK 490 00:20:59,908 --> 00:21:02,011 ASSESSMENT PIPELINE WOULD BE AN 491 00:21:02,011 --> 00:21:02,778 EXECUTIVE REPORT, SOMEWHAT 492 00:21:02,778 --> 00:21:05,214 SIMILAR AND IN ACCORD NATION 493 00:21:05,214 --> 00:21:08,650 WITH CDC, [INDISCERNIBLE] THAT 494 00:21:08,650 --> 00:21:09,451 DETAILS CEIRR EMERGENT OF THE 495 00:21:09,451 --> 00:21:14,790 STRAIN BUT ALONG THE WAY WE ARE 496 00:21:14,790 --> 00:21:15,724 DELIVERING A LOT OF INFORMATION 497 00:21:15,724 --> 00:21:18,127 TO THE FIELD WITH OUR 498 00:21:18,127 --> 00:21:20,229 CHARACTERIZATION STUDIES AS WELL 499 00:21:20,229 --> 00:21:21,964 AS CHARACTERIZATIONS SHARED 500 00:21:21,964 --> 00:21:23,699 WITHIN THE CEIRR NETWORK AND THE 501 00:21:23,699 --> 00:21:26,135 FIELD AS A WHOLE AND THE WRAP IT 502 00:21:26,135 --> 00:21:31,006 WAS INITIATED IN JANUARY, IT HAD 503 00:21:31,006 --> 00:21:33,675 2 MONTHS TO GET OUR FEET UNDER 504 00:21:33,675 --> 00:21:36,111 US, AND TAKE OFF RUNNING WITH 505 00:21:36,111 --> 00:21:38,480 THE BOVINE OUTBREAK THAT STARTED 506 00:21:38,480 --> 00:21:38,881 IN MARCH. 507 00:21:38,881 --> 00:21:40,315 NOW BEFORE WE GET BACK I JUST 508 00:21:40,315 --> 00:21:41,950 WANT TO DO A LITTLE BACKGROUND 509 00:21:41,950 --> 00:21:44,186 ON THE HIGHLY PATHOGENIC AVIAN 510 00:21:44,186 --> 00:21:45,320 INFLUENZA SO WE'RE ALL ON THE 511 00:21:45,320 --> 00:21:46,722 SAME PAGE. 512 00:21:46,722 --> 00:21:48,424 SO IN 1997, THE FIRST HUMAN CASE 513 00:21:48,424 --> 00:21:50,025 WAS REPORTED AND THIS WAS A 514 00:21:50,025 --> 00:21:52,761 HUMAN WHO HAD DIRECT CONTACT 515 00:21:52,761 --> 00:21:56,331 WITH AN A BIRD, SINCE THEN IT'S 516 00:21:56,331 --> 00:21:57,866 BEEN FAIRLY SPORADIC AND THERE 517 00:21:57,866 --> 00:22:00,702 HAVEN'T BEEN RESULTS OF DIRECT 518 00:22:00,702 --> 00:22:01,970 SUSTAINED HUMAN TO HUMAN 519 00:22:01,970 --> 00:22:04,273 TRANSMISSION, SO IT'S BEEN AGAIN 520 00:22:04,273 --> 00:22:05,908 IMPACT OR CONTACT WITH AN 521 00:22:05,908 --> 00:22:07,209 INFECTED ANIMAL OR VERY CLOSE 522 00:22:07,209 --> 00:22:11,647 CONTACT WITH AN INFECTED 523 00:22:11,647 --> 00:22:12,181 INDIVIDUAL AND HOUSEHOLD. 524 00:22:12,181 --> 00:22:14,983 BUT AS YOU CAN SEE WE HAVE A 10 525 00:22:14,983 --> 00:22:17,786 YEAR TIMELINE AND GETTING 526 00:22:17,786 --> 00:22:19,955 TOWARDS 2020, AND 2021, WE HAVE 527 00:22:19,955 --> 00:22:21,223 REGULAR SPIKES IN ACTIVITY SO 528 00:22:21,223 --> 00:22:22,424 WHAT THE QUESTION IS WHAT IS 529 00:22:22,424 --> 00:22:29,064 DIFFERENT NOW, AND THE ANSWER IS 530 00:22:29,064 --> 00:22:36,872 WE SAW THE ARRIVAL OF CLAYED 531 00:22:36,872 --> 00:22:38,307 2.3.4.4 B, AND SPREAD ACROSS 532 00:22:38,307 --> 00:22:39,641 AFRICA AND ASIA, IN THE 533 00:22:39,641 --> 00:22:40,909 FOLLOWING 2 YEARS THEY CROSSED 534 00:22:40,909 --> 00:22:42,077 NORTH AMERICA AND SOUTH AMERICA 535 00:22:42,077 --> 00:22:43,645 AND RESULT INDEED UNPRECEDENTED 536 00:22:43,645 --> 00:22:44,913 NUMBERS OF DEATHS IN WILD 537 00:22:44,913 --> 00:22:46,315 BITTERS AND OUTBREAKS IN 538 00:22:46,315 --> 00:22:47,282 DOMESTIC POULTRY. 539 00:22:47,282 --> 00:22:49,852 THE OTHER INTERESTING FEATURE 540 00:22:49,852 --> 00:22:50,719 ABOUT THIS PARTICULAR CLAYED IS 541 00:22:50,719 --> 00:22:52,321 THAT WE'RE SEEING MORE AND MORE 542 00:22:52,321 --> 00:22:54,189 SPILL OVER EVENTS TO MAMMALS, SO 543 00:22:54,189 --> 00:22:55,491 WE'RE TALKING ABOUT DAIRYICALITY 544 00:22:55,491 --> 00:22:59,128 TODAY BUT YOU ALL MAY REMEMBER 545 00:22:59,128 --> 00:23:01,463 THE MARINE MAMMAL DIE-OFFS THAT 546 00:23:01,463 --> 00:23:02,197 WERE BEING REPORTED ALONG THE 547 00:23:02,197 --> 00:23:04,600 COAST OF THE SOUTH AMERICA WHERE 548 00:23:04,600 --> 00:23:06,435 WE'RE SEEING H5 POP UP IN 549 00:23:06,435 --> 00:23:08,337 ANIMALS SUCH AS EELS AND 550 00:23:08,337 --> 00:23:10,105 DOLPHINS, WHICH IS COMPLETELY 551 00:23:10,105 --> 00:23:10,372 UNEXECKED. 552 00:23:10,372 --> 00:23:12,307 SINCE 2020 THERE HAVE BEEN 12 553 00:23:12,307 --> 00:23:14,843 HUMAN CASES OF CLAYED 2344 B AND 554 00:23:14,843 --> 00:23:17,880 THAT DOES INCLUDE THE RECENT H5 555 00:23:17,880 --> 00:23:19,615 CASES AFFILIATED WITH THE DAIRY 556 00:23:19,615 --> 00:23:22,284 KALGT OUTBREAK HERE IN THE 557 00:23:22,284 --> 00:23:23,552 UNITED STATES, SO LET'S TALK 558 00:23:23,552 --> 00:23:24,987 ABOUT THE UNITED STATES THEN, SO 559 00:23:24,987 --> 00:23:27,256 AS I MENTIONED, WE DIDN'T HAVE 560 00:23:27,256 --> 00:23:31,226 AN INTRODUCTION OF THE HIGH PATH 561 00:23:31,226 --> 00:23:33,996 244 B H5 N1 UNTIL 2021 AND 2022 562 00:23:33,996 --> 00:23:36,532 AND SINCE THEN WE'VE HAD 48 563 00:23:36,532 --> 00:23:37,599 STATES REPORT POULTRY 564 00:23:37,599 --> 00:23:38,834 INFECTIONS, WE'VE ALSO HAD CLOSE 565 00:23:38,834 --> 00:23:41,470 TO 10,000 CASES DETECTED IN WILD 566 00:23:41,470 --> 00:23:43,906 BIRDS AND WE'VE HAD A TOTAL NOW 567 00:23:43,906 --> 00:23:46,208 OF 4 HUMAN CASES, SO THE FIRST 568 00:23:46,208 --> 00:23:49,745 OF THOSE AS EMILY MENTIONED 569 00:23:49,745 --> 00:23:51,747 OCCURRED IN 2022, ON AN INFECTED 570 00:23:51,747 --> 00:23:52,714 POULTRY FARM, AGAIN THIS WAS A 571 00:23:52,714 --> 00:23:55,150 PERSON WHO WAS IN CLOSE CONTACT 572 00:23:55,150 --> 00:23:56,318 WITH AN AFFECTED BIRD AND THE 573 00:23:56,318 --> 00:23:58,754 FOLLOWING 3 HAVE BEEN AFFILIATED 574 00:23:58,754 --> 00:24:01,089 WITH THE BO VIET OUTBREAK AND 575 00:24:01,089 --> 00:24:11,600 THAT INCLUES CONTACT WITH THE 576 00:24:15,737 --> 00:24:17,339 AFFECTED ANIMALS. 577 00:24:17,339 --> 00:24:19,107 THE USDA PREPORTS HIGHLY 578 00:24:19,107 --> 00:24:21,176 PATHOGENIC IEE, AUDIENCE I HAVE 579 00:24:21,176 --> 00:24:25,280 AN INFLUENZA VIRUS FROM 580 00:24:25,280 --> 00:24:25,781 UNPASTEURIZE MILK FROM 581 00:24:25,781 --> 00:24:26,448 CONSCIENCE CONSCIENCE AND 582 00:24:26,448 --> 00:24:28,550 PARTICULAR TEXT, WE STARRED THE 583 00:24:28,550 --> 00:24:30,886 BALL ROLLING, WE HAD ADDITIONAL 584 00:24:30,886 --> 00:24:32,921 CASES INN FIRMED IN NUCLEOTIDES 585 00:24:32,921 --> 00:24:34,456 MEXICO AND NORTH CAROLINA AND 586 00:24:34,456 --> 00:24:37,326 SOUTH DAKOTA EMPLOY ALSO WITHIN 587 00:24:37,326 --> 00:24:39,695 THAT TIME FRAME CDC RECORDED A 588 00:24:39,695 --> 00:24:42,464 FIRST HUMAN CASE, A DIRY WORKER 589 00:24:42,464 --> 00:24:43,999 FOLLOWING EXPOSURE TO KAGHTS 590 00:24:43,999 --> 00:24:46,868 ACTUALLY PRESENTED WITH SYMPTOMS 591 00:24:46,868 --> 00:24:47,669 OF CONJURCHGHTIVITEIS ONLY. 592 00:24:47,669 --> 00:24:52,040 THEY WERE TREATED WITH 593 00:24:52,040 --> 00:24:54,276 OSLOTAMOVIR AND NO FOLLOW UP 594 00:24:54,276 --> 00:24:54,610 COMPLICATIONS. 595 00:24:54,610 --> 00:24:57,379 OT 24th THE US, DIDA RELEASES 596 00:24:57,379 --> 00:24:59,982 A FERAL ORDER REQUIRING TESTING 597 00:24:59,982 --> 00:25:03,218 OF LACTATING CATTLE OUT OF STATE 598 00:25:03,218 --> 00:25:04,052 AND RESTRICTED MOVEMENT OF 599 00:25:04,052 --> 00:25:06,288 FOLLOWING ANIMAL AND I WILL TALK 600 00:25:06,288 --> 00:25:08,490 ABOUT WHY THAT'S SO SIGNIFICANT. 601 00:25:08,490 --> 00:25:10,525 THE DAY LATER WE GET A CONFIRMED 602 00:25:10,525 --> 00:25:11,760 POSITIVE CASE FROM COLORADO SO 603 00:25:11,760 --> 00:25:13,195 NOW THE STATE COUNT IS UP TO 9 604 00:25:13,195 --> 00:25:15,297 WHICH IS WHERE IT HAS REMAINED 605 00:25:15,297 --> 00:25:17,699 THORS THOSE NUMBERS OF CASES 606 00:25:17,699 --> 00:25:20,002 WITHIN THOSE STATES CONTINUED TO 607 00:25:20,002 --> 00:25:20,269 INCREASE. 608 00:25:20,269 --> 00:25:23,372 ON MAY TENTH THE US, DIDA AND 609 00:25:23,372 --> 00:25:25,040 HHS ANOUNED SUPPORT TO FARMS TO 610 00:25:25,040 --> 00:25:27,342 REDUCE THE BURDEN OF TESTING AND 611 00:25:27,342 --> 00:25:28,043 IMPLEMENTATION OF NEW 612 00:25:28,043 --> 00:25:30,012 BIOSECURITY MEASURES, AND ALSO 613 00:25:30,012 --> 00:25:31,880 THE IMPACT OF H5 N1 CASES AS 614 00:25:31,880 --> 00:25:33,649 THESE FARMERS ARE HAVING TO PULL 615 00:25:33,649 --> 00:25:44,159 THEIR ANIMALS FROM THEIR DAIRY 616 00:25:51,166 --> 00:25:52,234 PRODUCTION LINES. 617 00:25:52,234 --> 00:25:54,936 --LOOKING AT PC R POSITIVE 618 00:25:54,936 --> 00:25:56,405 RETAIL MILK SAMPLES. 619 00:25:56,405 --> 00:25:58,407 ON MAY 22nd THE CDC REPORTS 620 00:25:58,407 --> 00:26:00,042 SECOND HUMAN CASE FOLLOWING 621 00:26:00,042 --> 00:26:01,410 EXPOSURE TO DAIRY CATTLE AND 622 00:26:01,410 --> 00:26:05,447 THEN 2 DAYS LATER THE USDA FOOD 623 00:26:05,447 --> 00:26:06,715 SAFETY INSPECTION SEVENS REPORTS 624 00:26:06,715 --> 00:26:08,250 THAT BY O PARTICLES WERE 625 00:26:08,250 --> 00:26:10,852 DETECTED IN THE MUSCLE TISSUE IN 626 00:26:10,852 --> 00:26:14,589 1 OUT OF 95 THEY TESTED. 627 00:26:14,589 --> 00:26:16,591 AND THEY'RE TALKING ABOUT 628 00:26:16,591 --> 00:26:17,759 COOKING STUDIES WHERE IF YOU 629 00:26:17,759 --> 00:26:18,927 FOLLOW THESE AND COOK THEM TO 630 00:26:18,927 --> 00:26:21,229 THE APPROPRIATE TEMPERATURES YOU 631 00:26:21,229 --> 00:26:22,731 REDUCE OR COMPLETELY ENACT VAIF 632 00:26:22,731 --> 00:26:29,938 ANY VIRUS THAT HAD BEEN 633 00:26:29,938 --> 00:26:30,372 INTRODUCED. 634 00:26:30,372 --> 00:26:32,507 THEN FINALLY LASTED THIS THEY 635 00:26:32,507 --> 00:26:34,876 REPORTED A THIRD HUMAN CASE FOR 636 00:26:34,876 --> 00:26:35,977 DAIRY CATTLE AND THIS 1 IS THAT 637 00:26:35,977 --> 00:26:38,547 THIS INDIVIDUAL IS NOW REPORTING 638 00:26:38,547 --> 00:26:41,550 WITH RESPIRATORY SYMPTOMS AND IN 639 00:26:41,550 --> 00:26:44,586 ADDITION TO CONJUNCTIVE ITIS. 640 00:26:44,586 --> 00:26:46,455 SO HERE IS OUR MAP OF THE 641 00:26:46,455 --> 00:26:46,822 AFFECTED STATES. 642 00:26:46,822 --> 00:26:54,463 AS YOU CAN SEE IT IS STILL 9 643 00:26:54,463 --> 00:27:03,105 THOUGH AS I MENTIONED, WE ARE 644 00:27:03,105 --> 00:27:04,473 STILL AT 69. 645 00:27:04,473 --> 00:27:06,908 ONE HERD WAS AN ALPACA FARM, AND 646 00:27:06,908 --> 00:27:09,745 THIS IS THE FIRST INTRODUCTION 647 00:27:09,745 --> 00:27:11,446 OF THIS VIRUS INTO ALPACAS AS 648 00:27:11,446 --> 00:27:11,780 WELL. 649 00:27:11,780 --> 00:27:15,150 SO I MENTIONED THE FEDERAL ORDER 650 00:27:15,150 --> 00:27:17,018 REDUCING THE TRANSFER OF COW 651 00:27:17,018 --> 00:27:19,054 SAYS ACROSSITATE LINES AND THIS 652 00:27:19,054 --> 00:27:20,021 IS IMPORTANT BECAUSE AS WE'VE 653 00:27:20,021 --> 00:27:23,692 COME TO LEARN, A LOT OF THESE 654 00:27:23,692 --> 00:27:30,031 LARGE DAIRY CONGLOMERATES HAVE 655 00:27:30,031 --> 00:27:31,600 FARMS IN THIS VARIOUS STATES, 656 00:27:31,600 --> 00:27:36,405 THEY HAVE LOCATIONS IN STATES 657 00:27:36,405 --> 00:27:37,572 FOR PARTICULAR PURPOSES. 658 00:27:37,572 --> 00:27:38,640 FOR EXAMPLE, THEY MAY HAVE DRY 659 00:27:38,640 --> 00:27:40,108 LOTS IN ACCIDENT IT TEXT, OR 660 00:27:40,108 --> 00:27:41,510 THEY MAY HAVE PRODUCTION FARMS 661 00:27:41,510 --> 00:27:44,713 IN MICHIGAN OR OHIO SO YOU HAVE 662 00:27:44,713 --> 00:27:45,747 VERY FREQUENT ELECTRONICS MITT 663 00:27:45,747 --> 00:27:47,482 THAT OCCURS BACK AND FORTH SO 664 00:27:47,482 --> 00:27:48,984 1EST MOST COMMON COMPREHENDS YOU 665 00:27:48,984 --> 00:27:50,752 HERE IS THAT YOU HAVE PREGNANT 666 00:27:50,752 --> 00:27:52,721 CATTLE THAT ARE MOVED TO THE 667 00:27:52,721 --> 00:27:54,723 OHIO, THEY ARE ALLOWED TO HAVE 668 00:27:54,723 --> 00:27:56,925 THE CALVES, THEY MOVE DIRECTLY 669 00:27:56,925 --> 00:27:58,960 INTO LACTATION APPROXIMATE AND 670 00:27:58,960 --> 00:28:00,362 MULLK, THE CALVES ARE SHIPPED 671 00:28:00,362 --> 00:28:02,798 BACK TO TEXAS AFTER 4 DAYS OF 672 00:28:02,798 --> 00:28:04,032 BIRTH, TEXAS OR INDIANA. 673 00:28:04,032 --> 00:28:06,334 SO LOTS OF MOVEMENT OF THE HERDS 674 00:28:06,334 --> 00:28:08,970 AND IT'S NOT AN ENTIRE HERD, 675 00:28:08,970 --> 00:28:11,540 IT'S THE UNITS OF HERDS, SO AS 676 00:28:11,540 --> 00:28:12,774 VIROLOGIST WE'RE VERY CONCERNED 677 00:28:12,774 --> 00:28:14,509 HERE, THERE'S A LOT OF MIXING 678 00:28:14,509 --> 00:28:19,848 AND POTENTIAL FOR SPREAD, IF 679 00:28:19,848 --> 00:28:23,251 THESE ANIMALS ARE INFECTED, 680 00:28:23,251 --> 00:28:26,521 THERE HAS BEEN SOME SPILL OVER 681 00:28:26,521 --> 00:28:28,557 COLLECTED, BUT SHOWING UP WITH 682 00:28:28,557 --> 00:28:29,925 NEUROLOGICAL SYMPTOMS ARE 683 00:28:29,925 --> 00:28:30,859 BINDNESS, OUR INVESTIGATORS WERE 684 00:28:30,859 --> 00:28:33,962 ACTUALLY ABLE TO HAVE ACCESS TO 685 00:28:33,962 --> 00:28:38,133 A DECEASED CAT WHERE THEY 686 00:28:38,133 --> 00:28:40,268 PERFORM TD NECROPSY WHERE THEY 687 00:28:40,268 --> 00:28:44,773 FOUND THAT THE CAT WAS 688 00:28:44,773 --> 00:28:49,010 EXPERIENCINGS VIRAL HEMORRHAGIC 689 00:28:49,010 --> 00:28:50,545 PULMONARY EDEMAA. 690 00:28:50,545 --> 00:28:51,746 AGAIN, WE HAVE 3 HUMAN CASES NOW 691 00:28:51,746 --> 00:28:55,083 THAT HAVE BEEN REPORTED ALL WITH 692 00:28:55,083 --> 00:28:56,551 CONJUVENGHTIVITEIS, AND THE MOST 693 00:28:56,551 --> 00:29:06,194 RECENT CASE DOES HAVE 694 00:29:06,194 --> 00:29:08,697 RESPIRATORY, AND THEY WERE 695 00:29:08,697 --> 00:29:10,332 TREATED WITH TAMAVIR, AND IT WAS 696 00:29:10,332 --> 00:29:10,565 GOOD. 697 00:29:10,565 --> 00:29:11,666 SO THAT'S IT AS A WHOLE. 698 00:29:11,666 --> 00:29:13,068 NOW I CAN TALK ABOUT WHAT WE'VE 699 00:29:13,068 --> 00:29:14,503 DONE, WE WERE WELL POSITIONED 700 00:29:14,503 --> 00:29:16,238 WITHIN OUR NETWORK OF VERY LONGS 701 00:29:16,238 --> 00:29:17,672 AND THEIR COLLABORATING 702 00:29:17,672 --> 00:29:18,406 VETERINARIANS TO GET SAMPLES 703 00:29:18,406 --> 00:29:20,175 EARLY ON AND BA THE FOREFRONT OF 704 00:29:20,175 --> 00:29:21,109 SOME OF THIS WORK. 705 00:29:21,109 --> 00:29:25,013 SO AS I MENTIONED WITHIN THE 706 00:29:25,013 --> 00:29:26,815 WRAP, WHAT WE CONSIDER A 707 00:29:26,815 --> 00:29:28,583 STANDARD SET OF VIRAL 708 00:29:28,583 --> 00:29:29,985 CHARACTERIZATION AND RISK 709 00:29:29,985 --> 00:29:33,722 ASSESSMENT ASSAYS SO THIS WILL 710 00:29:33,722 --> 00:29:34,923 BE SAMPLE COLLECTION WITH 711 00:29:34,923 --> 00:29:37,225 SURVEILLANCE GROUPS AND JUST OUR 712 00:29:37,225 --> 00:29:39,828 GENERAL ASIGNIFYS LOOKING AT 713 00:29:39,828 --> 00:29:43,098 BIOCHARACTERRIZATIONS FOR 714 00:29:43,098 --> 00:29:44,366 MAMMALIAN ADAPTATION, 715 00:29:44,366 --> 00:29:46,334 SENSITIVITY TO EXISTING 716 00:29:46,334 --> 00:29:48,403 ANTIVIRALS AND CROSS 717 00:29:48,403 --> 00:29:51,840 PROTECTIVITY, I'M SORRY CROSS 718 00:29:51,840 --> 00:29:54,676 PROTECTIVENESS, CROSS REACTIVITY 719 00:29:54,676 --> 00:29:58,980 OF OUR CURRENT H5 720 00:29:58,980 --> 00:30:00,415 CEIRENVIRONMENTAL STIEBILITY 721 00:30:00,415 --> 00:30:01,516 STUDIES AND REAGENT DEVELOPMENT. 722 00:30:01,516 --> 00:30:02,984 SO WE WERE ABLE TO UNDERTAKE 723 00:30:02,984 --> 00:30:05,587 MANY OF THESE STUDIES ON SITE 724 00:30:05,587 --> 00:30:08,690 VERY QUICKLY BECAUSE WE HAD 725 00:30:08,690 --> 00:30:10,125 THESE CONNECTIONS WITH OUR VETS, 726 00:30:10,125 --> 00:30:11,893 SO FOR EXAMPLE, IN OHIO, WE HAD 727 00:30:11,893 --> 00:30:13,662 EARLY ACCESS TO A FARM, AND WE 728 00:30:13,662 --> 00:30:16,064 WERE ABLE TO COLLECT 900 729 00:30:16,064 --> 00:30:18,900 NAISALLA SWAPS AND INFECT YOWZ 730 00:30:18,900 --> 00:30:25,607 MILK SAMPLES, HOWEVER, AND WE 731 00:30:25,607 --> 00:30:27,208 DID SET UP AN INVESTIGATIONAL 732 00:30:27,208 --> 00:30:29,177 STUDY ON THAT FARM HOWEVER AN 733 00:30:29,177 --> 00:30:30,779 INVESTIGATION WAS NOT ALLOWED ON 734 00:30:30,779 --> 00:30:33,481 SITE DUE TO MEDIA SCRUTINY FROM 735 00:30:33,481 --> 00:30:34,516 PARTICIPATING EARLY ON. 736 00:30:34,516 --> 00:30:38,520 SO THAT HIGHLIGHTS THE ACCESS 737 00:30:38,520 --> 00:30:40,322 ISSUE WE'RE HAVING FOR SAMPLES 738 00:30:40,322 --> 00:30:41,990 THAT EMILY REFERRED TO EARLIER. 739 00:30:41,990 --> 00:30:44,326 BUT WE HAVE OUR 900 SAMPLES 740 00:30:44,326 --> 00:30:46,628 THERE, WE WERE ABLE TO GET 741 00:30:46,628 --> 00:30:48,129 SAMPLES FROM TEXAS, WISCONSIN 742 00:30:48,129 --> 00:30:50,799 AND KANSAS, AND WE WERE APE TO 743 00:30:50,799 --> 00:30:52,000 START OUR RISK ASSESSMENT 744 00:30:52,000 --> 00:30:52,334 STUDIES. 745 00:30:52,334 --> 00:30:54,436 SO I WILL HIGHLIGHT A FEW OF 746 00:30:54,436 --> 00:30:57,839 THOSE NOW, SO THESE FIRST 2 ARE 747 00:30:57,839 --> 00:31:00,775 FROM ST. JUDE CEIRR, AND YOU CAN 748 00:31:00,775 --> 00:31:02,844 READ THESE REPORTS BUT THE FIRST 749 00:31:02,844 --> 00:31:04,846 1 IS TESTING ANTIVIRAL DRUGS 750 00:31:04,846 --> 00:31:08,383 SENSITIVITY AND RESISTANCE AND 751 00:31:08,383 --> 00:31:09,484 THEY LOOKAD BOVINE STRAINS FROM 752 00:31:09,484 --> 00:31:10,418 OHIO AND PARTICULAR TEXT AND 753 00:31:10,418 --> 00:31:16,891 THEY FOUND THEY ARE SUSCEPTIBLE 754 00:31:16,891 --> 00:31:23,098 TO INHIBITORS AND OSELTAMIVIR 755 00:31:23,098 --> 00:31:25,300 AND ZANAMIVIR, AND SUSCEPTIBLE 756 00:31:25,300 --> 00:31:29,771 TO THE CAP DEPENDENT 757 00:31:29,771 --> 00:31:30,305 ENDONUCLEACE INHIBITOR 758 00:31:30,305 --> 00:31:30,839 BALOXAVIR. 759 00:31:30,839 --> 00:31:31,673 SO THESE STUDIES OUR 760 00:31:31,673 --> 00:31:32,641 INVESTIGATORS HAVE CONCLUDED 761 00:31:32,641 --> 00:31:35,377 THAT THE FDA APPROVED ANTIVIRAL 762 00:31:35,377 --> 00:31:37,078 TREATMENTS ARE ALL STILL 763 00:31:37,078 --> 00:31:39,147 APPROPRIATE FOR THE BOVINE 764 00:31:39,147 --> 00:31:42,384 ISOLATES THAT WE'RE GETTING. 765 00:31:42,384 --> 00:31:48,957 WE ALSO COMPLETED TESTING OF H5 766 00:31:48,957 --> 00:31:51,292 CEIRRA WITH THE VACCINE, THIS 767 00:31:51,292 --> 00:31:53,628 DIFFERS BY 6 AMINO ACIDS IN THE 768 00:31:53,628 --> 00:31:57,132 HA PROTEIN BUT IT DOES ILLICIT 769 00:31:57,132 --> 00:31:59,334 CROSS REACTIVE ANTIBODIES TO THE 770 00:31:59,334 --> 00:31:59,801 BOVINE STRAIN TESTED. 771 00:31:59,801 --> 00:32:02,370 SO THE OTHER PART OF OUR 772 00:32:02,370 --> 00:32:03,638 BIOCHARACTERRIZATION STUDIES I 773 00:32:03,638 --> 00:32:05,540 WANT TO HEIGHT LIGHT TODAY COMES 774 00:32:05,540 --> 00:32:08,810 DOWN TO OUR N ANALYSIS AND OUR 775 00:32:08,810 --> 00:32:09,744 COMPUTATIONAL MODELING GROUPS 776 00:32:09,744 --> 00:32:13,748 AND SO AGAIN, THESE ARE ALSO 777 00:32:13,748 --> 00:32:15,116 PUBLISHEDOT SEER WEBSITE AND 778 00:32:15,116 --> 00:32:16,951 THEY THEIR OWN INDIVIDUAL 779 00:32:16,951 --> 00:32:18,420 WEBSITES HOSTING DATA AND I 780 00:32:18,420 --> 00:32:19,587 RECOMMEND CHECKING THEM OUT BUT 781 00:32:19,587 --> 00:32:21,322 THE FIRST IS A NEXT STRAIN BUILD 782 00:32:21,322 --> 00:32:22,957 THAT IS UPDATED REGULARLY WITH 783 00:32:22,957 --> 00:32:25,427 NEW DATA FROM THE USDA WHEN IT'S 784 00:32:25,427 --> 00:32:35,870 RELEASED AND IT CONTAINS, 785 00:32:36,404 --> 00:32:40,141 CANCATANNATED FROM THE OUTBREAK 786 00:32:40,141 --> 00:32:46,815 AND ALSO PROVIDING 1 SEPTORSOT 787 00:32:46,815 --> 00:32:47,215 THAT THERE. 788 00:32:47,215 --> 00:32:51,086 SO THE PURPOSE OF THIS IS TO 789 00:32:51,086 --> 00:32:52,487 UNDERSTAND HOW MUTATIONS ARISE 790 00:32:52,487 --> 00:32:54,489 MAY ADAPT TO MAMMALIAN AX DATA 791 00:32:54,489 --> 00:32:56,124 PROTECTIONATION, SO THIS IS 792 00:32:56,124 --> 00:32:58,393 SPECIFICITY FROM AN AVIAN 793 00:32:58,393 --> 00:32:59,894 SPECIFIC PREFERENCE TO A HUMAN 794 00:32:59,894 --> 00:33:01,663 SPECIFIC PREFERENCE AND SO ON 795 00:33:01,663 --> 00:33:05,400 AND SO FORTH. 796 00:33:05,400 --> 00:33:08,803 ALSO UNDERSTANDING HA STABILITY 797 00:33:08,803 --> 00:33:10,572 AND REACTIVITY AGAINST 798 00:33:10,572 --> 00:33:11,439 POLYCLONAL SERIES POINTSA. 799 00:33:11,439 --> 00:33:12,707 THESE CAN BE FOUND OUR WEBSITE. 800 00:33:12,707 --> 00:33:14,776 SO AS I MEKSED A FEW SLIDES AGO, 801 00:33:14,776 --> 00:33:17,112 WE HAVE A SET OF WHAT WE WOULD 802 00:33:17,112 --> 00:33:22,550 REFER TO AS TRADITIONAL RISK 803 00:33:22,550 --> 00:33:23,251 ASSESSMENT EXPERIMENTS BUT DUE 804 00:33:23,251 --> 00:33:26,554 TO THE NATURE OF THIS OUTBREAK 805 00:33:26,554 --> 00:33:29,824 AND THIS WHOLE FEATURE, WE'VE 806 00:33:29,824 --> 00:33:32,260 HAD TO PULL IN A COUPLE 807 00:33:32,260 --> 00:33:34,662 DIFFERENT EXPERIMENTS TO ANSWER 808 00:33:34,662 --> 00:33:37,899 THESE, THESE ARE INCLUDING KALGT 809 00:33:37,899 --> 00:33:38,533 AND MILK STUDIES. 810 00:33:38,533 --> 00:33:42,737 I WANT TO ADDRESS THE CATTLE 811 00:33:42,737 --> 00:33:44,572 STUDIES TODAY BUT I DO NOT HAVE 812 00:33:44,572 --> 00:33:46,775 DATA TO SHOW YOU BUT THESE ARE 813 00:33:46,775 --> 00:33:48,510 STUDIES BEING DONE IN HIGH 814 00:33:48,510 --> 00:33:51,946 CONTAIN AM SO BSL3 AG 815 00:33:51,946 --> 00:33:52,981 ENVIRONMENTS WHERE THEY'RE 816 00:33:52,981 --> 00:33:56,284 RETROFIT WIDE MILK EQUIPMENT 817 00:33:56,284 --> 00:33:57,418 BECAUSE THESE LACTATING KALGT 818 00:33:57,418 --> 00:33:59,854 HAVE TO BE MILK AT LEAST ONCE A 819 00:33:59,854 --> 00:34:00,188 DAY. 820 00:34:00,188 --> 00:34:02,891 THIS IS A HUGE UNDERTAKING FOR 821 00:34:02,891 --> 00:34:03,958 OUR INVESTIGATORS AS YOU CAN 822 00:34:03,958 --> 00:34:08,830 IMAGINE, AND THE STUDIES ARE 823 00:34:08,830 --> 00:34:10,365 ALL--THE PART OF BEING ONGOING 824 00:34:10,365 --> 00:34:12,000 OR JUST STARTING TODAY AND 825 00:34:12,000 --> 00:34:14,669 THEY'RE IDENTIFYING THE SITE OF 826 00:34:14,669 --> 00:34:16,404 VIRAL REPLICATION, CHARACTERIZED 827 00:34:16,404 --> 00:34:18,573 IN CLINICAL SIZE AND TIMELINE 828 00:34:18,573 --> 00:34:19,507 SHEDDING AND UNDERSTANDING 829 00:34:19,507 --> 00:34:21,009 TRANSMISSION, AND SO THIS 830 00:34:21,009 --> 00:34:21,709 TRANSMISSION PIECE IS 831 00:34:21,709 --> 00:34:22,310 PARTICULARLY IMPORTANT BECAUSE 832 00:34:22,310 --> 00:34:25,146 THIS IS SOMETHING THAT WE STILL 833 00:34:25,146 --> 00:34:26,381 HAVEN'T NAILED DOWN. 834 00:34:26,381 --> 00:34:27,482 IT BECAME FAIRLY CLEAR WITHIN 835 00:34:27,482 --> 00:34:29,350 THE FIRST 2 WEEKS OR SO OF THE 836 00:34:29,350 --> 00:34:31,653 OUTBREAK, WHERE WE'RE SEEING 837 00:34:31,653 --> 00:34:34,722 VIRUS SPREAD VERY RAPIDLY ACROSS 838 00:34:34,722 --> 00:34:36,991 THE MIDWEST, BUT IT'S NOT A 839 00:34:36,991 --> 00:34:38,059 DIRECT INTRODUCTION FROM WILD 840 00:34:38,059 --> 00:34:39,561 BIRTHS TO EACH STATE. 841 00:34:39,561 --> 00:34:44,999 WE'RE SEEING VIRUS FROM TEXAS BE 842 00:34:44,999 --> 00:34:45,967 GENETICALLY IDENTICAL FROM 843 00:34:45,967 --> 00:34:48,069 MICHIGAN AND WE KNOW IT'S BEEN 844 00:34:48,069 --> 00:34:49,103 TRANSFERRED TO THE 2 STATES AND 845 00:34:49,103 --> 00:34:50,638 THAT LED US TO KNOW THAT THERE 846 00:34:50,638 --> 00:34:52,340 IS MOVEMENT WITH THE HEARD BUT 847 00:34:52,340 --> 00:34:55,643 WHAT WE DON'T HUNDRED IS IF 848 00:34:55,643 --> 00:34:56,711 THERE'S COW-COW TRANSMISSION OR 849 00:34:56,711 --> 00:34:58,246 IF WE'RE GETTING DIRECT 850 00:34:58,246 --> 00:34:58,847 MECHANICAL TRANSITION IF YOU 851 00:34:58,847 --> 00:35:01,983 WILL FROM THE MILK PARLORS, SO 852 00:35:01,983 --> 00:35:06,487 WE'RE HOPING TO GET AN ANSWER O 853 00:35:06,487 --> 00:35:08,223 THOSE QUESTIONS WITH THE STUDY 854 00:35:08,223 --> 00:35:09,390 ONGOING AND UNDERSTAND ANY IMP 855 00:35:09,390 --> 00:35:11,593 KAYITIONS TO COW TO KAF FEEDING 856 00:35:11,593 --> 00:35:12,894 OR MILK CONSUCHGZ IF QUEER 857 00:35:12,894 --> 00:35:13,728 GETTING TRANSMISSION THERE AS 858 00:35:13,728 --> 00:35:14,062 WELL. 859 00:35:14,062 --> 00:35:20,668 WE ALSO HAVE AN H5 HA MRNA 860 00:35:20,668 --> 00:35:22,070 VACCINE STUDY, SO HOPEFULLY IT 861 00:35:22,070 --> 00:35:28,009 WILL BE A FEW WEEKS BEFORE WE 862 00:35:28,009 --> 00:35:28,676 GET DATA THERE. 863 00:35:28,676 --> 00:35:32,146 SO I WOULD LIKE TO HIGHLIGHT THE 864 00:35:32,146 --> 00:35:35,216 MILK STUDIES, WHICH IS SOMETHING 865 00:35:35,216 --> 00:35:37,085 THAT ANY VIROLOGIST WOULD SAY, 866 00:35:37,085 --> 00:35:39,020 I'M LOOKING AT RETAIL MILK 867 00:35:39,020 --> 00:35:41,122 EMPLOY BUT WE CATEGORIZED THEM 868 00:35:41,122 --> 00:35:42,891 INTO 2 STUDIES, SO THE IMMEDIATE 869 00:35:42,891 --> 00:35:44,626 QUESTION FOR RAW MILK IS 870 00:35:44,626 --> 00:35:46,661 UNDERSTANDING THE EFFICACY OF 871 00:35:46,661 --> 00:35:47,729 HEAT TREATMENT AND THEN 872 00:35:47,729 --> 00:35:49,497 ACTIVATING THE RIHAVE YOU SEEN 873 00:35:49,497 --> 00:35:51,900 BECAUSE PASTEURIZATION WAS MEANT 874 00:35:51,900 --> 00:35:52,867 TO ADDRESS PACTERIAL 875 00:35:52,867 --> 00:35:53,801 CONTAMINATION, NOT REALLY 876 00:35:53,801 --> 00:35:57,472 CONCERNED ABOUT VIRUS FROM THESE 877 00:35:57,472 --> 00:35:58,273 PARAMETERS WERE ESTABLISHED WE 878 00:35:58,273 --> 00:35:59,974 WOULD ALSO LIKE TO LOOK AT THE 879 00:35:59,974 --> 00:36:01,943 STABILITY OF VIRUSES ON SURVASES 880 00:36:01,943 --> 00:36:04,379 AT AEROSOLS AND AT REFRIGERATED 881 00:36:04,379 --> 00:36:05,680 TEMPERATURES AND THEN ULTIMATELY 882 00:36:05,680 --> 00:36:07,582 LOOK AT IMPLICATIONS OF RAW MILK 883 00:36:07,582 --> 00:36:09,450 INGESTION AND THEN ON THE 884 00:36:09,450 --> 00:36:10,852 PASTEURIZED MILK SIDE, WE WANTED 885 00:36:10,852 --> 00:36:12,520 TO START LOOK BEING AT RETAIL 886 00:36:12,520 --> 00:36:14,355 MILK TESTING AND THAT'S 1 OF THE 887 00:36:14,355 --> 00:36:17,025 FIRST STUDIES WE WERE ABLE TO 888 00:36:17,025 --> 00:36:17,458 COMPLETE. 889 00:36:17,458 --> 00:36:20,795 SO WE HAVE SOME RESEARCHERS, 890 00:36:20,795 --> 00:36:23,798 AGAIN, AFFILIATE WITH OUR SAIPT 891 00:36:23,798 --> 00:36:25,533 JUDE CEIRR CENTER AND WENT ON TO 892 00:36:25,533 --> 00:36:28,102 THE GROCERY STORE AND PURCHASED 893 00:36:28,102 --> 00:36:30,071 150 SAMPLES OF WHOLE MILK ACROSS 894 00:36:30,071 --> 00:36:30,905 THE MIDWESTERN UNITED STATES, 895 00:36:30,905 --> 00:36:32,674 THEY DIDN'T DO THIS IN A RANDOM 896 00:36:32,674 --> 00:36:34,876 WAY, THEY UNDERSTAND BY THE BAR 897 00:36:34,876 --> 00:36:35,810 CODES WHICH PROCESSING PLANTS 898 00:36:35,810 --> 00:36:38,479 AND THE DATES THAT THE MILK WAS 899 00:36:38,479 --> 00:36:39,981 SUPPLIED SO THEY WERE ABLE TO 900 00:36:39,981 --> 00:36:41,649 GET A NICE WIDE BREDTH OF 901 00:36:41,649 --> 00:36:41,983 SAMPLES. 902 00:36:41,983 --> 00:36:42,583 THERE. 903 00:36:42,583 --> 00:36:44,786 SO THEY TESTED APPROXIMATELY 150 904 00:36:44,786 --> 00:36:47,221 SAMPLES, VIA PC R, WITH H5 PROBE 905 00:36:47,221 --> 00:36:48,856 ANDS FOUND THAT 40% WERE 906 00:36:48,856 --> 00:36:50,591 POSITIVE AND THEY THEN SENT 907 00:36:50,591 --> 00:36:52,026 THOSE SAMPLES ON TO SAIPT JUDE 908 00:36:52,026 --> 00:36:54,062 WHO CONFIRMED THAT WITH A 909 00:36:54,062 --> 00:36:56,631 DIFFERENT SET OF H5 PROBES AND 910 00:36:56,631 --> 00:36:58,733 SO NOW WE KNOW WE HAVE RETAIL 911 00:36:58,733 --> 00:37:01,302 MILK THAT IS P, KREBS CYCLE R 912 00:37:01,302 --> 00:37:02,603 POSITIVE FOR INFLUENZA VIRUS SO 913 00:37:02,603 --> 00:37:04,872 THE NEXT QUESTION IS CAN LIVE 914 00:37:04,872 --> 00:37:08,609 VIRUS BE E COVERED OR THEY 915 00:37:08,609 --> 00:37:09,210 ENACTIVATED VIRAL PARTICLES. 916 00:37:09,210 --> 00:37:13,081 SO THEY DID THAT WORK BY PASSING 917 00:37:13,081 --> 00:37:19,487 THE MILK INTO EGGS AND MDCK 918 00:37:19,487 --> 00:37:22,190 CELLS, THEY DID LIVE, AND IT WAS 919 00:37:22,190 --> 00:37:25,660 NOT RECOVERED INDICATING THAT 920 00:37:25,660 --> 00:37:26,594 PASTEURIZATION KILLED THE 921 00:37:26,594 --> 00:37:28,763 BACTERIA, JUST TO BE SURE, THEY 922 00:37:28,763 --> 00:37:30,431 FED THE MICE RAW MILK AND 923 00:37:30,431 --> 00:37:32,767 APPEARS TO BE FINE, SO THESE 924 00:37:32,767 --> 00:37:33,434 ALINE QUITE NICELY WITH WHAT'S 925 00:37:33,434 --> 00:37:36,537 COMING OUT WITH THE FDA AND OUR 926 00:37:36,537 --> 00:37:37,505 COLLABORATORS, OUR INFLUENZA 927 00:37:37,505 --> 00:37:44,345 RESEARCHERS HERE HAVE BEEN 928 00:37:44,345 --> 00:37:46,314 EXTREMELY HELPFUL IN SHARING 929 00:37:46,314 --> 00:37:48,182 RESULTS AND PARAMETERS AND 930 00:37:48,182 --> 00:37:52,820 COLLEAGUES AT THE FDA AS WELL. 931 00:37:52,820 --> 00:37:55,156 SEE THE NEXT POINT WE ARE MOVING 932 00:37:55,156 --> 00:37:58,226 FROM OUR PASTEURIZED MILK TO 933 00:37:58,226 --> 00:38:00,061 TESTING AND WE FOWBD THAT VIRUS 934 00:38:00,061 --> 00:38:02,997 AND MILK HAS A MUCH HIGHER LEVEL 935 00:38:02,997 --> 00:38:04,732 OF CIVILITY THAN VIRUS AND LIKE 936 00:38:04,732 --> 00:38:08,369 PBS WHICH IS INTERESTING AS 937 00:38:08,369 --> 00:38:09,437 WE'RE THINKING ABOUT KIND OF 938 00:38:09,437 --> 00:38:11,906 RISK OF ECPOSURE IN THESE 939 00:38:11,906 --> 00:38:13,608 MILKING PARTNERS, OUR 940 00:38:13,608 --> 00:38:15,109 INVESTIGATORS FOUND THAT VIRUS 941 00:38:15,109 --> 00:38:17,412 AND RAW MILK CO PERSIST ON 942 00:38:17,412 --> 00:38:21,082 RUBBER LINERS AND PLASTIC ON 70% 943 00:38:21,082 --> 00:38:22,116 RELATIVE HUMIDITY FOR WELL OVER 944 00:38:22,116 --> 00:38:23,785 AN HOUR AND WHEN YOU ARE 945 00:38:23,785 --> 00:38:25,753 THINKINGOT GROUND AND YOU'RE 946 00:38:25,753 --> 00:38:27,588 MOVING COWS RAPIDLY IN AND OUT 947 00:38:27,588 --> 00:38:30,258 OF THE MILK PARLOR AS WELL AS 948 00:38:30,258 --> 00:38:31,993 DAIRY WORKERS, THERE'S A LOT OF 949 00:38:31,993 --> 00:38:33,628 LIVE VIRUS JUST HANGING AROUND. 950 00:38:33,628 --> 00:38:35,963 AND AGAIN THIS WORK HAS NOW BEEN 951 00:38:35,963 --> 00:38:37,465 PUBLISHED AS A PREPRINT AND IS 952 00:38:37,465 --> 00:38:40,902 ALSO CAN BE FOUND ON OUR 953 00:38:40,902 --> 00:38:41,769 CEIRR WEBSITE IF YOU ARE 954 00:38:41,769 --> 00:38:42,737 INTERESTED IN LEARNING MORE. 955 00:38:42,737 --> 00:38:44,172 SO THE FINAL PIECE OF WORK I 956 00:38:44,172 --> 00:38:46,407 WOULD LIKE TO HIGHLIGHT, THIS IS 957 00:38:46,407 --> 00:38:47,775 JUST RECENTLY PUBLISHED IN THE 958 00:38:47,775 --> 00:38:49,243 NEW ENGLAND JOURNAL OF MEDICINE 959 00:38:49,243 --> 00:38:50,745 ON PAY 24th, AND THIS IS 960 00:38:50,745 --> 00:38:53,247 PRACTICES A GROUP AFFILIATED 961 00:38:53,247 --> 00:38:56,084 WITH OUR CRYPT CEIRR CENTER 962 00:38:56,084 --> 00:38:58,519 WHICH IS MT. SINAI AND THEY DID 963 00:38:58,519 --> 00:39:00,488 A VARIETY OF MILK STUDIES WITH 964 00:39:00,488 --> 00:39:01,189 RAW MILK. 965 00:39:01,189 --> 00:39:02,757 THE FIRST THING THEY DID WAS 966 00:39:02,757 --> 00:39:03,858 HEAT TREATMENT STUDIES AND THEY 967 00:39:03,858 --> 00:39:06,194 WERE LOOKING AT THE PARAMETERS 968 00:39:06,194 --> 00:39:09,897 FOR 2 MONITOR PASTEURIZATION 969 00:39:09,897 --> 00:39:13,201 METHODS, THIS IS VAT PASTEURIZE 970 00:39:13,201 --> 00:39:15,837 EXPIGZ HIGH TEMPERATURE PASTURE 971 00:39:15,837 --> 00:39:20,408 EYATION, SO THIS EXISTS OF 30 972 00:39:20,408 --> 00:39:22,376 MINUTES AT 63-DEGREES FOR A 973 00:39:22,376 --> 00:39:26,214 LARGE VOLUME OF LIQUID AND THE 974 00:39:26,214 --> 00:39:28,316 OTHERS IS 72-DEGREES CELSIUS FOR 975 00:39:28,316 --> 00:39:30,518 152ndS BUT IT'S A CONTINUOUS 976 00:39:30,518 --> 00:39:31,886 SLOW PASTEURIZATION, AND THIS IS 977 00:39:31,886 --> 00:39:33,888 A SMALL TUBE THAT THE MILK IS 978 00:39:33,888 --> 00:39:35,723 MOVED THROUGH AND THE LIQUID IS 979 00:39:35,723 --> 00:39:36,357 CONSTANTLY MOVING. 980 00:39:36,357 --> 00:39:38,259 SO THAT ASPECT OF IT COULD NOT 981 00:39:38,259 --> 00:39:40,761 BE RECAPITULATED IN THE LAB, THE 982 00:39:40,761 --> 00:39:42,330 ONLY THINK THIS THEY COULD 983 00:39:42,330 --> 00:39:43,965 RECREATE WERE THE TIME AND 984 00:39:43,965 --> 00:39:44,665 TEMPERATURE PARAMETERS. 985 00:39:44,665 --> 00:39:48,035 AND SO THEY FOUND THAT THAT 986 00:39:48,035 --> 00:39:48,970 PASTEURIZATION DOES ENACTIVATE 987 00:39:48,970 --> 00:39:51,672 THE VIRUS FULLY BUT WELL IS 988 00:39:51,672 --> 00:39:52,607 RESIDUAL ACTIVITY DETECTED 989 00:39:52,607 --> 00:39:53,641 FOLLOWING THE HIGH TEMPERATURE 990 00:39:53,641 --> 00:39:55,376 SHORT TIME WHICH AGAIN JUST 991 00:39:55,376 --> 00:39:57,311 INDICATES THAT THE INDUSTRIAL 992 00:39:57,311 --> 00:39:58,946 CONDITIONS, THE CONTINUOUS FLOW, 993 00:39:58,946 --> 00:40:00,381 CONTINUES AND NEEDS TO BE LOOKED 994 00:40:00,381 --> 00:40:02,783 AT, WHICH ARE STUDIES THAT ARE 995 00:40:02,783 --> 00:40:05,720 NOW ONGOING WITH THE USDA ARS. 996 00:40:05,720 --> 00:40:07,855 SO THEY ALSO LOOKED AT VIRUS 997 00:40:07,855 --> 00:40:10,591 STABILITY IN RAW MILK AT 998 00:40:10,591 --> 00:40:12,126 4-DEGREES CELSIUS, BASICALLY 999 00:40:12,126 --> 00:40:13,394 JUST REFREJERATED SAMPLES OVER A 1000 00:40:13,394 --> 00:40:15,696 5 WEEK PERIOD AND IT OHM RESULTS 1001 00:40:15,696 --> 00:40:17,899 IN ABOUT 1-2 LOG DECLINE OF 1002 00:40:17,899 --> 00:40:20,902 VIRUS TITER WHICH OF COURSE HAS 1003 00:40:20,902 --> 00:40:23,404 IMPLICATIONS FOR, KIND OF THE 1004 00:40:23,404 --> 00:40:24,438 RAW MILK COMSUMPTION MARKET IF 1005 00:40:24,438 --> 00:40:26,507 YOU STORE RAW MILK FOR A LONG 1006 00:40:26,507 --> 00:40:31,179 TIME, IT'S STILL REMAINS 1007 00:40:31,179 --> 00:40:32,613 INFECTIOUS WHICH IS PROBLEMATIC, 1008 00:40:32,613 --> 00:40:38,586 THIS IS ANOTHER, WELL, ARE 1009 00:40:38,586 --> 00:40:42,690 FURTHER TAKEN ON BY LOOKING AT 1010 00:40:42,690 --> 00:40:45,092 ORAL INGESTION, WHERE THEY FED 1011 00:40:45,092 --> 00:40:46,794 MICE INFECTIOUS MILK AND THEY 1012 00:40:46,794 --> 00:40:48,763 DETERMINED THAT 1-2 DAYS OF 1013 00:40:48,763 --> 00:40:52,099 FEEDING, THE MICE ARE DEVELOPING 1014 00:40:52,099 --> 00:40:53,267 CLINICAL SYMPTOMS, ALL 1015 00:40:53,267 --> 00:40:54,802 EUTHANIZED BY DAY 4 AND THEY 1016 00:40:54,802 --> 00:41:01,776 FOUND HIGH TITERS IN THE LUNG, 1017 00:41:01,776 --> 00:41:04,078 TRAISHIA AND NAIS AT TURBINATES. 1018 00:41:04,078 --> 00:41:06,047 SO THAT WAS A PREY QUICK ROLL IN 1019 00:41:06,047 --> 00:41:11,652 TO SOME OF OUR EARLY ACTIVITIES 1020 00:41:11,652 --> 00:41:12,987 THERE IS A LOT OF WORK BEING 1021 00:41:12,987 --> 00:41:14,689 DONE BUT FOR NOW I'M HAPPY TO 1022 00:41:14,689 --> 00:41:25,032 TAKE ANY QUESTIONS. 1023 00:41:26,934 --> 00:41:27,068 OKAY. 1024 00:41:27,068 --> 00:41:30,371 >> SO WHEN IT SHOWS 40% 1025 00:41:30,371 --> 00:41:31,872 POSITIVE, IT'S THE MILK GETS 1026 00:41:31,872 --> 00:41:35,676 FULL, DO HAVE YOU ANY IDEA HOW 1027 00:41:35,676 --> 00:41:37,278 MANY INDIVIDUAL ANIMALS, HAVE 1028 00:41:37,278 --> 00:41:38,446 YOU LOOKED AT INDIVIDUAL 1029 00:41:38,446 --> 00:41:40,748 SAMPLES, IS THAT LIKE FROM 1 1030 00:41:40,748 --> 00:41:44,285 SUPER SHEDDER OR IS THAT 1031 00:41:44,285 --> 00:41:46,988 REFLECTING MULTIPLE INFECTIONS 1032 00:41:46,988 --> 00:41:47,955 WITHIN A GROUP? 1033 00:41:47,955 --> 00:41:48,556 >> THAT'S A REALLY GREAT 1034 00:41:48,556 --> 00:41:49,957 QUESTION AND SOMETHING WE ARE 1035 00:41:49,957 --> 00:41:51,359 CURRENTLY TRYING TO UNDERSTAND 1036 00:41:51,359 --> 00:41:53,094 HOW BEST TO REPRESENT BECAUSE 1037 00:41:53,094 --> 00:41:54,629 YOU'RE ABSOLUTELY RIGHT, THERE'S 1038 00:41:54,629 --> 00:41:56,697 A DIFFERENCE FROM A SAMPLE 1039 00:41:56,697 --> 00:42:03,804 COMING OFF THE FARM VERSUS 1040 00:42:03,804 --> 00:42:04,605 COMING OFF THE STORE. 1041 00:42:04,605 --> 00:42:06,707 WE WERE NOT NECESSARILY 1042 00:42:06,707 --> 00:42:08,009 INTERESTED IN TRACING THEM 1043 00:42:08,009 --> 00:42:09,744 FURTHER THAN THAT. 1044 00:42:09,744 --> 00:42:12,046 AGAIN, GETTING IT--THESE ACCESS 1045 00:42:12,046 --> 00:42:16,917 ISSUES USDA AND NOT WANTING TO 1046 00:42:16,917 --> 00:42:19,453 MAYBE FALSELY IDENTIFY A FARM AS 1047 00:42:19,453 --> 00:42:20,321 HAVING FALSE-POSITIVE IF THEY 1048 00:42:20,321 --> 00:42:22,456 DON'T BUT IT IS AN EXCELLENT 1049 00:42:22,456 --> 00:42:22,890 CONSIDERATION. 1050 00:42:22,890 --> 00:42:25,660 BUT THE VIRUS MUST BE IN OTHER 1051 00:42:25,660 --> 00:42:27,495 HERDS OR OTHER STATES, ARE YOU 1052 00:42:27,495 --> 00:42:28,929 LOOKING IN WASTE WATER, IN TEXAS 1053 00:42:28,929 --> 00:42:34,001 THEY'RE DOING THAT BUT IS-- 1054 00:42:34,001 --> 00:42:35,303 >> YES, SO, CEIRR INVESTIGATORS 1055 00:42:35,303 --> 00:42:37,104 ARE NOT CURRENTLY LOOKING IN 1056 00:42:37,104 --> 00:42:37,972 WASTE WATER ALTHOUGH WE HAVE THE 1057 00:42:37,972 --> 00:42:39,840 SAIBILITY TO DO SO, WE HAVE H5 1058 00:42:39,840 --> 00:42:40,908 PROBES WHICH IS SOMETHING THAT I 1059 00:42:40,908 --> 00:42:43,811 THINK WE ARE COLLABORATING WITH 1060 00:42:43,811 --> 00:42:45,546 CDC ON, CDC IS STARTING THOSE 1061 00:42:45,546 --> 00:42:46,947 EFFORTS IN EARNEST AND OF COURSE 1062 00:42:46,947 --> 00:42:48,249 THERE'S WATER SCAN WHICH HAS 1063 00:42:48,249 --> 00:42:53,187 BEEN DOING THIS FOR A WHILE. 1064 00:42:53,187 --> 00:42:56,657 THEY HAVE EXISTING CAN INFLUENZA 1065 00:42:56,657 --> 00:42:57,625 DATA BUT EVERYONE'S MOVING TRS 1066 00:42:57,625 --> 00:42:59,460 TRYING TO GET TO H5 SPECIFIC 1067 00:42:59,460 --> 00:43:01,429 DATA BUT THE WASTE PAWRT DATA HA 1068 00:43:01,429 --> 00:43:04,865 IS COMING OUT IS INTERESTING, 1069 00:43:04,865 --> 00:43:06,500 IT'S SHOWING SPIKES IN WILL 1070 00:43:06,500 --> 00:43:08,102 KACCTICAL, BUT NOT SHOWN 1071 00:43:08,102 --> 00:43:09,170 POSITIVE FOR DAIRY HERD 1072 00:43:09,170 --> 00:43:10,371 INFECTION, SO IT'S TRACKING DOWN 1073 00:43:10,371 --> 00:43:14,408 AND PARSING OUT WHAT THAT DATA 1074 00:43:14,408 --> 00:43:15,142 ACTUALLY MEANS. 1075 00:43:15,142 --> 00:43:16,777 WHILE NOT HAVING ACCESS TO THE 1076 00:43:16,777 --> 00:43:19,480 INDIVIDUAL FARM, IT'S AN 1077 00:43:19,480 --> 00:43:27,488 EPIDEMIOLOGICAL HURDLE, FOR 1078 00:43:27,488 --> 00:43:27,688 SURE. 1079 00:43:27,688 --> 00:43:29,023 >> AS THIS BEEN SEEN IN EUROPE. 1080 00:43:29,023 --> 00:43:30,758 >> NOT THAT WE ARE AWARE OF YET 1081 00:43:30,758 --> 00:43:32,827 AND WE HAVE INVESTIGATORS FROM 1082 00:43:32,827 --> 00:43:34,662 EUROPE THAT ARE COLLABORATORS 1083 00:43:34,662 --> 00:43:36,997 AND MEMBERS OF THE SERUM NETWORK 1084 00:43:36,997 --> 00:43:39,867 JOINING THE CALLS AND THERE ARE 1085 00:43:39,867 --> 00:43:41,168 ALSO EXPERIENCING SOME SIMILAR 1086 00:43:41,168 --> 00:43:43,337 HESITANCY FOR TESTING THERE, I 1087 00:43:43,337 --> 00:43:46,407 THINK MAYBE PEOPLE DON'T WANT TO 1088 00:43:46,407 --> 00:43:49,643 KNOW, BUT, YES, THEY ARE FROM 1089 00:43:49,643 --> 00:43:52,947 WHAT WE HAVE HEARD FROM THE, 1090 00:43:52,947 --> 00:43:54,281 LIKE DAIRY'S AFFILIATED WITH 1091 00:43:54,281 --> 00:44:02,089 ACADEMIC CENTERS, THEY'RE NOT 1092 00:44:02,089 --> 00:44:03,691 SHOWING ANY HIGH PATH. 1093 00:44:03,691 --> 00:44:06,026 >> LAUREN IS SALE OF RAW MILK 1094 00:44:06,026 --> 00:44:07,762 STILL ALLOWED IN THE STATES 1095 00:44:07,762 --> 00:44:09,864 WHERE THE OUTBREAKS ARE 1096 00:44:09,864 --> 00:44:10,564 OCCURRING? 1097 00:44:10,564 --> 00:44:11,599 >> YES, THAT'S THE BIG STICKING 1098 00:44:11,599 --> 00:44:13,100 POINT AND WHERE WE'RE TRYING TO 1099 00:44:13,100 --> 00:44:16,771 PUBLISH THE RAW MILK STUDIES, 1100 00:44:16,771 --> 00:44:18,672 THE FDA CAN ONLY CONTROL 1101 00:44:18,672 --> 00:44:20,441 INTERSTATE OR CROSS STATE LINES 1102 00:44:20,441 --> 00:44:23,144 OF RAW MILK WHICH IS ILLEGAL AND 1103 00:44:23,144 --> 00:44:25,379 IT DEPENDS ON THE STATE AND 1104 00:44:25,379 --> 00:44:26,680 THEIR LOCAL JURISDICTIONS BUT 1105 00:44:26,680 --> 00:44:28,382 MANY OF THEM HAVE THAT RAW MILK 1106 00:44:28,382 --> 00:44:30,217 IS LEGAL TO OBTAIN AND CONSUME. 1107 00:44:30,217 --> 00:44:31,886 >> THIS IS AN EXAMPLE WHERE WE 1108 00:44:31,886 --> 00:44:32,920 TALKED ABOUT COMMUNICATION WAS 1109 00:44:32,920 --> 00:44:35,122 BROUGHT UP THIS MORNING AND I 1110 00:44:35,122 --> 00:44:39,393 KNOW PROBABLY THE POPULATION 1111 00:44:39,393 --> 00:44:41,662 DOESN'T WANT TO BE TOLL THEY 1112 00:44:41,662 --> 00:44:43,164 CAN'T DRINK RAW MILK BUT MAYBE 1113 00:44:43,164 --> 00:44:44,799 THIS WOULD BE A CASE WHERE YOU 1114 00:44:44,799 --> 00:44:46,000 COULD TRY, WHAT ARE THE RIGHT 1115 00:44:46,000 --> 00:44:48,803 PEOPLE TO TRY TO EDUCATE PEOPLE 1116 00:44:48,803 --> 00:44:51,038 TO NOT DRINK RAW MILK AT THE 1117 00:44:51,038 --> 00:44:52,973 MOMENT AT LEAST NI THINK THE 1118 00:44:52,973 --> 00:44:55,075 MESSAGING AS GONE OUT AND IT'S 1119 00:44:55,075 --> 00:44:57,044 BEEN REITERATED A NUMBER OF 1120 00:44:57,044 --> 00:44:57,378 TIMES. 1121 00:44:57,378 --> 00:44:59,013 I'VE HEARD THOUGH THAT 1122 00:44:59,013 --> 00:45:01,315 SUBSEQUENT TO THESE REPORTS, THE 1123 00:45:01,315 --> 00:45:05,186 RAW MILK DRINKERS HAVE ONLY 1124 00:45:05,186 --> 00:45:05,986 INCREASED THEIR ENTHUSIASM FOR 1125 00:45:05,986 --> 00:45:10,157 THAT TYPE OF MILK. 1126 00:45:10,157 --> 00:45:11,459 IT'S PARADOXICAL TO ME BUT 1127 00:45:11,459 --> 00:45:13,294 THAT'S WHAT PEOPLE REPORT. 1128 00:45:13,294 --> 00:45:19,834 SO, YEAH, IT'S A PROBLEM. 1129 00:45:19,834 --> 00:45:22,336 >> [INDISCERNIBLE] GET RID OF 1130 00:45:22,336 --> 00:45:24,004 RAW MILK DRINKING H5 N1 DOESN'T 1131 00:45:24,004 --> 00:45:25,005 HAVE A CHANCE. 1132 00:45:25,005 --> 00:45:26,974 >> YOU HEARD IT SOMEWHAT AKIN TO 1133 00:45:26,974 --> 00:45:28,476 CHICKEN POX PARTIES WHERE PEOPLE 1134 00:45:28,476 --> 00:45:32,279 ARE ALMOST ASKING FOR ACCESS TO 1135 00:45:32,279 --> 00:45:32,713 RAW MILK. 1136 00:45:32,713 --> 00:45:34,482 >> I THINK WE HAVE A COMMENT 1137 00:45:34,482 --> 00:45:38,486 ONLINE FROM OUR CDC EXOFFICIO 1138 00:45:38,486 --> 00:45:40,354 MEMBER, DAN, DO YOU HAVE A 1139 00:45:40,354 --> 00:45:40,654 MICROPHONE? 1140 00:45:40,654 --> 00:45:42,189 CAN YOU SPEAK UP? 1141 00:45:42,189 --> 00:45:43,591 >> YEAH, IT WAS JUST TO THE 1142 00:45:43,591 --> 00:45:44,859 COMMENT ON THE WASTE WATER 1143 00:45:44,859 --> 00:45:47,862 TESTING THAT WE ARE ACTUALLY 1144 00:45:47,862 --> 00:45:49,463 INITIATING H5 SPECIFIC WASTE 1145 00:45:49,463 --> 00:45:50,831 WATER TESTING FOR SPECIFIC 1146 00:45:50,831 --> 00:45:52,199 LOCATIONS NOW AND THEN WASTE 1147 00:45:52,199 --> 00:45:55,803 WATER SCAN LIKE WAS MENTIONED IS 1148 00:45:55,803 --> 00:45:58,639 DOING THE H5 TESTING ALREADY, 1149 00:45:58,639 --> 00:45:59,807 BUT IT'S--IT IS A BRAVE NEW 1150 00:45:59,807 --> 00:46:01,342 WORLD TRYING TO FIGURE OUT HOW 1151 00:46:01,342 --> 00:46:03,210 EXACTLY HOW TO DO ALL THE WASTE 1152 00:46:03,210 --> 00:46:04,378 WATER TESTING BECAUSE IT DOES 1153 00:46:04,378 --> 00:46:06,380 REFLECT A MIX OF DUMPING OF 1154 00:46:06,380 --> 00:46:08,282 MILK, POSSIBLE HUMAN INFECTIONS, 1155 00:46:08,282 --> 00:46:09,583 BIRDS, ET CETERA, SO THERE'S A 1156 00:46:09,583 --> 00:46:11,418 LOT TO BE LEARNED BUT A LOT THAT 1157 00:46:11,418 --> 00:46:13,787 CAN BE DONE WITH WASTE FAWRT, 1158 00:46:13,787 --> 00:46:15,856 ESPECIALLY AND TESTING GETS VERY 1159 00:46:15,856 --> 00:46:18,759 COMPLICATED RIGHT NOW AND TO THE 1160 00:46:18,759 --> 00:46:23,831 POINT OF THE RAW MILK DRINKERS 1161 00:46:23,831 --> 00:46:27,067 ON YOUR SCORE, EMILLY'S COMMENT, 1162 00:46:27,067 --> 00:46:30,571 THERE ARE THOSE ACTIVELY SEEKING 1163 00:46:30,571 --> 00:46:33,607 OUT H5 N1 MILK SO THEY CAN GET 1164 00:46:33,607 --> 00:46:36,143 THE BENEFICIAL EXPOSURE TO THE 1165 00:46:36,143 --> 00:46:36,844 PATHOGENS THERE BECAUSE THEY 1166 00:46:36,844 --> 00:46:39,413 BELIEVE THE USE OF UNPASTEURIZED 1167 00:46:39,413 --> 00:46:49,823 MILK IS HELPFUL TO THEM. 1168 00:46:59,199 --> 00:46:59,567 >> THANK YOU LAUREN. 1169 00:46:59,567 --> 00:47:03,070 SO WE WILL MOVE FORWARD ON THE 1170 00:47:03,070 --> 00:47:06,507 ARK JEBDA NOW WITH PRESENTING 1171 00:47:06,507 --> 00:47:09,677 THE FISCAL YEAR 26 CONCEPTS FOR 1172 00:47:09,677 --> 00:47:12,112 COUNCIL CLEARANCE, THESE ARE FOR 1173 00:47:12,112 --> 00:47:13,614 NEW INITIATIVES THAT WOULD BE 1174 00:47:13,614 --> 00:47:15,249 FUNDED IN NEW YEAR 26. 1175 00:47:15,249 --> 00:47:21,322 OUR FIRST PRESENTER IS NANCY 1176 00:47:21,322 --> 00:47:25,492 ERNST, WHO IS THE PROFESSOR OF 1177 00:47:25,492 --> 00:47:26,660 COLLEGE AT DMID. 1178 00:47:26,660 --> 00:47:28,128 >> YES, THANK YOU. 1179 00:47:28,128 --> 00:47:30,431 IT'S A REALLY HARD PRESENTATION 1180 00:47:30,431 --> 00:47:31,966 TO FOLLOW WITH A REALLY BIG 1181 00:47:31,966 --> 00:47:33,601 CHANGE OF TOPIC HERE, I'M HERE 1182 00:47:33,601 --> 00:47:36,870 TO PRECEPT THE CONCEPT FOR THE 1183 00:47:36,870 --> 00:47:40,240 COMBATING ANTIBIOTIC RESISTANT 1184 00:47:40,240 --> 00:47:41,075 BACTERIA, INTERDISCIPLINARY 1185 00:47:41,075 --> 00:47:42,409 RESEARCH UNITS WHAT I WILLY 1186 00:47:42,409 --> 00:47:47,615 REFER TO KNOWN AS AS THE 1187 00:47:47,615 --> 00:47:47,881 CARBAROOs. 1188 00:47:47,881 --> 00:47:51,085 SO THIS CONCEPT IS TO SUPPORT 1189 00:47:51,085 --> 00:47:51,619 MULTIDISCIPLINARY RESEARCH 1190 00:47:51,619 --> 00:47:52,953 CENTERS FOCUSED ON DISCOVERY TO 1191 00:47:52,953 --> 00:47:54,888 EARLY DEVELOPMENT RESEARCH, TO 1192 00:47:54,888 --> 00:47:56,857 INFORM NEW APPROACHES TO PREVENT 1193 00:47:56,857 --> 00:47:59,960 DIAGNOSE AND TREAT ANTIBIOTIC 1194 00:47:59,960 --> 00:48:00,427 RESISTANT INFECTIONS. 1195 00:48:00,427 --> 00:48:02,696 AND SO THIS IS A NEW INITIATIVE, 1196 00:48:02,696 --> 00:48:05,866 BUT IT BUILDS ON A PREVIOUS 1197 00:48:05,866 --> 00:48:07,601 PROGRAM AND IT'S NEW BECAUSE 1198 00:48:07,601 --> 00:48:09,336 WE'RE CHANGING FROM A 1199 00:48:09,336 --> 00:48:10,504 COOPERATIVE AGREEMENT MECHANISM 1200 00:48:10,504 --> 00:48:15,909 TO A PO1 MECHANISM NOW I SHOULD 1201 00:48:15,909 --> 00:48:17,311 NOTE THAT BOTH OF THESE 1202 00:48:17,311 --> 00:48:19,647 MECHANISMS ARE SIMILAR IN 1203 00:48:19,647 --> 00:48:21,782 STRUCTURE, THEY'RE BOTH 1204 00:48:21,782 --> 00:48:24,451 MULTIPROJECT AND 1205 00:48:24,451 --> 00:48:25,953 MULTIDISCIPLINARY AND THEY 1206 00:48:25,953 --> 00:48:28,589 PROMOTE SYNERGY AMONG THE 1207 00:48:28,589 --> 00:48:31,659 PROJECTS AND INCLUDE 1208 00:48:31,659 --> 00:48:33,594 INVESTIGATIONS WITH DIVERSE SETS 1209 00:48:33,594 --> 00:48:34,428 OF EXPERTISE. 1210 00:48:34,428 --> 00:48:37,231 THIS CHANGE ALLOWS FOR 1211 00:48:37,231 --> 00:48:41,268 MAINTAINING A MULTIDISCIPLINARY 1212 00:48:41,268 --> 00:48:45,506 STRUCTURE, WHILE NOT BEING 1213 00:48:45,506 --> 00:48:46,340 OVERLY ADMINISTRATIVELY CUM 1214 00:48:46,340 --> 00:48:48,375 BUYERSOME EMPLOY SO WE 1215 00:48:48,375 --> 00:48:50,177 ANTICIPATE 4-5 ARK WARDS WITH 1216 00:48:50,177 --> 00:48:55,516 THE 50 YEAR COST OF $10 MILLION. 1217 00:48:55,516 --> 00:48:57,651 SO I PROBABLY DON'T HAVE TO TELL 1218 00:48:57,651 --> 00:48:58,819 YOU THAT ANTIBIOTIC RESISTANCE 1219 00:48:58,819 --> 00:49:02,222 IS A GROWING PUBLIC HEALTH 1220 00:49:02,222 --> 00:49:02,456 THREAT. 1221 00:49:02,456 --> 00:49:06,427 IN 2022, A GROUP OF 1222 00:49:06,427 --> 00:49:07,494 INTERNATIONAL INVESTIGATORS 1223 00:49:07,494 --> 00:49:10,030 REPORTED THE--1 OF THE MOST 1224 00:49:10,030 --> 00:49:11,398 COMPREHENSIVE ESTIMATES OF THE 1225 00:49:11,398 --> 00:49:16,170 GLOBE AT BURDEN OF ANTIBIOTIC 1226 00:49:16,170 --> 00:49:17,104 RESISTANCE TO DATE. 1227 00:49:17,104 --> 00:49:19,506 AND THEY ESTIMATED THAT THE 1228 00:49:19,506 --> 00:49:22,109 DEATHS ATTRIBUTABLE TO RESISTANT 1229 00:49:22,109 --> 00:49:22,943 BACTERIA WERE NEARLY EQUAL TO 1230 00:49:22,943 --> 00:49:25,813 THOSE FROM HIV AND MALARIA 1231 00:49:25,813 --> 00:49:26,080 COMBINED. 1232 00:49:26,080 --> 00:49:28,449 AND THE GRAPH ON THIS SLIDE 1233 00:49:28,449 --> 00:49:30,150 SHOWS THE TOP 2 BACTERIAL 1234 00:49:30,150 --> 00:49:32,052 PATHOGENS THAT ARE EITHER 1235 00:49:32,052 --> 00:49:35,723 ATTRIBUTABLE TOO OR ASSOCIATED 1236 00:49:35,723 --> 00:49:39,126 WITH THAT THIS DUE TO ANTIBIOTIC 1237 00:49:39,126 --> 00:49:39,560 RESISTANCE. 1238 00:49:39,560 --> 00:49:46,300 SO AS I SAID, THE CARBAROOs, 1239 00:49:46,300 --> 00:49:49,069 HAD AN EARLIER PROGRAM, IT WAS 1240 00:49:49,069 --> 00:49:52,072 SPHEABED IN 2021, WITH 2 CENTERS 1241 00:49:52,072 --> 00:49:54,141 BEING ADDED IN 2022, AND THE 1242 00:49:54,141 --> 00:49:55,008 CURRENT CENTERS ARE SHOWN HERE 1243 00:49:55,008 --> 00:49:55,709 ON THE SLIDE. 1244 00:49:55,709 --> 00:50:00,314 YOU CANEE THEY COVER A BROAD 1245 00:50:00,314 --> 00:50:01,949 SCOPE OF AREAS ON THE LEFT WE 1246 00:50:01,949 --> 00:50:04,184 HAVE 2 CENTERS THAT ARE FOCUSED 1247 00:50:04,184 --> 00:50:06,520 ON NOVEL AND NONANTIBIOTIC 1248 00:50:06,520 --> 00:50:06,954 APPROACHES. 1249 00:50:06,954 --> 00:50:08,989 THESE INCLUDE TWEPMENT OF 1250 00:50:08,989 --> 00:50:10,691 RECEPTOR ANALOGUES AND 1251 00:50:10,691 --> 00:50:12,893 MONOCLONAL ANTIBODIES TO PREVENT 1252 00:50:12,893 --> 00:50:15,129 PATHOGEN COLONIZATION AND 1253 00:50:15,129 --> 00:50:17,664 INFECTION AS WELL AS DEVELOPMENT 1254 00:50:17,664 --> 00:50:20,501 OF NEW NOVEL COMPOUNDS. 1255 00:50:20,501 --> 00:50:23,036 THEY ALSO INCLUDE IDENTIFICATION 1256 00:50:23,036 --> 00:50:27,474 OF UNIQUE PHAGE AND DEFINED 1257 00:50:27,474 --> 00:50:28,642 BACTERIAL CONSORTIA, TO PREVENT 1258 00:50:28,642 --> 00:50:31,078 AND TREAT INFECTION ANDS 1259 00:50:31,078 --> 00:50:32,045 RESISTANT INFECTIONS AT MUCOSAL 1260 00:50:32,045 --> 00:50:34,615 SITES. 1261 00:50:34,615 --> 00:50:39,319 SO THE HARVARD CARBIRU IS 1262 00:50:39,319 --> 00:50:40,954 FOCUSED ON ANTIBIOTIC TARGETS IN 1263 00:50:40,954 --> 00:50:42,589 GRAM NEGATIVE AND POSITIVE 1264 00:50:42,589 --> 00:50:44,324 BACTERIA AND THE 2 CENTERS ON 1265 00:50:44,324 --> 00:50:47,427 THE BOTTOM RIGHT ARE FOCUSED ON 1266 00:50:47,427 --> 00:50:49,830 MECHANISMS OF RESISTANCE AND 1267 00:50:49,830 --> 00:50:51,098 THEIR ASSOCIATION WITH 1268 00:50:51,098 --> 00:50:51,799 ANTIBIOTIC TREATMENT FAILURE AND 1269 00:50:51,799 --> 00:50:53,801 I SHOULD NOTE THAT THESE CENTERS 1270 00:50:53,801 --> 00:50:59,540 ARE NOT FOCUSED ON TRADITIONAL 1271 00:50:59,540 --> 00:51:03,844 MECHANISMS OF RESISTANCE BUT ON 1272 00:51:03,844 --> 00:51:06,513 TRANSIENT OR PHENOTYPIC, 1273 00:51:06,513 --> 00:51:07,648 TRANSIENT OR PHENOTYPIC CELL 1274 00:51:07,648 --> 00:51:13,921 STATES SUCH AS PERSISTENCE, 1275 00:51:13,921 --> 00:51:14,555 HETEROPERSISTENCE OR TOLERANCE. 1276 00:51:14,555 --> 00:51:19,426 SO AS I MENTIONED, AND AS YOU 1277 00:51:19,426 --> 00:51:20,994 SEE, THESE CENTERS COVER A 1278 00:51:20,994 --> 00:51:22,396 DIVERSITY OF POPPICS BUT IT'S 1279 00:51:22,396 --> 00:51:24,798 BEEN REWARDING THAT WITH THESE 1280 00:51:24,798 --> 00:51:26,834 CENTERS, AFTER COMING TOGETHER 1281 00:51:26,834 --> 00:51:28,268 IN THIS PROGRAM, HAVE FORMED 1282 00:51:28,268 --> 00:51:30,337 COLLABORATIONS AND ARE SHARING 1283 00:51:30,337 --> 00:51:34,174 TECHNOLOGIES BETWEEN THE CENTERS 1284 00:51:34,174 --> 00:51:37,444 SO IT'S REALLY BEEN AN ADMIN 1285 00:51:37,444 --> 00:51:38,879 RECORDS AND ADDED VALUE BY 1286 00:51:38,879 --> 00:51:40,581 BRINGING THEM TOGETHER. 1287 00:51:40,581 --> 00:51:44,151 SO NIAID SUPPORTS A NUMBER OF 1288 00:51:44,151 --> 00:51:44,852 PROGRAMS FOR ANTIBIOTIC 1289 00:51:44,852 --> 00:51:45,786 RESISTANCE THROUGH THE RESEARCH 1290 00:51:45,786 --> 00:51:47,754 PIPELINE AND A FEW OF THEM ARE 1291 00:51:47,754 --> 00:51:50,657 ON THIS SLIDE, THE CARBIRUs AS 1292 00:51:50,657 --> 00:51:53,760 I SAID ARE ON THE FUNDAMENTAL 1293 00:51:53,760 --> 00:51:54,895 EARLY RESEARCH TRANSLATIONAL 1294 00:51:54,895 --> 00:51:55,128 STUDIES. 1295 00:51:55,128 --> 00:51:56,930 WE ALSO HAVE VARIOUS RFAs FROM 1296 00:51:56,930 --> 00:51:59,233 TIME TO TIME FOR PATHOIEN OR 1297 00:51:59,233 --> 00:52:01,368 SPECIFIC AREAS, OUR CENTERS OF 1298 00:52:01,368 --> 00:52:02,903 EXCELLENCE FOR TRANSLATIONAL 1299 00:52:02,903 --> 00:52:05,105 RESEARCH, ARE FOCUSED MORE ON 1300 00:52:05,105 --> 00:52:06,940 TRANSLATIONAL DEVELOPMENT AND WE 1301 00:52:06,940 --> 00:52:10,010 ALSO HAVE OUR PRECLINICAL 1302 00:52:10,010 --> 00:52:12,779 SERVICES AND OUR CONTRACTS FOR 1303 00:52:12,779 --> 00:52:14,581 DEVELOPMENT OF MEDICAL 1304 00:52:14,581 --> 00:52:15,282 COUNTERMEASURES. 1305 00:52:15,282 --> 00:52:17,951 WE ALSO HAVE OUR ANTIBIOTICS 1306 00:52:17,951 --> 00:52:19,987 RESISTANCE LEADERSHIP GROUP 1307 00:52:19,987 --> 00:52:21,388 WHICH IS NAID'S CLINICAL 1308 00:52:21,388 --> 00:52:29,696 RESEARCH NETWORK FOR ANTIBIOTIC 1309 00:52:29,696 --> 00:52:32,699 RESISTANCE RESEARCH. 1310 00:52:32,699 --> 00:52:34,234 SO THE CARBIRUs HAVE BEEN IN 1311 00:52:34,234 --> 00:52:35,636 EXISTENCE FOR A COUPLE YEARS BUT 1312 00:52:35,636 --> 00:52:39,239 THEY HAVE A FEW NOTABLE 1313 00:52:39,239 --> 00:52:41,074 ACCOMPLISHMENTS ON THIS SLIDE. 1314 00:52:41,074 --> 00:52:51,318 THE FIRST IS GOING TO BE 1315 00:52:51,318 --> 00:52:52,352 ANTIBIOTICS, NOVEL ZOSURABALPIN 1316 00:52:52,352 --> 00:52:58,625 AND IT KILLS DRUG RESISTANCE 1317 00:52:58,625 --> 00:52:59,359 A.BAUMANNII, AND THEY 1318 00:52:59,359 --> 00:53:00,427 IEE, AUDIENCE DENTIFIED THAT IT 1319 00:53:00,427 --> 00:53:02,262 HAS A UNIQUE MECHANISM OF 1320 00:53:02,262 --> 00:53:03,563 ACTION, DIFFERENT THAN OTHER 1321 00:53:03,563 --> 00:53:05,065 ANTIBIOTICS THAT ARE KNOWN AND 1322 00:53:05,065 --> 00:53:07,501 THAT IT INHIBITS A COMPLEXOT 1323 00:53:07,501 --> 00:53:10,137 INNER MEMBRANE OF THE BACTERIA 1324 00:53:10,137 --> 00:53:12,105 THAT'S INVOFFED IN LPS TRANSPORT 1325 00:53:12,105 --> 00:53:15,008 THAT LEADS TO THE BUILD UP OF 1326 00:53:15,008 --> 00:53:19,846 TOXIC LEVELS OF LPS AND CELL 1327 00:53:19,846 --> 00:53:21,782 DEATH. 1328 00:53:21,782 --> 00:53:32,225 THE WASHINGTON UNIVERSITY 1329 00:53:35,562 --> 00:53:36,229 CARBIRU INVESTIGATORS STUDIED 1330 00:53:36,229 --> 00:53:40,100 GRAM-NEG5 PATHOIENS. 1331 00:53:40,100 --> 00:53:42,436 THE EMORY CARBIRU, HAS SHOWN 1332 00:53:42,436 --> 00:53:43,637 THAT HETERORESISTANCE WHICH HAS 1333 00:53:43,637 --> 00:53:46,206 I SAID IS 1 OF THESE TRANSIENT 1334 00:53:46,206 --> 00:53:49,376 MECHANISMS OF ANTIBIOTIC 1335 00:53:49,376 --> 00:53:50,944 RESISTANCE, COULD CONTRIBUTE TO 1336 00:53:50,944 --> 00:53:52,779 ANTIBIOTIC TREATMENT FAILURE 1337 00:53:52,779 --> 00:53:54,548 THAT'S BEEN OBSERVED WHICH IS A 1338 00:53:54,548 --> 00:53:56,416 NEW ANTIBIOTIC THAT HAS HAD SOME 1339 00:53:56,416 --> 00:53:59,052 CONFLICTING SUCCESS IN THE 1340 00:53:59,052 --> 00:53:59,286 CLINIC. 1341 00:53:59,286 --> 00:54:01,054 AND RECENT DATA SHOWS THAT MAY 1342 00:54:01,054 --> 00:54:06,960 BE DUE TO AMPLIFICATION OF 1343 00:54:06,960 --> 00:54:08,428 OTHERWISE INEFFECTIVE BETA 1344 00:54:08,428 --> 00:54:14,401 LACKED BASIS IN THE CELLS. 1345 00:54:14,401 --> 00:54:24,945 THE DISCOVERY OF THE NOVEL PHAGE 1346 00:54:26,980 --> 00:54:28,849 DESTROYS PSEUDOMOMAS AERAGIROSA 1347 00:54:28,849 --> 00:54:33,053 BIOFILMS SINNEST GISTIC WITH 1348 00:54:33,053 --> 00:54:33,353 ANTIBIOTICS. 1349 00:54:33,353 --> 00:54:35,922 WE ALLUDED TO IT WOULD BE 1350 00:54:35,922 --> 00:54:37,891 FUNCTIONAL CHARACTERIZATION AND 1351 00:54:37,891 --> 00:54:39,092 BOTH BACTERIAL HOST FACTOR IS 1352 00:54:39,092 --> 00:54:40,694 IMPORTANT IN INFECTION AND 1353 00:54:40,694 --> 00:54:40,994 RESISTANCE. 1354 00:54:40,994 --> 00:54:42,229 STUDIES TO IMPROVE OUR 1355 00:54:42,229 --> 00:54:44,898 UNDERSTANDING OF THE GENETIC AND 1356 00:54:44,898 --> 00:54:45,432 PHENOTYPIC MECHANISMS OF 1357 00:54:45,432 --> 00:54:51,705 RESIEVANCE AND THE ROLE IN 1358 00:54:51,705 --> 00:54:52,773 ANTIBIOTIC TREATMENT FAILURE, 1359 00:54:52,773 --> 00:54:54,274 THE DISCOVERY AND VALDATION OF 1360 00:54:54,274 --> 00:54:55,909 EARLY DRUG TARGETS AND 1361 00:54:55,909 --> 00:54:56,443 SCREENING. 1362 00:54:56,443 --> 00:54:58,011 CHARACTERIZATION AND VALIDATION 1363 00:54:58,011 --> 00:55:02,382 OF NOVEL ANTIBOTTICS AND 1364 00:55:02,382 --> 00:55:03,350 NONANTIBIOTICS PRODUCTS AS WELL 1365 00:55:03,350 --> 00:55:04,951 AS STUDIES TO IMPROVE OUR 1366 00:55:04,951 --> 00:55:06,987 UNDERSTANDING OF THE HOST 1367 00:55:06,987 --> 00:55:09,723 RESPONSE TO ELIM NAT INFECTION 1368 00:55:09,723 --> 00:55:11,491 AND UNDERSTAND HOW ORGANISMS 1369 00:55:11,491 --> 00:55:14,127 EVADE THE IMMUNE RESPONSES. 1370 00:55:14,127 --> 00:55:16,797 WE'RE ALSO INTERESTED IN STUDIES 1371 00:55:16,797 --> 00:55:17,964 ON HUMAN ASSOCIATED MICROBIAL 1372 00:55:17,964 --> 00:55:19,399 COMMUNITIES AND THE ROLE THEY 1373 00:55:19,399 --> 00:55:23,804 PLAY IN SUSCEPTIBILITY AND 1374 00:55:23,804 --> 00:55:25,072 RESISTANT TO INFECTIONS, AS WELL 1375 00:55:25,072 --> 00:55:26,740 AS THE SYSTEM LEVEL USE OF 1376 00:55:26,740 --> 00:55:28,842 APPROACHES TO IDENTIFY HOST AND 1377 00:55:28,842 --> 00:55:29,876 BACTERIAL INTERACTIONS IMPORTANT 1378 00:55:29,876 --> 00:55:39,252 FOR INFECTION AND RESISTANCE. 1379 00:55:39,252 --> 00:55:42,022 SO THE CARBIRUs WILL FOLK US 1380 00:55:42,022 --> 00:55:44,357 ONED TOP GLOBAL ANTIBIOTIC 1381 00:55:44,357 --> 00:55:46,193 RESISTANT PATHOIENS PLUS CDC 1382 00:55:46,193 --> 00:55:47,360 URGENT THREATS AS LOS ANGELESED 1383 00:55:47,360 --> 00:55:51,231 HERE, THESE WOULD BE THE 1384 00:55:51,231 --> 00:55:56,736 CARBAPENTINE REGIMEN UMKC 1385 00:55:56,736 --> 00:56:04,277 RESISTANCE AND AND KR, MDR 1386 00:56:04,277 --> 00:56:12,586 PSEUDOMONAS AERUGINOSA, DRUG 1387 00:56:12,586 --> 00:56:14,488 RESISTANT GONORRHOEAE, 1388 00:56:14,488 --> 00:56:16,356 METHICILLIN-RESISTANT STAFFY LO 1389 00:56:16,356 --> 00:56:21,027 COCCUS AURUOUS, AND VAINK O 1390 00:56:21,027 --> 00:56:22,996 MICEIN-RESISTANT ENTHUSIASMER O 1391 00:56:22,996 --> 00:56:27,134 OKRRK COCCI, AND DRUG RESISTANT 1392 00:56:27,134 --> 00:56:29,503 STREPT O CAUCUS, AND OVER ALL 1393 00:56:29,503 --> 00:56:31,037 THEY WERE SUPPORTIVE OF THE 1394 00:56:31,037 --> 00:56:32,439 PROGRAM AND ENTHUSIASTIC AND I 1395 00:56:32,439 --> 00:56:34,841 HOPE I CAPTURED THEIR COMMENTS 1396 00:56:34,841 --> 00:56:35,809 PROARPLY HERE, I WELCOME ANY OF 1397 00:56:35,809 --> 00:56:37,677 YOU TO CORRECT ME IF I'M WRONG. 1398 00:56:37,677 --> 00:56:39,513 THE BROAD SCOPE OF THE THE 1399 00:56:39,513 --> 00:56:41,715 PROGRAM WAS NOTED BUT I HOPE I 1400 00:56:41,715 --> 00:56:44,351 TOLD YOU IN MY PRESENTATION HOW 1401 00:56:44,351 --> 00:56:46,853 THAT'S BEEN SOMEWHAT 1402 00:56:46,853 --> 00:56:47,187 ADVANTAGEOUS. 1403 00:56:47,187 --> 00:56:49,923 THEY ALSO NOTED TO INSURE THAT 1404 00:56:49,923 --> 00:56:52,559 PROJECTS ARE MULTIDISCIPLINARY 1405 00:56:52,559 --> 00:56:53,260 AND SINNER GESTIC. 1406 00:56:53,260 --> 00:56:55,595 AND I WAS ASKED TO KIND OF 1407 00:56:55,595 --> 00:56:56,496 MODIFY THE HOST RESPONSE COPE 1408 00:56:56,496 --> 00:56:59,633 THAT WE HAD INITIALLY INCLUDED 1409 00:56:59,633 --> 00:57:02,135 AND I DID THAT IN THE 1410 00:57:02,135 --> 00:57:03,703 PRESENTATION THAT I PRESENTED. 1411 00:57:03,703 --> 00:57:14,247 AND SO WITH THAT, I'LL TAKE ANY 1412 00:57:17,184 --> 00:57:17,617 QUESTIONS. 1413 00:57:17,617 --> 00:57:20,554 >> ANY QUESTIONS FROM COUNCIL 1414 00:57:20,554 --> 00:57:24,057 MEMBERS ON THE CARBIRU IN 1415 00:57:24,057 --> 00:57:28,828 GENERAL OR JUST COMMENTS? 1416 00:57:28,828 --> 00:57:34,167 >> GUESS THAT H5 M1 PRESENTATION 1417 00:57:34,167 --> 00:57:35,802 GOT EVERYBODY SOBER. 1418 00:57:35,802 --> 00:57:42,876 NTHANK YOU NANCY. 1419 00:57:42,876 --> 00:57:43,176 >> THANKS. 1420 00:57:43,176 --> 00:57:48,782 >> SO OUR FIRST 3 CONCEPT 1421 00:57:48,782 --> 00:57:51,151 PROPOSALS ARE IN THE BUNDLE OF 1422 00:57:51,151 --> 00:57:53,453 ANTIBACTERIAL RESISTANCE AND THE 1423 00:57:53,453 --> 00:57:58,692 NEXT PRESENTER IS JEREMY STARR, 1424 00:57:58,692 --> 00:58:00,160 WHO IS ONLINE. 1425 00:58:00,160 --> 00:58:04,364 JEREMY WILL TALK ABOUT--HE'S IN 1426 00:58:04,364 --> 00:58:08,468 THE DRUG QUEPMENT CENTER OR 1427 00:58:08,468 --> 00:58:10,103 SECTION OF OBRRTR AND HE WILL 1428 00:58:10,103 --> 00:58:14,241 TALK ABOUT CHEMISTRY CENTERS FOR 1429 00:58:14,241 --> 00:58:15,976 COMBATING ANTIBIOTIC RESISTANT 1430 00:58:15,976 --> 00:58:17,744 BACTERIA, THE CC-FOR CARB. 1431 00:58:17,744 --> 00:58:19,379 JEREMY ARE YOU THERE HAD. 1432 00:58:19,379 --> 00:58:27,587 >> YES, I'M HERE, CAN YOU HEAR 1433 00:58:27,587 --> 00:58:28,588 ME? 1434 00:58:28,588 --> 00:58:29,256 >> YES. 1435 00:58:29,256 --> 00:58:31,558 >> THANK YOU EMILY, I AM JEREMY 1436 00:58:31,558 --> 00:58:38,431 STA, RR, I AM IN THE DRUG 1437 00:58:38,431 --> 00:58:39,766 DEVELOPMENT SECTION OF OBRRTR, 1438 00:58:39,766 --> 00:58:42,769 AND I WILL TALK ABOUT THE 1439 00:58:42,769 --> 00:58:45,272 CHEMISTRY CENTER FOR COMBATING 1440 00:58:45,272 --> 00:58:46,473 ANTIBI ATTIC RESIFT ANT 1441 00:58:46,473 --> 00:58:49,809 BACTERIA, SO THIS IS A FISCAL 1442 00:58:49,809 --> 00:58:51,344 YEAR 26 CONCEPT, OBJECTIVES OF 1443 00:58:51,344 --> 00:58:53,813 THIS CONCEPT ARE TO CONTINUE THE 1444 00:58:53,813 --> 00:58:56,349 CURRENTLY SUCCESSFUL KRRK C FOR 1445 00:58:56,349 --> 00:58:58,885 CARB INITIATIVES SO THIS IS AIAN 1446 00:58:58,885 --> 00:59:00,287 CONCEPT IN CONTINUING THE 1447 00:59:00,287 --> 00:59:03,690 ORIGINAL CONCEPT, WE PLANNED TO 1448 00:59:03,690 --> 00:59:06,459 EXPAND THE CC FOR CARB COMPOUND 1449 00:59:06,459 --> 00:59:08,561 COLLECTION WITH ADDITIONAL NOVEL 1450 00:59:08,561 --> 00:59:10,330 CHEMO TYPES FOR ANTIBIOTIC 1451 00:59:10,330 --> 00:59:13,266 RESIST APT BACTERIA, THE 1452 00:59:13,266 --> 00:59:18,338 MECHANISM BY WHICH WE DEVELOPED 1453 00:59:18,338 --> 00:59:19,639 NEW LIBRARIES, INVOLVES 1454 00:59:19,639 --> 00:59:20,473 COLLABORATING WITH EXTERNAL 1455 00:59:20,473 --> 00:59:26,379 RESEARCHERS TO BRING THEIR IDEAS 1456 00:59:26,379 --> 00:59:28,948 INTO C C4 CARB, DESIGN NEW 1457 00:59:28,948 --> 00:59:33,687 LIBRARIES AROUND THOSE CONCEPTS 1458 00:59:33,687 --> 00:59:37,123 AND THEN 60ICIZE THOSE 1459 00:59:37,123 --> 00:59:37,390 COMPOUNDS. 1460 00:59:37,390 --> 00:59:38,658 THOSE COMPOUNDS ARE THEN 1461 00:59:38,658 --> 00:59:42,762 INSERTED INTO THE CC4 CARB 1462 00:59:42,762 --> 00:59:43,830 FEBRUARY THE PUBLIC AND PROVIDED 1463 00:59:43,830 --> 00:59:45,532 BA BEING TO THOSE COLLABORATORS 1464 00:59:45,532 --> 00:59:46,466 ISSUES THE PHYSICAL SAMPLES SO 1465 00:59:46,466 --> 00:59:51,671 THEY CAN USE THEM IN THEIR OWN 1466 00:59:51,671 --> 00:59:51,938 RESEARCH. 1467 00:59:51,938 --> 00:59:55,842 SO 1 OF THOSE OBJECTIVES THAT WE 1468 00:59:55,842 --> 00:59:57,377 PROVIDE COMPOUNDS TO EXTERNAL 1469 00:59:57,377 --> 00:59:58,878 RESEARCHERS AT STARTING POINTS 1470 00:59:58,878 --> 01:00:00,947 FOR THEIR DRUG DISCOVERY 1471 01:00:00,947 --> 01:00:04,718 PROGRAMS, THAT'S NOT LIMITED TO 1472 01:00:04,718 --> 01:00:05,752 OUR INITIAL COLLABORATORS BUT 1473 01:00:05,752 --> 01:00:09,723 ALSO IS OPEN TO PRETTY MUCH 1474 01:00:09,723 --> 01:00:15,161 ANYONE WHO HAS A REASONABLE 1475 01:00:15,161 --> 01:00:16,096 REQUEST. 1476 01:00:16,096 --> 01:00:18,264 ADDITIONALLY, THE CONCEPT 1477 01:00:18,264 --> 01:00:20,133 INVOLVES SOME TIER 1 INVITRO 1478 01:00:20,133 --> 01:00:23,403 TESTING OF NEW ANTIBACTERIAL 1479 01:00:23,403 --> 01:00:25,372 COMPOUNDS PRODUCED BY CC4 CARB 1480 01:00:25,372 --> 01:00:28,141 AND THAT GIVES US SORT OF A 1481 01:00:28,141 --> 01:00:30,643 COMPLETE PICTURE OF THIS REALLY 1482 01:00:30,643 --> 01:00:31,678 CHEMICAL MATTER TAKEN--THEY 1483 01:00:31,678 --> 01:00:32,078 WE'RE GENERATING. 1484 01:00:32,078 --> 01:00:35,448 SO AS I SAID, THIS IS A RENEWAL 1485 01:00:35,448 --> 01:00:38,518 CONCEPT, MECHANISM IS N01 AND WE 1486 01:00:38,518 --> 01:00:44,290 INTEND 1 AWARD FROM THIS 1487 01:00:44,290 --> 01:00:47,527 CONCEPT. 1488 01:00:47,527 --> 01:00:49,229 NEXT SLIDE. 1489 01:00:49,229 --> 01:00:51,631 SO THE BACKGROUND, THE SO THE 1490 01:00:51,631 --> 01:00:55,468 MAIN DRIVER FOR CC4 CARB IS THE 1491 01:00:55,468 --> 01:01:00,306 LACK OF APPROPRIATE CHEMICAL 1492 01:01:00,306 --> 01:01:02,242 MATTER FOR DISCOVERING NEW DRUGS 1493 01:01:02,242 --> 01:01:04,878 ESPECIALLY FOR GRAM NEGATIVES 1494 01:01:04,878 --> 01:01:07,113 BUT GENERALLY FOR ANTIMICROBIAL 1495 01:01:07,113 --> 01:01:07,680 RESISTANT BACTERIA. 1496 01:01:07,680 --> 01:01:10,483 THE PROBLEM IS ILLUSTRATED FROM 1497 01:01:10,483 --> 01:01:15,155 THIS CHART THAT WAS TAKEN FROM 1498 01:01:15,155 --> 01:01:17,290 [INDISCERNIBLE] PAPER SHOWING 1499 01:01:17,290 --> 01:01:20,927 THE CHEMICAL SPACE HERE ON THE 1500 01:01:20,927 --> 01:01:22,095 VIRTUAL MACHINIAL ACCESS, THE 1501 01:01:22,095 --> 01:01:26,533 [INDISCERNIBLE] ON THE X-AXIS, 1502 01:01:26,533 --> 01:01:28,168 MOLECULAR WEIGHT SO THE CHEMICAL 1503 01:01:28,168 --> 01:01:30,570 SPACE OF ALL DRUGS AND MOST 1504 01:01:30,570 --> 01:01:31,638 CHEMICAL MATTER YOU MIGHT FIND 1505 01:01:31,638 --> 01:01:33,606 IN A CORPORATE KREENING LIBRARY 1506 01:01:33,606 --> 01:01:37,377 IS SHOWN, AND THE PATCH OF GRAY 1507 01:01:37,377 --> 01:01:39,913 POINTS REPRESENTS WHERE TYPICAL 1508 01:01:39,913 --> 01:01:41,948 CHEMICAL MATTER FALLS, HOWEVER 1509 01:01:41,948 --> 01:01:43,817 THE COLORED POINTS WHICH HERE 1510 01:01:43,817 --> 01:01:45,985 REPRESENT PSEUDOMOAN ISOTOPE 1511 01:01:45,985 --> 01:01:49,255 ACTIVE COMPOUNDS, FALL WELL 1512 01:01:49,255 --> 01:01:52,025 OUTSIDE OF THAT CLUSTER, 1513 01:01:52,025 --> 01:01:53,660 COMPOUNDS, AND THERE ARE MANY 1514 01:01:53,660 --> 01:01:55,595 OTHER EXAMPLES WHERE THIS HAS 1515 01:01:55,595 --> 01:01:58,231 BEEN ILTRAITED WHERE GRAM 1516 01:01:58,231 --> 01:02:00,033 NEGATIVE ESPECIALLY ARE JUST IN 1517 01:02:00,033 --> 01:02:02,135 A DIFFERENT CHEMICAL SPACE THAN 1518 01:02:02,135 --> 01:02:04,070 WHERE YOU TYPICALLY LOOK FOR 1519 01:02:04,070 --> 01:02:08,374 DRUGS FOR OTHER HUMAN TARGETS. 1520 01:02:08,374 --> 01:02:11,311 CONSEQUENTLY WHEN SAY IN THE 1521 01:02:11,311 --> 01:02:13,947 PHARMACEUTICAL INDUSTRY AND NIEW 1522 01:02:13,947 --> 01:02:18,451 ANTIBACTERIAL PROGRAM IS 1523 01:02:18,451 --> 01:02:20,086 STARTED, THE SCREENING PROCESS 1524 01:02:20,086 --> 01:02:21,588 IS SKEWED AWAY FROM THE KIND OF 1525 01:02:21,588 --> 01:02:23,623 CHEMICAL MATTER THAT WOULD BE 1526 01:02:23,623 --> 01:02:24,924 ACTIVE AGAINST THESE AGENTS 1527 01:02:24,924 --> 01:02:27,227 BECAUSE IT OFTEN DERIVED FROM 1528 01:02:27,227 --> 01:02:28,361 THE RESIDUAL CHEMICAL MATTER 1529 01:02:28,361 --> 01:02:31,097 FROM OTHER PROGRAMS TARGETING 1530 01:02:31,097 --> 01:02:32,932 HUMAN TARGETS. 1531 01:02:32,932 --> 01:02:36,503 SO THIS PROBLEM IS WELL KNOWN, 1532 01:02:36,503 --> 01:02:37,670 IT WAS IDENTIFIED YEARS AGO NOW 1533 01:02:37,670 --> 01:02:39,939 AND WAS PART OF THE BASIS FOR 1534 01:02:39,939 --> 01:02:43,743 THE ORIGINAL CONCEPT THAT WAS 1535 01:02:43,743 --> 01:02:45,411 APPROVED FOR CC4 CARB, AND THAT 1536 01:02:45,411 --> 01:02:48,715 BOILS DOWN TO THEIR BEING 1537 01:02:48,715 --> 01:02:49,516 CORPORATE KREENING LIBRARIES 1538 01:02:49,516 --> 01:02:51,150 THAT LOOK LIKE TYPICAL TRUGS AND 1539 01:02:51,150 --> 01:02:54,153 A LACK OF CHEMICAL LIBRARIES, 1540 01:02:54,153 --> 01:02:54,954 ESPECIALLY FOR GRAM NEGATIVE 1541 01:02:54,954 --> 01:02:59,259 TARGETS AND O THIS IS A NEED TO 1542 01:02:59,259 --> 01:03:02,795 BUILD TAYLORED CHEMICAL MATTER 1543 01:03:02,795 --> 01:03:04,430 FOR ANTIBACTERIAL DISCOVERY 1544 01:03:04,430 --> 01:03:05,932 ESPECIALLY GRAM NEGATIVES, THIS 1545 01:03:05,932 --> 01:03:12,038 IS IDENTIFIED IN A NUMBER OF 1546 01:03:12,038 --> 01:03:13,406 PLACES NODABLY HERE IN THE 1547 01:03:13,406 --> 01:03:15,909 SCIENTIFIC ROADMAP WHERE THESE 1548 01:03:15,909 --> 01:03:18,678 SPECIFICALLY CALLED OUT THE NEED 1549 01:03:18,678 --> 01:03:20,413 TO PROACTIVELY SYNTHESIZE NEW 1550 01:03:20,413 --> 01:03:22,582 CHEMICAL LIBRARIES WITH GRAM 1551 01:03:22,582 --> 01:03:26,085 NEGATIVE TYPE PHYSICAL CHEMICAL 1552 01:03:26,085 --> 01:03:27,487 PROPERTIES, AND THAT IS 1553 01:03:27,487 --> 01:03:30,123 FUNDAMENTALLY THE PURPOSE FOR 1554 01:03:30,123 --> 01:03:37,931 CC4 CARB, NEXT SLIDE. 1555 01:03:37,931 --> 01:03:41,501 SO AS I SAID CC4 CARB HAS 1556 01:03:41,501 --> 01:03:44,604 EXISTED AS AN ACTIVE CONTRACT 1557 01:03:44,604 --> 01:03:44,904 SINCE 2021. 1558 01:03:44,904 --> 01:03:47,373 SO WE HAVE KEY ACCOMPMENTS TO 1559 01:03:47,373 --> 01:03:47,907 TALK ABOUT. 1560 01:03:47,907 --> 01:03:56,015 AS OF FEBRUARY OF THIS YEAR WE 1561 01:03:56,015 --> 01:03:58,084 MATE 2571 COMPOUNDS ACROSS 35 1562 01:03:58,084 --> 01:03:59,919 DIVERSE SCAFFOLDS, AND AS OF 1563 01:03:59,919 --> 01:04:02,589 THIS YEAR, THERE WERE 1800 AND 1564 01:04:02,589 --> 01:04:06,259 THEY THEY HAD BEEN TESTED IN ANN 1565 01:04:06,259 --> 01:04:07,760 SILLARY TEST ORDER FOR MIC 1566 01:04:07,760 --> 01:04:09,329 TESTING AND EVEN THOUGH MIC 1567 01:04:09,329 --> 01:04:12,432 TESTING IS NOT INCLUED IN THE 1568 01:04:12,432 --> 01:04:15,635 ORIGINAL CONCEPT, WE BOLTED IT 1569 01:04:15,635 --> 01:04:17,003 ON THROUGH PRECLINICAL SERVICES 1570 01:04:17,003 --> 01:04:19,072 THAT BECAME EARLY IN THE PROGRAM 1571 01:04:19,072 --> 01:04:24,477 BECAME OBVIOUS THAT WE NEEDED TO 1572 01:04:24,477 --> 01:04:26,346 HAVE SOME DATA ON ALL THE 1573 01:04:26,346 --> 01:04:28,848 COMPOUNDS WE MADE SO WE 1574 01:04:28,848 --> 01:04:29,916 UNDERSTOOD THE VALUE OF THE 1575 01:04:29,916 --> 01:04:32,452 THINGS WE'RE MAKING AND WE COULD 1576 01:04:32,452 --> 01:04:34,420 CROSS COMPARE THE VARIOUS 1577 01:04:34,420 --> 01:04:37,924 CHEMICAL LIBRARIES THAT WE'RE 1578 01:04:37,924 --> 01:04:41,961 MAKING WITHIN THE COLLECTION FOR 1579 01:04:41,961 --> 01:04:42,195 CARB. 1580 01:04:42,195 --> 01:04:43,863 AS A RESULT BECAUSE WE--WE--YOU 1581 01:04:43,863 --> 01:04:46,666 DOING TESTING WE HAVE ALREADY 1582 01:04:46,666 --> 01:04:48,101 IDENTIFIED APPROXIMATELY 20 1583 01:04:48,101 --> 01:04:50,803 LIBRARIES NOW THAT HAD NEW 1584 01:04:50,803 --> 01:04:52,572 UNEXPECTED GRAM NEGATIVE 1585 01:04:52,572 --> 01:04:58,344 ACTIVITY OF VARIOUS TYPES AND 1586 01:04:58,344 --> 01:05:00,513 THROUGH OUR OUTREACH EFFORTS WE 1587 01:05:00,513 --> 01:05:02,949 HAVE HAD ENGAGEMENT WITH OVER 50 1588 01:05:02,949 --> 01:05:05,685 EXTERNAL RESEARCHERS AROUND THE 1589 01:05:05,685 --> 01:05:06,386 WORLD. 1590 01:05:06,386 --> 01:05:08,221 THROUGH OUR OUTREACH, THERE HAVE 1591 01:05:08,221 --> 01:05:10,957 BEEN 3 PATENT APPLICATIONS 1592 01:05:10,957 --> 01:05:13,860 FILED, 4 MANUSCRIPTS IN 1593 01:05:13,860 --> 01:05:14,994 PREPARATION OR 6 NEW RESEARCH 1594 01:05:14,994 --> 01:05:20,433 GRANTS THAT WERE SUPPORTED BY 1595 01:05:20,433 --> 01:05:23,603 DATA OR INTERACTIONS. 1596 01:05:23,603 --> 01:05:25,571 SO ON THE RIGHT, YOU CAN SEE A 1597 01:05:25,571 --> 01:05:29,308 MAP OF THE WORLD WITH SORT OF 1598 01:05:29,308 --> 01:05:33,613 COLOR HEAT MAP OF WHERE WE HAVE 1599 01:05:33,613 --> 01:05:33,980 INTEREST. 1600 01:05:33,980 --> 01:05:36,683 SO WE SEE INTEREST IN OUR 1601 01:05:36,683 --> 01:05:37,350 WEBSITES GLOBALLY, PARTICULARLY 1602 01:05:37,350 --> 01:05:41,854 IN THE U.S. OF COURSE, BUT IN 1603 01:05:41,854 --> 01:05:47,293 EUROPE, AND ASIA AND PRETTY 1604 01:05:47,293 --> 01:05:47,827 MUCHIN'RE EVERY CONINENT. 1605 01:05:47,827 --> 01:05:49,295 WE DO HAVE A WEBSITE. 1606 01:05:49,295 --> 01:05:50,697 THE WEB ADDRESS IS SHOWN BELOW 1607 01:05:50,697 --> 01:05:52,532 THE MAP AND WE ALSO GENERATED 1608 01:05:52,532 --> 01:05:55,768 THE STATEMENT IN A FEW OTHER 1609 01:05:55,768 --> 01:05:59,872 WAYS THAT PI, THE CURRENT CC4 1610 01:05:59,872 --> 01:06:02,742 CARB IS PRESENTED WILD AMR 1611 01:06:02,742 --> 01:06:06,612 CONGRESS IN 2023, ALSO THE 2024 1612 01:06:06,612 --> 01:06:07,747 MANUFACTURES CONFERENCE AND 1613 01:06:07,747 --> 01:06:12,085 THERE IS A GUARD PIECE SEMINAR 1614 01:06:12,085 --> 01:06:13,352 DISCUSSING CC4 CARB IN SOME 1615 01:06:13,352 --> 01:06:16,222 DETAIL WHICH YOU CAN WATCH ON 1616 01:06:16,222 --> 01:06:20,927 YouTUBE AT THE LINK AT THE 1617 01:06:20,927 --> 01:06:21,861 BOTTOM. 1618 01:06:21,861 --> 01:06:22,328 NEXT SLIDE. 1619 01:06:22,328 --> 01:06:26,499 SO THE SCOPE OF SUPPORT FOR THE 1620 01:06:26,499 --> 01:06:30,870 FY26 CONCEPT IS SHOWN HERE ON 1621 01:06:30,870 --> 01:06:31,437 THIS SLIDE. 1622 01:06:31,437 --> 01:06:32,905 I'LL POINT OUT A FEW THINGS THAT 1623 01:06:32,905 --> 01:06:34,207 HAVE CHANGED FROM THE PREVIOUS 1624 01:06:34,207 --> 01:06:36,109 CONCEPT AS I GO THROUGH THE 1625 01:06:36,109 --> 01:06:36,442 BULLET POINTS. 1626 01:06:36,442 --> 01:06:40,113 SO THIS IS A COMPLEX CONTRACT 1627 01:06:40,113 --> 01:06:43,683 WITH SEVERAL MOVING PARTS 1628 01:06:43,683 --> 01:06:46,786 DIVIDED INTO 4 CATEGORIES OF 1629 01:06:46,786 --> 01:06:50,089 PERFORMANCE, SO THE FIRST 1 IS 1630 01:06:50,089 --> 01:06:51,724 LIBRARY DESIGN AND LIBRARY 1631 01:06:51,724 --> 01:06:59,665 DESIGN ITSELF INVOLVES MULTIPLE 1632 01:06:59,665 --> 01:07:00,600 FUNCTIONS THE FIRST 1 IS 1633 01:07:00,600 --> 01:07:04,637 OUTREACH SO THIS IS A PRETTY 1634 01:07:04,637 --> 01:07:05,571 SIGNIFICANT OUTREACH FOR 1635 01:07:05,571 --> 01:07:06,739 COLLABORATORS AND BRING THEM IN 1636 01:07:06,739 --> 01:07:08,841 FROM ALL OVER THE WORLD AND 1637 01:07:08,841 --> 01:07:11,244 BRING THEM IN FROM THE 1638 01:07:11,244 --> 01:07:11,744 ANTIBACTERIAL RESEARCH 1639 01:07:11,744 --> 01:07:13,146 COMMUNITY, THOSE ARE REVIEWED BY 1640 01:07:13,146 --> 01:07:14,881 THE CONTRACTOR WHICH IS OUR TI, 1641 01:07:14,881 --> 01:07:18,551 ALSO BY A SCIENTIFIC ADVISORY 1642 01:07:18,551 --> 01:07:20,153 BOARD, THOSIFY KEY OPINION 1643 01:07:20,153 --> 01:07:21,687 LEADERS IN THE WORLD, AND 1644 01:07:21,687 --> 01:07:24,891 THEY'RE ALSO REVIEWED BY NIAID 1645 01:07:24,891 --> 01:07:27,627 PROGRAM OFFICERS, PARTICULARLY 1646 01:07:27,627 --> 01:07:27,860 MYSELF. 1647 01:07:27,860 --> 01:07:31,597 IN ARK DITION TO THOSE ELEMENTS, 1648 01:07:31,597 --> 01:07:33,099 LIBRARY DESIGN COMPONENT 1649 01:07:33,099 --> 01:07:36,569 INVOLVES AN 18 MONTH EMBARGO 1650 01:07:36,569 --> 01:07:37,370 PERIOD FOR INTELLECTUAL 1651 01:07:37,370 --> 01:07:38,905 PROPERTY, SO THIS IS--THIS IS 1652 01:07:38,905 --> 01:07:42,608 NEW, THIS IS NOT PART OF THE 1653 01:07:42,608 --> 01:07:43,976 ORIGINAL CONCEPTS, AS A POINT OF 1654 01:07:43,976 --> 01:07:48,881 CONTRAST WHEN THIS IS ORIGINALLY 1655 01:07:48,881 --> 01:07:50,082 PROPOSED ABOUT 5 YEARS AGO, THE 1656 01:07:50,082 --> 01:07:53,553 BELIEF WAS THAT WE WERE 1657 01:07:53,553 --> 01:07:54,187 OPERATING PRETTY COMPETITIVELY 1658 01:07:54,187 --> 01:07:55,922 AND THERE WOULD BE NO NEED TO 1659 01:07:55,922 --> 01:08:00,560 HAVE ANY INTELLECTUAL PROPERTY 1660 01:08:00,560 --> 01:08:01,828 PROVISIONS WITH ANY CHEMICAL 1661 01:08:01,828 --> 01:08:04,797 MATTER AT THIS STAGE OF 1662 01:08:04,797 --> 01:08:05,832 DEVELOPMENT. 1663 01:08:05,832 --> 01:08:06,399 UNFORTUNATELY THAT BECAME A 1664 01:08:06,399 --> 01:08:09,368 NONSTARTER WHEN WE GOT THE 1665 01:08:09,368 --> 01:08:13,039 CONTRACT UP AND RUNNING AND 1666 01:08:13,039 --> 01:08:13,673 STARTED ENGAGING COLLABORATORS 1667 01:08:13,673 --> 01:08:16,375 NOBODY TO WORK WITH US IF THERE 1668 01:08:16,375 --> 01:08:18,211 WERE NO INTELLECTUAL PROPERTY 1669 01:08:18,211 --> 01:08:20,813 PROTECTIONS EVEN AT THE VERY 1670 01:08:20,813 --> 01:08:24,550 EARLY STAGE OF CHEMICAL MATTER 1671 01:08:24,550 --> 01:08:25,384 THAT WE'RE CONTEMPLATING. 1672 01:08:25,384 --> 01:08:27,486 SO AS I RESULT WE DID IMPLEMENT 1673 01:08:27,486 --> 01:08:30,957 AN 18 MONTH EMBARGO PERIOD, THIS 1674 01:08:30,957 --> 01:08:32,358 INVOLVES PROTECTING THE PRIVACY 1675 01:08:32,358 --> 01:08:36,696 OF THE NEW IDEAS THAT WERE 1676 01:08:36,696 --> 01:08:38,264 DISCUSSING WITH COLLABORATORS OR 1677 01:08:38,264 --> 01:08:41,434 AN 18 MONTH PERIOD AFTER WHICH 1678 01:08:41,434 --> 01:08:43,302 IT DOES THE COMPOUNDS AND 1679 01:08:43,302 --> 01:08:44,237 SAMPLES ARE MADE AVAILABLE TO 1680 01:08:44,237 --> 01:08:46,005 THE PUBLIC BUT DURING THAT TIME 1681 01:08:46,005 --> 01:08:49,942 THAT ALLOWS FOR THE IDEA 1682 01:08:49,942 --> 01:08:52,812 ORIGINATOR TO DO WHATEVER PATENT 1683 01:08:52,812 --> 01:08:53,880 FILES OR OTHER INTELLECTUAL 1684 01:08:53,880 --> 01:08:55,281 PROPERTY PROTECTING MECH INFORM 1685 01:08:55,281 --> 01:08:58,584 THEY WOULD LIKE TO IMPLEMENT. 1686 01:08:58,584 --> 01:09:02,255 ONCE WE PUT THAT IN PLACE, WE 1687 01:09:02,255 --> 01:09:03,823 HAD VERY LITTLE TROUBLE 1688 01:09:03,823 --> 01:09:04,523 CONVINCING COLLABORATORS TO WORK 1689 01:09:04,523 --> 01:09:06,592 WITH US AND THAT WAS A VERY NICE 1690 01:09:06,592 --> 01:09:08,227 SOLUTION SO WE DO PLAN TO 1691 01:09:08,227 --> 01:09:10,763 INCLUDE IT FROM THE START IN THE 1692 01:09:10,763 --> 01:09:13,499 NEW CONCEPTS FOR THE 1693 01:09:13,499 --> 01:09:16,469 CONTINUATION OF CC4 CARB. 1694 01:09:16,469 --> 01:09:19,005 OBVIOUSLY IT BEING LIBRARY 1695 01:09:19,005 --> 01:09:20,139 DESIGN, DESIGNING COMPOUND 1696 01:09:20,139 --> 01:09:22,441 LIBRARIES IS A KEY FUNCTION ONCE 1697 01:09:22,441 --> 01:09:26,779 WE'VE GOTTEN THROUGH THE HURDLE, 1698 01:09:26,779 --> 01:09:28,080 OF ENGAGING COLLABORATORS HAVING 1699 01:09:28,080 --> 01:09:30,049 IDEAS REVIEWED, THOSE IDEAS DO 1700 01:09:30,049 --> 01:09:31,651 BECOME COMPOUND LIBRARIES THAT 1701 01:09:31,651 --> 01:09:35,421 ARE DESIGNED BY RTI IN 1702 01:09:35,421 --> 01:09:36,822 COLLABORATION WITH THE 1703 01:09:36,822 --> 01:09:37,256 COLLABORATORS. 1704 01:09:37,256 --> 01:09:41,594 OUR GOAL WITH THIS CONCEPT IS 50 1705 01:09:41,594 --> 01:09:44,897 NEW DESIGNS OVER 5 YEARS PERIOD. 1706 01:09:44,897 --> 01:09:48,434 THAT'S JUST 1 OF THE FUNCTIONS, 1707 01:09:48,434 --> 01:09:50,136 ANOTHER FUNCTION EVEN THOUGH IT 1708 01:09:50,136 --> 01:09:55,875 HAS 2 2 BULLETS EVEN THOUGH ITS 1709 01:09:55,875 --> 01:09:58,210 MOST OF THE LABOR INVOLVED IS 1710 01:09:58,210 --> 01:10:00,947 THE COMPOUND SYNTHESIS, SO 1711 01:10:00,947 --> 01:10:03,115 THAT'S THE LIBRARY HAVING 1712 01:10:03,115 --> 01:10:04,317 BETWEEN 50 AND 300 COMPOUNDS IN 1713 01:10:04,317 --> 01:10:06,719 IT, AND ALL THESE COMPOUNDS HAVE 1714 01:10:06,719 --> 01:10:07,887 TO KNOW SYNTHESIZED 1715 01:10:07,887 --> 01:10:10,656 CHARACTERIZED IN SOME CASES, 1716 01:10:10,656 --> 01:10:12,625 CHEMISTRY WORK HAS TO BE DONE TO 1717 01:10:12,625 --> 01:10:15,828 OPTIMIZE ROUTES TO ENABLE ACCESS 1718 01:10:15,828 --> 01:10:19,265 TO THE DESIGN COMPOUNDS, SO 1719 01:10:19,265 --> 01:10:21,667 THERE'S AN EXTENSIVE AMOUNT OF 1720 01:10:21,667 --> 01:10:24,971 CHEMISTRY LABOR GOING ON AT RTI 1721 01:10:24,971 --> 01:10:26,172 FOR DELIVERING THESE COMPOUNDS. 1722 01:10:26,172 --> 01:10:29,141 OUR GOAL WITH THE NEW CONCEPT IS 1723 01:10:29,141 --> 01:10:30,676 10,000 COMPOUNDS, TO GO OVER THE 1724 01:10:30,676 --> 01:10:35,281 5 YEAR PERFORMANCE PERIOD. 1725 01:10:35,281 --> 01:10:36,282 SO I MENTIONED COMPOUND TESTING 1726 01:10:36,282 --> 01:10:38,517 WAS NOT PART OF THE ORIGINAL 1727 01:10:38,517 --> 01:10:40,853 CONCEPT ABOUT 5 YEARS AGO AND 1728 01:10:40,853 --> 01:10:45,624 THAT WE ARE CURRENTLY DOING IT 1729 01:10:45,624 --> 01:10:46,392 THROUGH PRECLINICAL SERVICES. 1730 01:10:46,392 --> 01:10:47,927 IT'S BEEN QUITE SUCCESSFUL IN 1731 01:10:47,927 --> 01:10:52,231 MANY WAYS AND SO, WE WANT IT TO 1732 01:10:52,231 --> 01:10:54,900 BE AN INTEGRAL PART OF CC4 CARB 1733 01:10:54,900 --> 01:10:56,769 GOING FORWARD, SO IN THE NEW 1734 01:10:56,769 --> 01:10:58,871 CONCEPT WE ADDED IT AS A KEY 1735 01:10:58,871 --> 01:11:03,576 FUNCTION, SOPHISTICATED WE WILL 1736 01:11:03,576 --> 01:11:05,711 CONDUCT TIER 1 INVITRO TESTING 1737 01:11:05,711 --> 01:11:06,846 ON ALL COMPOUNDS. 1738 01:11:06,846 --> 01:11:08,681 IN ADDITION THORS THOSE 3 1739 01:11:08,681 --> 01:11:10,649 FUNCTIONS WHENEVER YOU'RE 1740 01:11:10,649 --> 01:11:11,984 GENERATING PHYSICAL SAMPLES OF 1741 01:11:11,984 --> 01:11:13,552 CHEMICAL MATTER, YOU HAVE TO 1742 01:11:13,552 --> 01:11:14,820 MANAGE THOSE SAMPLES, TAKE CARE 1743 01:11:14,820 --> 01:11:19,592 OF THEM, STORE THEM CORRECTLY, 1744 01:11:19,592 --> 01:11:20,793 ALSO ARRANGE FOR DELIVERY OF THE 1745 01:11:20,793 --> 01:11:24,764 SAMPLES TO TESTING ASSAYS AND TO 1746 01:11:24,764 --> 01:11:26,065 REQUESTERS WHO WANT TO USE THEM 1747 01:11:26,065 --> 01:11:28,367 IN THEIR OWN TESTING ASSAYS. 1748 01:11:28,367 --> 01:11:30,770 SO WE HAVE A COMPOUND MANAGEMENT 1749 01:11:30,770 --> 01:11:32,304 FUNCTION THAT WILL TORE AND 1750 01:11:32,304 --> 01:11:33,406 MAINTAIN THE COMPOUND COLLECTION 1751 01:11:33,406 --> 01:11:38,044 AS WELL AS MANAGE THE GRIEWKS 1752 01:11:38,044 --> 01:11:42,415 SAMPLES TO REQUESTERS. 1753 01:11:42,415 --> 01:11:43,749 NEXT SLIDE. 1754 01:11:43,749 --> 01:11:45,484 SO THE SCOPE OF SUPPORT WAS IN 1755 01:11:45,484 --> 01:11:47,319 TEXT FORM IN THE PREVIOUS SLIDE 1756 01:11:47,319 --> 01:11:49,555 AND THE SLIDE I'M SHOWING IT IN 1757 01:11:49,555 --> 01:11:53,192 THE MORE SCHEMATIC FORM, THIS IS 1758 01:11:53,192 --> 01:11:55,027 HOW CC4 CARB WORKS, ACROSS THE 1759 01:11:55,027 --> 01:11:56,796 TOP LINE YOU HAVE THE LIBRARY 1760 01:11:56,796 --> 01:11:58,064 DESIGN FUNCTION WHERE THE 1761 01:11:58,064 --> 01:12:01,133 APPLICANT OR THE COLLABORATOR 1762 01:12:01,133 --> 01:12:06,272 BRINGS AN IDEA TO CC4 CARB, 1763 01:12:06,272 --> 01:12:09,308 OFTEN IN RESPONSE TO DIRECT 1764 01:12:09,308 --> 01:12:11,544 CONTACT WITH BRUCE OR SOMEBODY 1765 01:12:11,544 --> 01:12:14,046 FROM RTI WHO'S ACTING AS A 1766 01:12:14,046 --> 01:12:15,014 LIAISON BETWEEN CC4 CARB AND YOU 1767 01:12:15,014 --> 01:12:18,217 KNOW IS PART OF THE OUTREACH 1768 01:12:18,217 --> 01:12:18,451 PROGRAM. 1769 01:12:18,451 --> 01:12:20,553 SO THE APPLICANT BRENGS THE IDEA 1770 01:12:20,553 --> 01:12:23,089 INTO THE RTI AND UNDERGOES 1771 01:12:23,089 --> 01:12:25,724 ADMINISTRATOR REVIEW FOLLOWED BY 1772 01:12:25,724 --> 01:12:27,326 SCIENTIFIC ADVISORY BOARD OR 1773 01:12:27,326 --> 01:12:29,528 REVIEW AND THEN IF IT PASSES 1774 01:12:29,528 --> 01:12:35,468 THOSE REVIEWS IT GOES INTO 1775 01:12:35,468 --> 01:12:36,836 LIBRARY DESIGN. 1776 01:12:36,836 --> 01:12:37,837 WHERE THE COMPOUNDS ARE DESIGNED 1777 01:12:37,837 --> 01:12:40,005 TO BE PART OF THAT LIBRARY. 1778 01:12:40,005 --> 01:12:42,875 AFTER THE COMPOUNDS ARE DESIGNED 1779 01:12:42,875 --> 01:12:45,077 IT GOES TO NAID FOR REVIEW SO 1780 01:12:45,077 --> 01:12:45,811 EVERY DISCREET COMPOUND THAT 1781 01:12:45,811 --> 01:12:47,680 GOES INTO THE COLLECTION IS 1782 01:12:47,680 --> 01:12:50,583 REVIEWED AND APPROVED BY NIAID 1783 01:12:50,583 --> 01:12:52,051 FOR ITS SYNTHESIZED. 1784 01:12:52,051 --> 01:12:53,719 ONCE THAT HAPPENS, I LPC R POR 1785 01:12:53,719 --> 01:12:56,088 THE LIBRARY DESIGN GOES INTO THE 1786 01:12:56,088 --> 01:12:57,456 SYNTHESIS CUE. 1787 01:12:57,456 --> 01:13:00,526 IT'S EVENTUALLY SYNTHESIZED AND 1788 01:13:00,526 --> 01:13:02,461 THOSE SAMPLES ARE DIVIDED INTO 1789 01:13:02,461 --> 01:13:05,664 MATERIAL THAT GOES INTO COMPOUND 1790 01:13:05,664 --> 01:13:06,732 MANAGEMENT, ALONG THE BOTTOM ROW 1791 01:13:06,732 --> 01:13:09,201 WHICH WILL SUPPLY PUBLIC 1792 01:13:09,201 --> 01:13:11,871 REQUESTS OR IT GOES BACK TO AND 1793 01:13:11,871 --> 01:13:13,706 PART TELEVISION GOES BACK TO THE 1794 01:13:13,706 --> 01:13:15,141 APPLICANTS SO THAT THEY CAN DO 1795 01:13:15,141 --> 01:13:17,877 THEIR OWN TESTING AND USE IT FOR 1796 01:13:17,877 --> 01:13:19,278 THEIR OWN PRODUCT DEVELOPMENT. 1797 01:13:19,278 --> 01:13:21,180 WHAT'S NOT SHOWN IN THIS 1798 01:13:21,180 --> 01:13:25,351 SCHEMATIC IS THAT A THIRD 1799 01:13:25,351 --> 01:13:28,554 DIVISION WILL GO OFF TO TIER 1 1800 01:13:28,554 --> 01:13:30,156 INVITRO TESTING AFTER COMPOUND 1801 01:13:30,156 --> 01:13:38,764 SYNTHESIS UNDER THE NEW CONCEPT. 1802 01:13:38,764 --> 01:13:39,331 NEXT SLIDE. 1803 01:13:39,331 --> 01:13:42,735 SOPHISTICATED I HAVE MET WITH 1804 01:13:42,735 --> 01:13:44,003 COUNCIL MEMBERS 1805 01:13:44,003 --> 01:13:44,603 DR. [INDISCERNIBLE] AND 1806 01:13:44,603 --> 01:13:45,738 DR. KD--SALLY THEY WERE STROJLY 1807 01:13:45,738 --> 01:13:47,039 SUPPORTIVE WITH THE CONCEPT, 1808 01:13:47,039 --> 01:13:50,976 THEY DID PROVIDE VERY USEFUL 1809 01:13:50,976 --> 01:13:53,746 FEEDBACK, 1 IS TO REMIND ME OR 1810 01:13:53,746 --> 01:13:55,681 ASK ME ABOUT WHETHER LIBRARY 1811 01:13:55,681 --> 01:13:58,684 PLANS COULD CONSIDER MODALITIES 1812 01:13:58,684 --> 01:13:59,552 SIMPLY BEYOND DIRECTING 1813 01:13:59,552 --> 01:14:01,287 MATERIALS AND THE ANSWER TO THAT 1814 01:14:01,287 --> 01:14:04,023 IS ABSOLUTELY YES, AND ANYTHING 1815 01:14:04,023 --> 01:14:07,526 THAT ADDRESSES THE BROAD 1816 01:14:07,526 --> 01:14:08,394 QUESTION OF ANTIMICROBIAL 1817 01:14:08,394 --> 01:14:13,199 RESISTANCE AND LOOKS LIKE A 1818 01:14:13,199 --> 01:14:15,267 POTENTIAL PATH FORWARD AGAINST 1819 01:14:15,267 --> 01:14:18,804 SOME GRAM NEGATIVE OR OTHER 1820 01:14:18,804 --> 01:14:19,471 DIFFICULT BACTERIAL PATHOIEN IS 1821 01:14:19,471 --> 01:14:22,641 ON THE TABLE AND BUT SUBJECT TO 1822 01:14:22,641 --> 01:14:25,077 THE REVIEW PROCESS THAT I 1823 01:14:25,077 --> 01:14:25,444 DESCRIBED. 1824 01:14:25,444 --> 01:14:27,846 THEY ASK ME TO EMPHASIZE THE 18 1825 01:14:27,846 --> 01:14:32,785 MONTH EMBARGO PERIOD WHICH I 1826 01:14:32,785 --> 01:14:34,253 HOPE I CLARIFIED AND THEY 1827 01:14:34,253 --> 01:14:35,087 BROUGHT UP AN INTERESTING POINT 1828 01:14:35,087 --> 01:14:38,657 WHICH WAS NOT PART OF MY 1829 01:14:38,657 --> 01:14:40,359 ORIGINAL PRESENTATION BUT I 1830 01:14:40,359 --> 01:14:42,428 THINK IT'S REALLY IMPORTANT TO 1831 01:14:42,428 --> 01:14:44,530 NOTE IS THAT 1 OF THE BENEFITS 1832 01:14:44,530 --> 01:14:47,933 OF VIEWING THE TIER 1 DATA, 1833 01:14:47,933 --> 01:14:52,371 HAVING THE TIER 1 DATA 1834 01:14:52,371 --> 01:14:54,640 GENERATION INTEGRATED IN THE CC4 1835 01:14:54,640 --> 01:14:56,542 CARB IS THAT IT'S GOING TO BE 1836 01:14:56,542 --> 01:14:58,143 VERY CONSIST EPT DATA ACROSS A 1837 01:14:58,143 --> 01:15:00,112 LARGE NUMBER OF COMPOUNDS WHICH 1838 01:15:00,112 --> 01:15:02,081 IS ENABLING FOR MACHINE LEARN XG 1839 01:15:02,081 --> 01:15:04,817 GETS AROUND SOME OF THE 1840 01:15:04,817 --> 01:15:07,319 DIFFICULTIES THAT MACHINE 1841 01:15:07,319 --> 01:15:08,020 LEARNING APPROACHES RUN INTO 1842 01:15:08,020 --> 01:15:10,322 WITH SORT OF RAW DATA COLLECTED 1843 01:15:10,322 --> 01:15:14,026 FROM THE OPEN LITERATURE WHERE 1844 01:15:14,026 --> 01:15:16,528 ASSAY IS RUN UNDER DIFFERENT 1845 01:15:16,528 --> 01:15:17,930 CONDITIONS AND OFTEN THERE'S 1846 01:15:17,930 --> 01:15:20,799 SELECTION BIAS AND WHATOOSE 1847 01:15:20,799 --> 01:15:21,066 PUBLISHED. 1848 01:15:21,066 --> 01:15:23,035 HERE WE WILL HAVE ULTIMATELY A 1849 01:15:23,035 --> 01:15:28,807 BODY OF 10 OR 15,000 COMPOUNDS 1850 01:15:28,807 --> 01:15:29,975 WITH INVITRO DATA RUN UNDER 1851 01:15:29,975 --> 01:15:32,177 EXACTLY THE SAME CONDITIONS AND 1852 01:15:32,177 --> 01:15:34,713 ALL OF IT WILL BE REPORTED AND 1853 01:15:34,713 --> 01:15:40,019 AVAILABLE FOR US IN THE FUTURE 1854 01:15:40,019 --> 01:15:50,095 MACHINE LEARNING EFFORT. 1855 01:15:50,095 --> 01:15:50,663 NEXT SLIDE. 1856 01:15:50,663 --> 01:15:52,631 SO THIS IS THE END OF MY NEW 1857 01:15:52,631 --> 01:15:54,199 SLIDE, I JUST BROUGHT BACK THE 1858 01:15:54,199 --> 01:15:58,370 CONCEPT SLIDE AND HAPPY TO 1859 01:15:58,370 --> 01:16:00,439 ANSWER ANY QUESTIONS. 1860 01:16:00,439 --> 01:16:01,640 THANK YOU. 1861 01:16:01,640 --> 01:16:02,474 >> THANK YOU JEREMY. 1862 01:16:02,474 --> 01:16:13,018 ANY QUESTIONS FOR JEREMY ON CC4 1863 01:16:13,285 --> 01:16:14,720 CARB CONCEPT. 1864 01:16:14,720 --> 01:16:16,021 OKAY, JUST REMEMBERING I NEED TO 1865 01:16:16,021 --> 01:16:18,757 REMIND YOU THAT YOU DO HAVE TO 1866 01:16:18,757 --> 01:16:20,693 VOTE ON THESE IN YOUR 1867 01:16:20,693 --> 01:16:21,427 INDEPENDENT COUNCIL BOOK WHETHER 1868 01:16:21,427 --> 01:16:24,530 OR NOT, I THINK THERE'S AN 1869 01:16:24,530 --> 01:16:26,965 OPPORTUNITY TO WRITE SUGGESTIONS 1870 01:16:26,965 --> 01:16:27,399 IN A BOX. 1871 01:16:27,399 --> 01:16:32,004 SO AS I MENTIONED WE HAVE A 1872 01:16:32,004 --> 01:16:36,742 BUNDLE OF ANTIBACTERIAL 1873 01:16:36,742 --> 01:16:40,412 RESISTANT CONCEPTS, DEVELOPING 1874 01:16:40,412 --> 01:16:40,846 BETTER ANTIBACTERIAL 1875 01:16:40,846 --> 01:16:42,715 COUNTERMEASURES, AND THE NEXT 1 1876 01:16:42,715 --> 01:16:44,583 IS CALLED CENTERS FOR 1877 01:16:44,583 --> 01:16:50,422 ACCELERATING PHAGE THERAPY TO 1878 01:16:50,422 --> 01:16:54,193 COMBAT ESCAPE PATHOGENS AND 1879 01:16:54,193 --> 01:17:04,670 KYUNG MOON WILL PRESENT THAT 1880 01:17:05,137 --> 01:17:05,270 TODAY. 1881 01:17:05,270 --> 01:17:08,006 MAYBE STAND A LITTLE CLOSER TO 1882 01:17:08,006 --> 01:17:08,507 THE MICROPHONE. 1883 01:17:08,507 --> 01:17:18,984 OR TRY TO PROJECT A LITTLE. 1884 01:17:20,285 --> 01:17:24,189 >> OKAY, SO THIS CONCEPT IS FOR 1885 01:17:24,189 --> 01:17:26,592 CENTERS FOR ACCELERATING PHAGE 1886 01:17:26,592 --> 01:17:28,627 THERAPY TO COMBAT ESKAPE 1887 01:17:28,627 --> 01:17:29,661 PATHOIENS AND THE OBLIGATIONS 1888 01:17:29,661 --> 01:17:31,830 YECTIVE IS TO ESTABLISH 1889 01:17:31,830 --> 01:17:32,965 MULTIDISCIPLINARY COLLABORATIVE 1890 01:17:32,965 --> 01:17:34,366 RESEARCH CENTERS FOCUSED ON 1891 01:17:34,366 --> 01:17:36,435 DEVELOPING ROBUST ASSAYS AND 1892 01:17:36,435 --> 01:17:38,537 TOOLS FOR ADVANCING PHAGE 1893 01:17:38,537 --> 01:17:42,641 THERAPY INTO CLINICAL TRIALS. 1894 01:17:42,641 --> 01:17:46,245 SO IF THESE ARE NEW, THE FUNDING 1895 01:17:46,245 --> 01:17:50,115 MECHANISM IS THE PO1 AND WE 1896 01:17:50,115 --> 01:17:51,417 ANTICIPATE AWARDING 2-3 CENTERS 1897 01:17:51,417 --> 01:17:58,223 WITH A FIRST YEAR TOTAL COST OF 1898 01:17:58,223 --> 01:17:59,191 $6 MILLION. 1899 01:17:59,191 --> 01:18:00,459 SO PHAGE THERAPY IS CONSIDERED 1900 01:18:00,459 --> 01:18:03,629 AS A LEADING ALTERNATIVE TO 1901 01:18:03,629 --> 01:18:07,332 TREAT INFECTIONS DUE TO AR 1902 01:18:07,332 --> 01:18:07,666 PATHOIENS. 1903 01:18:07,666 --> 01:18:10,769 IT'S NOTABLE BENEFITS ARE IT'S A 1904 01:18:10,769 --> 01:18:14,106 PATHOIENS SPECIFIC SO THE 1905 01:18:14,106 --> 01:18:16,074 BENEFICIAL MICROBIOME IS 1906 01:18:16,074 --> 01:18:21,713 PRESERVED, PREVENTING SECONDARY 1907 01:18:21,713 --> 01:18:24,349 INFECTIONS TO CHANGE THE CD, IT 1908 01:18:24,349 --> 01:18:28,053 IS KNOWN TO BE SAFE, PRACTICES 1909 01:18:28,053 --> 01:18:29,555 REPORTS FROM PREVIOUS STUDIES. 1910 01:18:29,555 --> 01:18:33,625 SO BRIEFLY LOOKING AT THE RECENT 1911 01:18:33,625 --> 01:18:35,794 DEVELOPMENT IN 2019 NIAID 1912 01:18:35,794 --> 01:18:38,230 PUBLISHED A FRAMEWORK AND 1913 01:18:38,230 --> 01:18:40,532 EMPHASIZING PAGE THERAPIES 1914 01:18:40,532 --> 01:18:44,903 ABILITY TO COMBAT AR BACKERRIA. 1915 01:18:44,903 --> 01:18:47,806 BEFORE 2020 VARIOUS STUDIES WERE 1916 01:18:47,806 --> 01:18:53,545 MOSTLY CONDUCTED WITHOUT 1917 01:18:53,545 --> 01:18:55,481 RANDOMIZATION IN GROUPS OR CASE 1918 01:18:55,481 --> 01:18:57,115 STUDIES, SO VERY LITTLE 1919 01:18:57,115 --> 01:19:01,854 STATISTICAL DATA WERE COLLECTED. 1920 01:19:01,854 --> 01:19:04,389 SO SINCE THEN MULTIPLE RANDOMIZE 1921 01:19:04,389 --> 01:19:05,557 CLINICAL TRIALS HAVE BEEN 1922 01:19:05,557 --> 01:19:09,661 LAUNCHED TO ADDRESS THE PREVIOUS 1923 01:19:09,661 --> 01:19:10,896 LIMITATIONS. 1924 01:19:10,896 --> 01:19:12,731 HOWEVER, LARGER STUDIES WERE 1925 01:19:12,731 --> 01:19:15,734 NEEDED TO SHOW CLINICAL 1926 01:19:15,734 --> 01:19:16,001 EFFICACY. 1927 01:19:16,001 --> 01:19:19,404 SO INCLAUDED IN THESE OF THE 1928 01:19:19,404 --> 01:19:25,377 TRIALS, WE HAVE 2 NIAID'S 1929 01:19:25,377 --> 01:19:28,780 SPONSORED TRIALS. 1930 01:19:28,780 --> 01:19:31,850 ARLG'S TRIAL AND [INDISCERNIBLE] 1931 01:19:31,850 --> 01:19:35,854 AND ANOTHER 1 TO TREAT SHIgE 1932 01:19:35,854 --> 01:19:38,824 LLA INFECTIONS IN HEALTHY ADULTS 1933 01:19:38,824 --> 01:19:46,164 AND BOTH STUDIES ENROLLING 1934 01:19:46,164 --> 01:19:46,431 SUBSETS. 1935 01:19:46,431 --> 01:19:48,834 SO BASIC RESEARCH AT THE BASIC, 1936 01:19:48,834 --> 01:19:49,568 TRANSLATIONAL AND CLINICAL 1937 01:19:49,568 --> 01:19:53,772 LEVELS HAVE BEEN SUPPORTED BY 1938 01:19:53,772 --> 01:19:55,674 VARIOUS NIAID PROGRAMS. 1939 01:19:55,674 --> 01:19:57,142 ESPECIALLY SINCE 2014 A FEW 1940 01:19:57,142 --> 01:19:59,678 RFAs ALONG WITH THE 1941 01:19:59,678 --> 01:20:01,647 PRECLINICAL SERVES HAVE 1942 01:20:01,647 --> 01:20:02,648 SUPPORTED TRANSLATIONAL RESEARCH 1943 01:20:02,648 --> 01:20:08,086 AS SHOWN IN THIS BOX. 1944 01:20:08,086 --> 01:20:10,589 DESPITE THESE EFFORTS, THERE ARE 1945 01:20:10,589 --> 01:20:14,359 4 MAJOR SCIENTIFIC GAPS FOR 1946 01:20:14,359 --> 01:20:17,863 DEVELOPING ROBUST PHASE PRODUCTS 1947 01:20:17,863 --> 01:20:20,165 EMPLOY FIRST WE DON'T HAVE 1948 01:20:20,165 --> 01:20:21,099 STANDARDIZED ASSAYS AND TOOLS 1949 01:20:21,099 --> 01:20:24,970 WHICH ARE CRUCIAL FOR DESIGNING 1950 01:20:24,970 --> 01:20:28,073 CLINICAL TRIALS IN ORDER TO 1951 01:20:28,073 --> 01:20:29,274 OBLIGATIONS STAIN, RECREATE 1952 01:20:29,274 --> 01:20:30,576 REPRODUCIBLE DATA. 1953 01:20:30,576 --> 01:20:34,379 SO 1 EXAMPLE IS BASIC 1954 01:20:34,379 --> 01:20:35,080 ACACCEPTIBILITY TEST, THE 1955 01:20:35,080 --> 01:20:39,618 CURRENT INVITRO TEST OF THOSE 1956 01:20:39,618 --> 01:20:42,921 LED, PHAGES ABILITY, PHAGES 1957 01:20:42,921 --> 01:20:44,957 ACTIVITY IN [INDISCERNIBLE] AND 1958 01:20:44,957 --> 01:20:45,457 INFECTION SITES. 1959 01:20:45,457 --> 01:20:51,029 ALSO WITHOUT A STANDARDIZED 1960 01:20:51,029 --> 01:20:53,565 ASSAY, WE GET INCONSISTENT DATA 1961 01:20:53,565 --> 01:20:55,834 ACROSS DIFFERENT LABS. 1962 01:20:55,834 --> 01:20:59,838 SECOND, WE DON'T HAVE PROPER 1963 01:20:59,838 --> 01:21:03,008 INVITRO MODELS FOR PHAGE 1964 01:21:03,008 --> 01:21:04,142 RESEARCH. 1965 01:21:04,142 --> 01:21:05,444 FOR EXAMPLE, CHRONIC INFECTION 1966 01:21:05,444 --> 01:21:08,480 AND MODEL CELL MAKING. 1967 01:21:08,480 --> 01:21:10,248 THE CURRENT TESTS ARE MOSTLY 1968 01:21:10,248 --> 01:21:14,820 BASED ON HEALTHY ANIMAL MODELS 1969 01:21:14,820 --> 01:21:15,654 WITH ACCURATE INDUCTIONS. 1970 01:21:15,654 --> 01:21:19,791 WE ALSO DO NOT HAVE NEW MODELS 1971 01:21:19,791 --> 01:21:22,394 INCLUDING ORGANOIDS, 2 MONITOR 1972 01:21:22,394 --> 01:21:25,130 THE PHASE AND BACTERIA IN 1973 01:21:25,130 --> 01:21:27,299 INYEKSS IN IN VIVO AND TO ARK 1974 01:21:27,299 --> 01:21:30,302 ASSESSES THE HUMAN RESPONSES 1975 01:21:30,302 --> 01:21:32,137 THIRD, WE DON'T HAVE THE 1976 01:21:32,137 --> 01:21:35,907 STRATEGIES TO EVALUATE THE PKPD 1977 01:21:35,907 --> 01:21:37,309 RELATIONSHIP IN MODELS FOR 1978 01:21:37,309 --> 01:21:38,010 PHAGES. 1979 01:21:38,010 --> 01:21:39,778 AGAIN, THE CURRENT MODELING 1980 01:21:39,778 --> 01:21:44,282 FAILS TO CONSIDER THAT THE PKPD 1981 01:21:44,282 --> 01:21:50,022 PHAGES THOSE ARE ALL 1982 01:21:50,022 --> 01:21:51,089 CONVENTIONAL ANTIBIOTICS. 1983 01:21:51,089 --> 01:21:54,860 OF COURSE, WE DON'T HAVE 1984 01:21:54,860 --> 01:21:56,728 [INDISCERNIBLE] ROUTES FOR 1985 01:21:56,728 --> 01:21:59,731 DOSAGES IN PHAGES. 1986 01:21:59,731 --> 01:22:00,699 THEREFORE MORE ANIMAL STUDIES 1987 01:22:00,699 --> 01:22:05,103 ARE REQUIRED TO CHARACTERIZE THE 1988 01:22:05,103 --> 01:22:06,238 PHASE DISTRIBUTION AND 1989 01:22:06,238 --> 01:22:09,107 CONCENTRATION . 1990 01:22:09,107 --> 01:22:11,476 SO HEAR I WANT TO EMPHASIZE 2 1991 01:22:11,476 --> 01:22:13,545 THINGS, WOB CONVENTIONAL ASPECT 1992 01:22:13,545 --> 01:22:15,047 BIOTICS HAVE FAILED TO FILL 1993 01:22:15,047 --> 01:22:17,949 THESE GAPS WHILE PHAGES DO NOT. 1994 01:22:17,949 --> 01:22:21,386 THIS HAS AN AMAZING HINDRANCE TO 1995 01:22:21,386 --> 01:22:25,490 PEOPLE IN THERAPY AND TESTING IT 1996 01:22:25,490 --> 01:22:25,791 VIGOROUSLY. 1997 01:22:25,791 --> 01:22:27,726 WITH A PROPER TOOLS AND 1998 01:22:27,726 --> 01:22:30,362 RESOURCES, WE CAN DEVELOP PHAGES 1999 01:22:30,362 --> 01:22:35,367 AS VIGOROUSLY AS WE DID FOR 2000 01:22:35,367 --> 01:22:35,667 ANTIBIOTICS. 2001 01:22:35,667 --> 01:22:38,236 TWO, THESE SCIENTIFIC GAPS ARE 2002 01:22:38,236 --> 01:22:42,174 HIGHLY EQUALING ACROSS DIFFERENT 2003 01:22:42,174 --> 01:22:42,674 FIELDS. 2004 01:22:42,674 --> 01:22:44,176 HOWEVER, THE EXISTING PROGRAMS 2005 01:22:44,176 --> 01:22:48,513 ARE LIMITED IN THEIR SCOPE AND 2006 01:22:48,513 --> 01:22:52,818 EXPERTISE, THEREFORE WE NEED A 2007 01:22:52,818 --> 01:22:53,719 MORE COLLABORATIVE WORK. 2008 01:22:53,719 --> 01:22:56,021 SO WHAT ARE THE SCIENTIFIC NEEDS 2009 01:22:56,021 --> 01:22:57,989 AND OPPORTUNITIES AND WHY WOULD 2010 01:22:57,989 --> 01:23:00,292 THIS INITIATIVE BE SUCCESSFUL 2011 01:23:00,292 --> 01:23:01,193 NOW. 2012 01:23:01,193 --> 01:23:03,528 SO WE NEEDED TO STANDARDIZE 2013 01:23:03,528 --> 01:23:08,400 INVITRO METHOD TO ISOLATE AND 2014 01:23:08,400 --> 01:23:10,836 DETERMINE PAGES ACTIVITIES 2015 01:23:10,836 --> 01:23:12,804 AGAINST TARGETED BACTERIA IN 2016 01:23:12,804 --> 01:23:14,573 INFECTION SITES IN DEVELOPING 2017 01:23:14,573 --> 01:23:15,974 PROPERTY INVITRO AND IN VIVO 2018 01:23:15,974 --> 01:23:21,580 MODELS IS IMPORTANT FOR 2019 01:23:21,580 --> 01:23:23,115 CONDUCTING PHAGE TOCKSIBILITY 2020 01:23:23,115 --> 01:23:31,323 TEST AND FOR EVALUATING PKPD. 2021 01:23:31,323 --> 01:23:31,890 CONDUCTING SYSTEMS 2022 01:23:31,890 --> 01:23:35,594 PHARMAICOLOGGIC STUDIES OF 2023 01:23:35,594 --> 01:23:37,562 PHAGES TO DELIVER INTO PHAGE 2024 01:23:37,562 --> 01:23:38,029 ANDS PRODUCTS. 2025 01:23:38,029 --> 01:23:41,967 THIS PROGRAM WILL MEET THESE 2026 01:23:41,967 --> 01:23:44,503 NEEDS BY IMPLEMENTING THE 2027 01:23:44,503 --> 01:23:46,037 MULTIDISCIPLINARY RESEARCH. 2028 01:23:46,037 --> 01:23:47,672 THE OPPORTUNITIES ARE UTILIZING 2029 01:23:47,672 --> 01:23:50,942 ASSAYS AND TOOLS IN PRECLINICAL 2030 01:23:50,942 --> 01:23:54,112 SERVICES TO HELP OTHER STUDIES 2031 01:23:54,112 --> 01:23:55,914 AND IN LEVERAGING IT'S RESOURCES 2032 01:23:55,914 --> 01:23:58,316 TO IMPROVE THE EFFICACY AND 2033 01:23:58,316 --> 01:24:01,720 QUALITY OF BETA PRODUCTS. 2034 01:24:01,720 --> 01:24:05,290 AND THE ULTIMATE OUTCOME WILL BE 2035 01:24:05,290 --> 01:24:06,558 ACCELERATING PHAGE PRODUCT 2036 01:24:06,558 --> 01:24:07,993 DEVELOPMENT TOWARD ADVANCED 2037 01:24:07,993 --> 01:24:14,766 THERAPEUTICS TO FUTURE CLINICAL 2038 01:24:14,766 --> 01:24:15,000 STUDIES. 2039 01:24:15,000 --> 01:24:16,768 SO WE BELIEVE THE TIME IS RIGHT 2040 01:24:16,768 --> 01:24:18,136 FOR THIS INITIATIVE SINCE THERE 2041 01:24:18,136 --> 01:24:20,472 IS A GROWING INTEREST FOR PHAGE 2042 01:24:20,472 --> 01:24:20,906 THERAPY. 2043 01:24:20,906 --> 01:24:22,541 THEREFORE WE NEED TO ENHANCE THE 2044 01:24:22,541 --> 01:24:25,777 PHAGE PIPELINE WHICH REQUIRES 2045 01:24:25,777 --> 01:24:31,583 DEDICATED AND COORDINATED AND 2046 01:24:31,583 --> 01:24:32,217 COLLABORATIVE EFFORTS. 2047 01:24:32,217 --> 01:24:35,754 SO AS MENTIONED EARLIER, WE 2048 01:24:35,754 --> 01:24:38,123 ANTICIPATE AWARDING 2-3 CENTERS 2049 01:24:38,123 --> 01:24:40,025 THAT CAN LEVERAGE THE RESOURCES 2050 01:24:40,025 --> 01:24:43,595 WITH DIVERSE EXPERTISE TO 2051 01:24:43,595 --> 01:24:45,764 DEVELOP ASSAYS AND TOOLS. 2052 01:24:45,764 --> 01:24:49,801 WE ENVISION EACH CENTER 2053 01:24:49,801 --> 01:24:50,769 INCLUDING OUR MULTIDISCIPLINARY 2054 01:24:50,769 --> 01:24:54,372 TEAM, IN EACH CENTER, IT ALSO 2055 01:24:54,372 --> 01:24:56,441 REQUIRED TO HAVE SYNERGISTIC 2056 01:24:56,441 --> 01:24:58,210 PROCESS AND TARGETING A LIST TO 2057 01:24:58,210 --> 01:25:00,612 1 ESCAPE PATHOIEN AND HAVE TO 2058 01:25:00,612 --> 01:25:03,481 HAVE ANNUAL AND MONTHLY MEETING 2059 01:25:03,481 --> 01:25:09,855 TO ENHANCE COLLABORATION AMONG 2060 01:25:09,855 --> 01:25:11,790 DIFFERENT CENTERS. 2061 01:25:11,790 --> 01:25:14,726 THE PROGRAM TRANSLATIONAL 2062 01:25:14,726 --> 01:25:15,927 RESEARCH RANGING FROM 2063 01:25:15,927 --> 01:25:17,429 [INDISCERNIBLE] TO THE 2064 01:25:17,429 --> 01:25:18,697 FOLLOWING, DEVELOPING USER 2065 01:25:18,697 --> 01:25:20,498 FRIENDLY AND HIGH THROUGH PUT 2066 01:25:20,498 --> 01:25:22,567 ASSAYS AND TOOLS, GENERATING 2067 01:25:22,567 --> 01:25:24,169 PROPER INVITRO AND IN VIVO 2068 01:25:24,169 --> 01:25:28,506 MODELS FOR PAID RESEARCH, 2069 01:25:28,506 --> 01:25:30,375 PERFORMING SYSTEMS OF 2070 01:25:30,375 --> 01:25:31,543 PHARMAICOLOGICAL STUDIES TO 2071 01:25:31,543 --> 01:25:34,279 EVALUATE PKPD AND TO ASSESS 2072 01:25:34,279 --> 01:25:38,750 VALENCEY, ROUTES AND DOSAGES. 2073 01:25:38,750 --> 01:25:40,552 UNDERSTANDING THE HUMAN'MUNE 2074 01:25:40,552 --> 01:25:45,190 RESPONSE TO IMPROVE PHAGE'S 2075 01:25:45,190 --> 01:25:49,261 STABILITY AND MONITORING SAFETY 2076 01:25:49,261 --> 01:25:50,829 AND TOXICITY. 2077 01:25:50,829 --> 01:25:52,464 WE WILL NOT WORK ON SCIENCE THAT 2078 01:25:52,464 --> 01:25:54,366 DOES NOT CONTRIBUTE TO 2079 01:25:54,366 --> 01:25:58,870 PRECLINICAL DEVELOP EXPMENT 2080 01:25:58,870 --> 01:25:59,838 CLINICAL TRIALS. 2081 01:25:59,838 --> 01:26:01,706 SO WE THANK DR. MARY 2082 01:26:01,706 --> 01:26:03,942 [INDISCERNIBLE] AND DR. TAYLOR 2083 01:26:03,942 --> 01:26:05,810 FOR THEIR COMMENT AND OVERALL, 2084 01:26:05,810 --> 01:26:12,250 THEY ARE THE STRONGEST OF THIS 2085 01:26:12,250 --> 01:26:14,319 PROGRAM AND CONCERTED IMPORTANT. 2086 01:26:14,319 --> 01:26:15,453 THEY ALSO RECOGNIZED THE 2087 01:26:15,453 --> 01:26:17,956 SCIENTIFIC NEED FOR THIS PROGRAM 2088 01:26:17,956 --> 01:26:20,458 AND MEETING THIS NEED WILL 2089 01:26:20,458 --> 01:26:22,727 ULTIMATELY PAVE THE WAY FOR 2090 01:26:22,727 --> 01:26:28,633 FUTURE LARGE CLINICAL TRIALS. 2091 01:26:28,633 --> 01:26:31,703 THEY SUGGIEST THE PROGRAM 2092 01:26:31,703 --> 01:26:32,203 INSURES COLLABORATIVE 2093 01:26:32,203 --> 01:26:33,705 INFORMATION IN CENTERS AND HAVE 2094 01:26:33,705 --> 01:26:36,675 A SPECIFIC REVIEW PANEL WITH 2095 01:26:36,675 --> 01:26:41,880 PHAGE EXPERTISE AND A VOIDS ANY 2096 01:26:41,880 --> 01:26:45,984 ONGOING PROGRAM ESPECIALLY WITH 2097 01:26:45,984 --> 01:26:47,686 CETRS. 2098 01:26:47,686 --> 01:26:51,756 SO IN SUMMARY, THIS IS THE 2099 01:26:51,756 --> 01:26:56,194 CONTEXT ESTABLISHED CENTERS FOR 2100 01:26:56,194 --> 01:26:57,362 ACCELERATING ADVANCED THERAPY 2101 01:26:57,362 --> 01:27:03,134 AND STUDY OF PATHOIENS, WE 2102 01:27:03,134 --> 01:27:05,537 ANTICIPATE AWARDING 2-3 CENTERS 2103 01:27:05,537 --> 01:27:07,505 THE FIRST YEAR FOR A COST OF 6 2104 01:27:07,505 --> 01:27:08,540 NILE VIRUSSION DOLLARS. 2105 01:27:08,540 --> 01:27:15,880 SO WITH THAT, THANK YOU FOR YOUR 2106 01:27:15,880 --> 01:27:19,884 ATTENTION. 2107 01:27:19,884 --> 01:27:20,518 >> THANK YOU KYUNG. 2108 01:27:20,518 --> 01:27:25,991 COMMENTS OR QUESTIONS FROM ANY 2109 01:27:25,991 --> 01:27:28,159 COUNCIL MEMBERS. 2110 01:27:28,159 --> 01:27:28,960 OR ANYBODY ELSE? 2111 01:27:28,960 --> 01:27:30,362 WE'RE A LITTLE AHEAD OF 2112 01:27:30,362 --> 01:27:32,464 SCHEDULE, WE DIDN'T PUT A BREAK 2113 01:27:32,464 --> 01:27:35,100 IN THE AIENDA BUT IF--SHOULD WE 2114 01:27:35,100 --> 01:27:37,135 JUST KEEP GOING, DOES ANYBODY 2115 01:27:37,135 --> 01:27:44,175 NEED TO KNOW THE RESTROOM I 2116 01:27:44,175 --> 01:27:48,646 THINK AND SAY MAYBE EVEN 3:15 OR 2117 01:27:48,646 --> 01:27:51,182 3:20 IF WE KEEP OUR CURRENT 2118 01:27:51,182 --> 01:27:51,383 PACE. 2119 01:27:51,383 --> 01:27:53,718 SO NEXT DISCOVERY DEVELOPMENT OF 2120 01:27:53,718 --> 01:27:56,755 NOVEL THERAPEUTICS FOR SELECT 2121 01:27:56,755 --> 01:27:58,690 FUNNINGAAL PATHOGENS AND BAOYING 2122 01:27:58,690 --> 01:28:09,167 LIU IS GOING TO PRESENT THIS 2123 01:28:13,171 --> 01:28:13,438 CONCEPT. 2124 01:28:13,438 --> 01:28:15,607 >> THANK YOU FOR THE OPPORTUNITY 2125 01:28:15,607 --> 01:28:16,674 TO PRESENT. 2126 01:28:16,674 --> 01:28:22,180 >> WE NEED SLIDES. 2127 01:28:22,180 --> 01:28:29,020 >> YEAH, PREFERABLY. 2128 01:28:29,020 --> 01:28:30,955 THANK YOU. 2129 01:28:30,955 --> 01:28:34,292 >> OUR PURPOSE OF THIS CONCEPT 2130 01:28:34,292 --> 01:28:37,395 IS TO DORPHY AND DEVELOPMENT OF 2131 01:28:37,395 --> 01:28:40,432 NOVEL THERAPEUTICS FOR SELECT 2132 01:28:40,432 --> 01:28:43,902 FUNGAL PATHOGENS INCLUDING DRUG 2133 01:28:43,902 --> 01:28:48,940 RESISTANCE CANDID A SPACES, 2134 01:28:48,940 --> 01:28:55,480 PARTICULARLY CANDIDA AURIS, AND 2135 01:28:55,480 --> 01:28:58,950 ASPER GILLUS, COCCIDIOIDES, AND 2136 01:28:58,950 --> 01:29:01,586 MUCORALES, AND WE PROPOSE OUR 2137 01:29:01,586 --> 01:29:03,021 R21/R33 MECHANISM AND ANTICIPATE 2138 01:29:03,021 --> 01:29:07,625 8-10 AWARDS WITH A FIRST YEAR 2139 01:29:07,625 --> 01:29:10,095 BUDGET OF 2.4 MILLION EMPLOY 2140 01:29:10,095 --> 01:29:10,995 SOME BACKGROUND. 2141 01:29:10,995 --> 01:29:13,198 IN THIS FUNGAL INFECTION 2142 01:29:13,198 --> 01:29:14,833 ACCOUNTS FOR ALMOST 1 HALF 2143 01:29:14,833 --> 01:29:16,801 MILLION DEATHS EVERY YEAR, 2144 01:29:16,801 --> 01:29:19,804 INEREDDER TO ADDRESS THIS UNMET 2145 01:29:19,804 --> 01:29:21,706 MEDICAL NEED, IN 2019, AND FOR 2146 01:29:21,706 --> 01:29:23,775 THE FIRST TIME FUNGI WERE 2147 01:29:23,775 --> 01:29:30,582 INCLUDED IN THE CDC, AMR THREAT 2148 01:29:30,582 --> 01:29:33,885 LIST ESPECIALLY CANDIDA AURIS 2149 01:29:33,885 --> 01:29:40,492 LISTED AS A THREAT. 2150 01:29:40,492 --> 01:29:46,898 IN 2022 LED A LIST, AS WELL AS 2151 01:29:46,898 --> 01:29:48,366 PERCEIVED PUBLIC HEALTH. 2152 01:29:48,366 --> 01:29:50,735 AND LASTLY, IN THE NIAID 2153 01:29:50,735 --> 01:29:53,705 BIODEFENSE AND EMERGING 2154 01:29:53,705 --> 01:29:59,144 INFECTIOUS DISEASE PATHOGENS, 2155 01:29:59,144 --> 01:30:02,814 COCIDIOIDES, MUCORALES AND AMR 2156 01:30:02,814 --> 01:30:04,249 WERE ALL INCLUDED. 2157 01:30:04,249 --> 01:30:06,918 SO THE SELECT FUNGAL PATHOIEN 2158 01:30:06,918 --> 01:30:10,822 FOR THIS INITIATIVE REFLECT THE 2159 01:30:10,822 --> 01:30:14,692 CURRENT PRIORITIES AUTHORIZED IN 2160 01:30:14,692 --> 01:30:15,927 THE BIO3 DOCUMENTS. 2161 01:30:15,927 --> 01:30:18,396 WHAT ABOUT THE ANTIFUNGALS IN 2162 01:30:18,396 --> 01:30:20,331 THE CLINICAL SETTING? 2163 01:30:20,331 --> 01:30:23,401 CURRENTLY, THERE ARE ONLY 3 2164 01:30:23,401 --> 01:30:24,469 MAJOR CLASSES OF ANTIFUNGALS IN 2165 01:30:24,469 --> 01:30:28,006 THE TREATMENT OF THE FUNGAL 2166 01:30:28,006 --> 01:30:30,408 INFECTIONS, THEY ARE POLINGS FOR 2167 01:30:30,408 --> 01:30:34,479 EXAMPLE, AND FOR TYROSEEN B, FOR 2168 01:30:34,479 --> 01:30:35,713 EXAMPLE, FLU CONSALIVA--SALIVA, 2169 01:30:35,713 --> 01:30:43,988 AND [INDISCERNIBLE] FOR EXAMPLE, 2170 01:30:43,988 --> 01:30:45,690 CASPOFUNNINGIN. 2171 01:30:45,690 --> 01:30:47,992 BETWEEN 1980 AND 202040 YEARS A 2172 01:30:47,992 --> 01:30:49,894 TOTAL OF 40 ANTIFUNGALS APRAWFED 2173 01:30:49,894 --> 01:30:51,729 TO THE FDA AND ALL OF THEM 2174 01:30:51,729 --> 01:30:53,598 BELONG TO THE SAME EXISTING 3 2175 01:30:53,598 --> 01:30:56,734 CLASSES SO THE TREATMENT APGZ IS 2176 01:30:56,734 --> 01:30:57,869 EXTREMELY LIMITED. 2177 01:30:57,869 --> 01:31:03,541 OVER THE PAST 3 YEARS, 3 NEW 2178 01:31:03,541 --> 01:31:08,513 ANTIFUNGALS WERE APPROVED. 2179 01:31:08,513 --> 01:31:09,714 AGAIN FLUCONAZOLE, AND WHERE 2180 01:31:09,714 --> 01:31:12,083 [INDISCERNIBLE] IS A NUMBER OF 2181 01:31:12,083 --> 01:31:22,594 THE NEW MEMBER TO THE FAMILY. 2182 01:31:29,500 --> 01:31:31,302 FIRST THERE ARE LIMITED OPGS 2183 01:31:31,302 --> 01:31:33,671 CURRENTLY, WE ONLY HAVE 3 MAJOR 2184 01:31:33,671 --> 01:31:37,508 CLASSES OF ANTIFUNGALS AND 2 OF 2185 01:31:37,508 --> 01:31:40,144 THEM TARGETS GHASTERAL OR 2186 01:31:40,144 --> 01:31:41,980 GASTROSYNTHESIS PATHWAY WHICH IS 2187 01:31:41,980 --> 01:31:44,616 RELATED TO FUNGAL CELL MEMBRANE 2188 01:31:44,616 --> 01:31:47,385 INTEGRITY AND 1 OF THEM TARGETS 2189 01:31:47,385 --> 01:31:48,620 FUNGAL CELL WALL GENESIS 2190 01:31:48,620 --> 01:31:52,257 PATHWAY, SO THE TARGETS ARE VERY 2191 01:31:52,257 --> 01:31:52,957 LIMITED. 2192 01:31:52,957 --> 01:31:54,792 EVEN WITH TREATMENT, THE 2193 01:31:54,792 --> 01:31:56,761 EFFICACY IS VERY LIMITED SO 2194 01:31:56,761 --> 01:32:00,198 OVERALL, IN THIS FUNGAL 2195 01:32:00,198 --> 01:32:03,301 INFECTION, IS ABOUT 20%. 2196 01:32:03,301 --> 01:32:07,572 AND SECOND, THE TOXICITY, IS 2197 01:32:07,572 --> 01:32:10,008 ABUNDANT, [INDISCERNIBLE] MAY BE 2198 01:32:10,008 --> 01:32:12,744 FOR TYROSEEN B, THE RENAL 2199 01:32:12,744 --> 01:32:14,345 TOXICITY MAKES THE TREATMENT 2200 01:32:14,345 --> 01:32:17,415 EXTREMELY CHALLENGING AND THE 4 2201 01:32:17,415 --> 01:32:19,017 AZOLE DRUGS, DRUG-DRUG 2202 01:32:19,017 --> 01:32:21,286 INTERACTIONS ALSO CONTRIBUTE TO 2203 01:32:21,286 --> 01:32:22,920 THE POOR TREATMENT OUTCOME. 2204 01:32:22,920 --> 01:32:25,590 AND THIRD, THE EMERGING 2205 01:32:25,590 --> 01:32:27,959 RESISTANCE AND PATHOGEN FOR 2206 01:32:27,959 --> 01:32:31,095 EXAMPLE, SOME CLINICAL ISOLATES 2207 01:32:31,095 --> 01:32:33,398 OF CANDIDA AURIS HAVE BEEN 2208 01:32:33,398 --> 01:32:35,667 RESISTANT TO ALL 3 MAJOR CLASSES 2209 01:32:35,667 --> 01:32:36,034 OF ANTIFUNGALS. 2210 01:32:36,034 --> 01:32:39,103 YOU KNOW IN OTHER WORDS THEY ARE 2211 01:32:39,103 --> 01:32:41,539 NO TREATMENT OPTIONS FOR THIS 2212 01:32:41,539 --> 01:32:44,042 TYPE OF INFECTION. 2213 01:32:44,042 --> 01:32:47,078 AND THE LASTLY, ANTIFUNGAL DRUG 2214 01:32:47,078 --> 01:32:51,149 THEMSELVES ALSO HAD MEDICATIONS, 2215 01:32:51,149 --> 01:32:53,484 PROSEENS AND THESE DO NOT HAVE 2216 01:32:53,484 --> 01:32:56,220 ORAL MEDICATION AND FOR THE 2217 01:32:56,220 --> 01:32:57,288 PRELIMINARY CANNED WHAT 2218 01:32:57,288 --> 01:32:59,257 INFECTION, THE POOR TARGET 2219 01:32:59,257 --> 01:33:03,561 EXPOSURE MAKE THE TREATMENT 2220 01:33:03,561 --> 01:33:04,195 EXTREMELY DIFFICULT. 2221 01:33:04,195 --> 01:33:05,930 FOR THIS PAPER, I SUMMARIZED 2222 01:33:05,930 --> 01:33:09,967 MOST OF THE CURRENT ANTIFUNGAL 2223 01:33:09,967 --> 01:33:11,803 IN THE [INDISCERNIBLE] IN THE 2224 01:33:11,803 --> 01:33:13,771 CLINICAL SPACE. 2225 01:33:13,771 --> 01:33:19,444 OUT OF THESE 7 ANTIFUNGALS, ONLY 2226 01:33:19,444 --> 01:33:22,113 KD--SALLY WATRULY FIRST IN CLASS 2227 01:33:22,113 --> 01:33:27,552 WITH NOVEL MECHANISM OF ACTION 2228 01:33:27,552 --> 01:33:31,222 MOST OF THEM HAVE BROAD SPECTRUM 2229 01:33:31,222 --> 01:33:32,924 AND THEY ARE ACTIVE AGAINST 2230 01:33:32,924 --> 01:33:42,734 YEAST AS WELL AS MOUSE WITH THE 2231 01:33:42,734 --> 01:33:43,401 EXCEPTION OF [INDISCERNIBLE], 2232 01:33:43,401 --> 01:33:44,535 AND FROM THE PEOPLE, YOU CAN 2233 01:33:44,535 --> 01:33:48,139 ALSO SEE QUITE A NUMBER OF THEM 2234 01:33:48,139 --> 01:33:50,775 HAVE ORAL FORMULATION AND SOME 2235 01:33:50,775 --> 01:33:52,777 OF THEM HAVE [INDISCERNIBLE] 2236 01:33:52,777 --> 01:33:57,115 FORMULATION SO TO SUMMARIZE THE 2237 01:33:57,115 --> 01:33:58,750 CURRENT ANTIFUNGAL CLINICAL 2238 01:33:58,750 --> 01:34:01,919 PATHWAY CAN PROVIDE A POTENTIAL 2239 01:34:01,919 --> 01:34:07,558 BETTER TREATMENT OPTION FOR 2240 01:34:07,558 --> 01:34:09,627 FUNGAL INFECTIONS THEY CAN POWER 2241 01:34:09,627 --> 01:34:11,362 EXISTENCE, THEY CAN POWER 2242 01:34:11,362 --> 01:34:12,864 EXPANDED DRUG DELIVERY OR 2243 01:34:12,864 --> 01:34:16,134 APPROACH AND THEY CAN DO A NOVL 2244 01:34:16,134 --> 01:34:16,934 MECHANISM OF ACTION. 2245 01:34:16,934 --> 01:34:19,570 THE OTHER TOOL INCREASED 2246 01:34:19,570 --> 01:34:22,206 LIKELIHOOD OF SUCCESS AND THE 2247 01:34:22,206 --> 01:34:23,741 DIVERSITY OF ANTIFUNGAL DRUG 2248 01:34:23,741 --> 01:34:26,577 CLUSTERS, WE NEED TO PRIME THE 2249 01:34:26,577 --> 01:34:28,880 PIPELINE FROM EARLY PHASE, FROM 2250 01:34:28,880 --> 01:34:34,485 THE EARLY DORPHY AND PRECLINICAL 2251 01:34:34,485 --> 01:34:35,653 DEVELOPMENT STAGE. 2252 01:34:35,653 --> 01:34:37,221 THAT'S EXACTLY WHAT THIS 2253 01:34:37,221 --> 01:34:38,222 INITIATIVE IS ABOUT. 2254 01:34:38,222 --> 01:34:42,660 SO WHAT THE CONCEPT IS ABOUT. 2255 01:34:42,660 --> 01:34:45,496 THIS CONCEPT WILL SUPPORT EARLY 2256 01:34:45,496 --> 01:34:47,965 STAGE, ANTIFUNGAL DORPHY AND THE 2257 01:34:47,965 --> 01:34:52,670 PRECLINICAL DEVELOPMENT. 2258 01:34:52,670 --> 01:34:53,805 SO IDEALLY THE GRADUATES FROM 2259 01:34:53,805 --> 01:34:56,507 THIS CONCEPT CAN FIT INTO THE 2260 01:34:56,507 --> 01:35:02,313 FUTURE RO-1 APPLICATION, FOR THE 2261 01:35:02,313 --> 01:35:03,881 FUNGAL SPECIFIC EAA ALL TREY 2262 01:35:03,881 --> 01:35:09,253 PRIVATE SECTOR FOR DEVELOPMENT. 2263 01:35:09,253 --> 01:35:13,491 IN TERMS OF SCOPE OF SUPPORT, WE 2264 01:35:13,491 --> 01:35:17,962 ARE PROPOSING MOUSE DRIVEN R21, 2265 01:35:17,962 --> 01:35:20,598 R33 MECHANISM, A NOVEL 2266 01:35:20,598 --> 01:35:24,235 THERAPEUTIC IS DEFIED AT LEAST 2267 01:35:24,235 --> 01:35:26,737 [INDISCERNIBLE], IT CAN BE AGENT 2268 01:35:26,737 --> 01:35:28,272 WITH A NOVEL MECHANISM OF 2269 01:35:28,272 --> 01:35:32,276 ACTION, IT CAN BE AN AGENT 2270 01:35:32,276 --> 01:35:34,679 AGAINST A NOVEL, NONTRADITIONAL 2271 01:35:34,679 --> 01:35:36,781 TARGET FOR EXAMPLE, MONOCLONAL 2272 01:35:36,781 --> 01:35:37,548 ANTIBODY. 2273 01:35:37,548 --> 01:35:42,119 IT CAN BE AN AGENT AGAINST A 2274 01:35:42,119 --> 01:35:45,523 TRADITIONAL TARGET WITH 2275 01:35:45,523 --> 01:35:47,358 SIGNIFICANT IMPROVEMENT ON 2276 01:35:47,358 --> 01:35:47,792 [INDISCERNIBLE] AND 2277 01:35:47,792 --> 01:35:48,159 DISTRIBUTION. 2278 01:35:48,159 --> 01:35:51,496 IT CAN BE AN AGENT THAT CAN 2279 01:35:51,496 --> 01:35:54,198 OVERCOME RESISTANCE MECHANISMS 2280 01:35:54,198 --> 01:35:55,600 ASSOCIATE WIDE A TRADITIONAL 2281 01:35:55,600 --> 01:35:55,933 TARGET. 2282 01:35:55,933 --> 01:36:00,605 SO HERE I ALSO GAVE SEVERAL 2283 01:36:00,605 --> 01:36:01,672 EXAMPLES FOR SUPPORTED ACTIVITY 2284 01:36:01,672 --> 01:36:07,845 INCLUDE BUT NOT LIMITED TOO, 2285 01:36:07,845 --> 01:36:09,380 SOMEHOW TARGET IDENTIFICATION, 2286 01:36:09,380 --> 01:36:12,016 VALIDATION, HIT TO LEAD, LEAD 2287 01:36:12,016 --> 01:36:16,187 OPTIMIZATION, AND EARLY 2288 01:36:16,187 --> 01:36:16,687 PRECLINICAL DEVELOPMENT 2289 01:36:16,687 --> 01:36:18,656 ACTIVITIES, BUT NOW TO INCLUDE 2290 01:36:18,656 --> 01:36:22,059 THE ENABLING STUDIES AND AGAIN 2291 01:36:22,059 --> 01:36:23,060 GMP MANUFACTURING. 2292 01:36:23,060 --> 01:36:28,132 THOSE ARE VERY EXPENSIVE 2293 01:36:28,132 --> 01:36:28,599 ACTIVITIES. 2294 01:36:28,599 --> 01:36:30,167 OUR COUNCIL FEEDBACK, I WOULD 2295 01:36:30,167 --> 01:36:34,272 LIKE TO THANK DR. PALMER AND 2296 01:36:34,272 --> 01:36:37,375 DR. [INDISCERNIBLE] FOR THEIR 2297 01:36:37,375 --> 01:36:38,643 TIME AND CONSIDERATION. 2298 01:36:38,643 --> 01:36:40,845 BOTH OF THEM STRANG'RE STRONGLY 2299 01:36:40,845 --> 01:36:42,146 SUPPORT THIS INITIATIVE, THEY 2300 01:36:42,146 --> 01:36:44,982 RECOGNIZE THE NEED TO DISCOVER 2301 01:36:44,982 --> 01:36:46,350 AND DEVELOP NOVEL ANTIFUNGAL 2302 01:36:46,350 --> 01:36:49,186 THERAPEUTICS AND THE THREAT OF 2303 01:36:49,186 --> 01:36:51,055 EMERGING AND ANTIFUNGAL 2304 01:36:51,055 --> 01:36:51,355 RESISTANCE. 2305 01:36:51,355 --> 01:36:54,025 IN TERMS OF SCOPE, DR. PALMER 2306 01:36:54,025 --> 01:36:56,694 ALSO COMMENTED THE DEFINITION OF 2307 01:36:56,694 --> 01:37:01,933 NOVEL THERAPEUTICS REFLECTS THE 2308 01:37:01,933 --> 01:37:02,867 CURRENT ANTIFUNGAL NEEDS. 2309 01:37:02,867 --> 01:37:04,035 DR. [INDISCERNIBLE] HAD A 2310 01:37:04,035 --> 01:37:06,304 QUESTION ON WHETHER THE AMOUNT 2311 01:37:06,304 --> 01:37:08,306 OF FUNDING IS SUFFICIENT TO R33. 2312 01:37:08,306 --> 01:37:11,976 TO ANSWER THAT THE CURRENT 2313 01:37:11,976 --> 01:37:13,144 2.4 MILLION IS ONLY FOR THE 2314 01:37:13,144 --> 01:37:16,314 FIRST YEAR AND THEN BY THE END 2315 01:37:16,314 --> 01:37:20,217 OF YEAR 2, WE ANTICIPATE 50% OF 2316 01:37:20,217 --> 01:37:24,889 R21 WE WILL TRANSITION TO R33. 2317 01:37:24,889 --> 01:37:29,026 AND LASTLY, AS PALMER SUGGESTED 2318 01:37:29,026 --> 01:37:31,295 DURING THE INITIATIVE 2319 01:37:31,295 --> 01:37:32,463 DEVELOPMENT STAGE, MAKE IT A 2320 01:37:32,463 --> 01:37:37,001 CAREER, THERE WOULD BE NO DIRECT 2321 01:37:37,001 --> 01:37:41,405 R33 OPTION SO IN ORDER TO BE 2322 01:37:41,405 --> 01:37:44,609 ELIGIBLE FOR THE PROGRAM MATCHED 2323 01:37:44,609 --> 01:37:46,677 SUCCESSFULLY ACHIEVE THE 2324 01:37:46,677 --> 01:37:50,514 MILESTONE PROPOSED FROM R21. 2325 01:37:50,514 --> 01:37:52,750 WITH THAT I CONCLUDE MY 2326 01:37:52,750 --> 01:37:53,084 PRESENTATION. 2327 01:37:53,084 --> 01:38:03,361 HAPPY TO TAKE ANY QUESTIONS. 2328 01:38:03,361 --> 01:38:04,428 >> THANK YOU KYUNG, ANY COMMENTS 2329 01:38:04,428 --> 01:38:14,939 OR QUESTIONS ON THIS CONCEPT? 2330 01:38:16,073 --> 01:38:18,075 OKAY, WE CAN KEEP GOING, WE HAVE 2331 01:38:18,075 --> 01:38:27,385 1 MORE CONCEPT TO PRESENT. 2332 01:38:27,385 --> 01:38:30,755 KRISTI C ONNOLY FROM THE 2333 01:38:30,755 --> 01:38:32,390 [INDISCERNIBLE] BRANCH WILL TALK 2334 01:38:32,390 --> 01:38:36,427 ABOUT NEW TREATMENTS FOR GENITAL 2335 01:38:36,427 --> 01:38:36,661 HERPES. 2336 01:38:36,661 --> 01:38:37,962 NTHANKS EMILY AND THANK YOU FOR 2337 01:38:37,962 --> 01:38:39,764 THE OPPORTUNITY TO PRESENT OUR 2338 01:38:39,764 --> 01:38:41,565 CONCEPT TODAY ON NEW TREATMENTS 2339 01:38:41,565 --> 01:38:43,701 FOR GENITAL HERPES, THIS HAS 2340 01:38:43,701 --> 01:38:46,671 BEEN A COLLABORATION BETWEEN THE 2341 01:38:46,671 --> 01:38:48,839 SECTION ON TRANSMISSION 2342 01:38:48,839 --> 01:38:51,108 INFECTIONS BRANCH AS WELL AS 2343 01:38:51,108 --> 01:38:52,376 VIROLOGY BRANCH, APPLICATIONS 2344 01:38:52,376 --> 01:38:53,911 FOR THIS INITIATIVE WOULD COME 2345 01:38:53,911 --> 01:38:54,845 TO BOTH BRANCHES. 2346 01:38:54,845 --> 01:38:58,516 SO THIS IS A NEW CONCEPT, FOR 2347 01:38:58,516 --> 01:39:00,818 THE TREATMENT--FOR NEW 2348 01:39:00,818 --> 01:39:02,219 TREATMENTS FOR GENITAL HERPES 2349 01:39:02,219 --> 01:39:03,988 WITH THE OBJECTIVE TO STIMULATE 2350 01:39:03,988 --> 01:39:06,123 DEVELOPMENT OF NEW TREEPTS THAT 2351 01:39:06,123 --> 01:39:07,758 SUPPRESS SHEDDING AND LESION 2352 01:39:07,758 --> 01:39:08,359 FORMATION AND REDUCE 2353 01:39:08,359 --> 01:39:11,462 TRANSMISSION AND THIS IS ALL A 2354 01:39:11,462 --> 01:39:14,098 BI PHASIC MECHANISM, USING THE 2355 01:39:14,098 --> 01:39:17,702 R21 AND R33 FUNDING WHERE AGAIN 2356 01:39:17,702 --> 01:39:20,971 APPROXIMATELY 50% OF THE AWARDS 2357 01:39:20,971 --> 01:39:22,573 THAT MEET THE MILESTONES AND THE 2358 01:39:22,573 --> 01:39:23,774 R21 WOULD BE ANTICIPATED TO MOVE 2359 01:39:23,774 --> 01:39:27,812 ON TO THE R33 PHASE OF FUNDING. 2360 01:39:27,812 --> 01:39:31,749 WE ARE ANTICIPATING 7-10 R21 2361 01:39:31,749 --> 01:39:33,184 AWARDS WITH A FIRST YEAR TOTAL 2362 01:39:33,184 --> 01:39:37,421 COST FOR THE INITIATIVE OF 2363 01:39:37,421 --> 01:39:38,155 AROUND $3.5 MILLION. 2364 01:39:38,155 --> 01:39:40,691 SO FOR PEOPLE LIVING WITH 2365 01:39:40,691 --> 01:39:42,193 GENITAL HERPES, THE CURRENT 2366 01:39:42,193 --> 01:39:43,394 TREATMENT IS NOT SATISFACTORY, 2367 01:39:43,394 --> 01:39:46,063 THIS 1 CYSTS OF LIFE LONG 2368 01:39:46,063 --> 01:39:49,166 THERAPY AND THERE'S A GREAT WANT 2369 01:39:49,166 --> 01:39:50,935 TO PREVENT SYMPTOMATIC 2370 01:39:50,935 --> 01:39:52,336 RECURRENCES, THE DURANNENT 2371 01:39:52,336 --> 01:39:58,375 THERAPIES ARE ONLY PARTIALLY 2372 01:39:58,375 --> 01:40:00,678 REDUCE SLEDDING AND TRANSMISSION 2373 01:40:00,678 --> 01:40:01,479 OF THE VIRUS. 2374 01:40:01,479 --> 01:40:03,681 CURRENTENER ACTIVITIES AND 2375 01:40:03,681 --> 01:40:05,783 PROJECTSYS FOR HSV RELY ON 2376 01:40:05,783 --> 01:40:07,618 NUCLEOICIDE ANALOGUES WHICH HAS 2377 01:40:07,618 --> 01:40:12,790 BEEN A PROBLEM FOR IMMUNO 2378 01:40:12,790 --> 01:40:13,657 COMPROMISED PATIENTS AFTER LONG 2379 01:40:13,657 --> 01:40:14,091 TIME TREATMENT. 2380 01:40:14,091 --> 01:40:16,093 AND THIS WAS A RESEARCH GAP THAT 2381 01:40:16,093 --> 01:40:17,394 WAS IESHES DENTIFIED FROM THE 2382 01:40:17,394 --> 01:40:19,330 WORKSHOP WE HELD IN CONJUNCTION 2383 01:40:19,330 --> 01:40:22,767 WITH THE CDC IN THE FALL OF 2384 01:40:22,767 --> 01:40:23,234 2022. 2385 01:40:23,234 --> 01:40:24,869 THERE ARE LIMITED THERAPEUTIC 2386 01:40:24,869 --> 01:40:27,805 OPTIONS CURRENTLY FOR TREATING 2387 01:40:27,805 --> 01:40:30,674 HSV INFECTION, BUT WELL IS A 2388 01:40:30,674 --> 01:40:32,343 VERY ROBUST BASIC RESEARCH 2389 01:40:32,343 --> 01:40:35,312 COMMUNITY, SO THERE'S BEEN A LOT 2390 01:40:35,312 --> 01:40:36,747 OF SIGNIFICANT UNDERSTANDING ON 2391 01:40:36,747 --> 01:40:38,015 A MOLECULAR BASIS OF 2392 01:40:38,015 --> 01:40:39,950 REACTIVATION AND SHEDDING THAT 2393 01:40:39,950 --> 01:40:41,685 BEING BE LEVERAGED INTO 2394 01:40:41,685 --> 01:40:43,053 TRANSLATIONAL RESEARCH AND 2395 01:40:43,053 --> 01:40:44,922 MOVING IT TOWARDS THE 2396 01:40:44,922 --> 01:40:47,124 THERAPEUTIC VACCINE OR ANTIVIRAL 2397 01:40:47,124 --> 01:40:47,825 DRUG DESEEN SPACE. 2398 01:40:47,825 --> 01:40:50,694 THERE HAVE NOT BEEN NOVEL 2399 01:40:50,694 --> 01:40:51,862 TARGETS IDENTIFIED SUCH AS 2400 01:40:51,862 --> 01:40:53,831 BUDDING PROTEINS OR PACKAGING 2401 01:40:53,831 --> 01:40:56,400 PROTEINS THAT COULD BE USED FOR 2402 01:40:56,400 --> 01:40:58,903 ANTIVIRAL THERAPY, SHOWN HERE IS 2403 01:40:58,903 --> 01:41:01,906 THE GINNY PIG MODEL WHICH IS THE 2404 01:41:01,906 --> 01:41:03,507 GOLD STANDARD ANIMAL MODEL THAT 2405 01:41:03,507 --> 01:41:06,477 HAS BEEN USED TO RECAPITULATE 2406 01:41:06,477 --> 01:41:07,611 CHRONIC AND RECURRENT INFECTIONS 2407 01:41:07,611 --> 01:41:08,879 AND A MODEL SUCH AS THIS COULD 2408 01:41:08,879 --> 01:41:10,614 BE USED FOR THE DOWN THE ROAD IN 2409 01:41:10,614 --> 01:41:13,417 THE R33 PART OF THE FUNDING TO 2410 01:41:13,417 --> 01:41:17,388 LOOK AT EFFICACY STUDIES. 2411 01:41:17,388 --> 01:41:19,890 SO THIS INITIATIVE FIDS WITHIN 2412 01:41:19,890 --> 01:41:21,826 DMID SCIENTIFIC PRIORITIES OF 2413 01:41:21,826 --> 01:41:23,994 MAINTAINING A ROBUST PORTFOLIO 2414 01:41:23,994 --> 01:41:25,296 BASIC TRANSLATIONAL CLINICAL 2415 01:41:25,296 --> 01:41:27,164 RESEARCH AND MICROBIOLOGY AND 2416 01:41:27,164 --> 01:41:28,132 INFECTIOUS DISEASES, WOULD 2417 01:41:28,132 --> 01:41:30,401 REALLY LIKE TO CAPITALIZE ON ALL 2418 01:41:30,401 --> 01:41:31,569 THE BASIC RESEARCH THAT'S BEEN 2419 01:41:31,569 --> 01:41:34,705 GOING ON TO TRY TO MOVE MORE 2420 01:41:34,705 --> 01:41:36,307 INTO THE TRANSLATIONAL SPACE. 2421 01:41:36,307 --> 01:41:41,812 THIS ALSO ALIGNS WITH THE GOALS 2422 01:41:41,812 --> 01:41:47,918 OF THE 2023, 2023 TRANSNIH PLAN 2423 01:41:47,918 --> 01:41:49,486 FOR HERPES SIMPLEX VIRUS 2424 01:41:49,486 --> 01:41:51,689 RESEARCH, SUPPORTING 1 OF THE 4 2425 01:41:51,689 --> 01:41:53,691 ARMS THE HSV TREATMENT AND 2426 01:41:53,691 --> 01:41:55,326 CURATIVE STRATEGIES THAT WAS 2427 01:41:55,326 --> 01:41:55,626 IDENTIFIED. 2428 01:41:55,626 --> 01:41:57,094 SO WE WANT TO KEEP THIS 2429 01:41:57,094 --> 01:41:58,362 INITIATIVE BROAD. 2430 01:41:58,362 --> 01:42:00,798 WE'RE REALLY INTERESTED IN 2431 01:42:00,798 --> 01:42:02,433 IDENTIFYING NEW TARGETING 2432 01:42:02,433 --> 01:42:04,001 SYSTEMYS, NEW CANDIDATES OF THE 2433 01:42:04,001 --> 01:42:06,904 TREATMENT DONE BY HERPES TO 2434 01:42:06,904 --> 01:42:09,006 INCLUDE ANTIVIRAL THERAPEUTICS 2435 01:42:09,006 --> 01:42:13,377 SUCH AS NONNUCLEOICIDE ANALOGUES 2436 01:42:13,377 --> 01:42:15,212 AND IMPROVED NUCLEOTIDES, THESE 2437 01:42:15,212 --> 01:42:17,481 COULD ALSO SINNER UTILIZE WITH 2438 01:42:17,481 --> 01:42:19,450 CURRENT REGIMENS. 2439 01:42:19,450 --> 01:42:20,417 THERAPEUTIC VACCINES ARE ANOTHER 2440 01:42:20,417 --> 01:42:22,152 MECHANISM THAT COULD REDUCE OR 2441 01:42:22,152 --> 01:42:23,120 ELIMINATE REACTIVATION SIMPLE 2442 01:42:23,120 --> 01:42:25,322 TOMS AND TRANSMISSION UNLIKE 2443 01:42:25,322 --> 01:42:27,992 PROPHYLACTIC VACCINES WHICH ARE 2444 01:42:27,992 --> 01:42:28,926 ADMINISTERED TO PREVENT 2445 01:42:28,926 --> 01:42:31,328 ACQUISITION OF AN INFECTION, AND 2446 01:42:31,328 --> 01:42:32,396 THERAPY AND PEWIC VACCINE BEING 2447 01:42:32,396 --> 01:42:34,498 HELP A PATIENT THAT'S ALREADY 2448 01:42:34,498 --> 01:42:43,507 INFECTED, MANAGE THEIR SYMPTOMS. 2449 01:42:43,507 --> 01:42:45,209 MONOCLONAL ANTIBODIES VISIT BEEN 2450 01:42:45,209 --> 01:42:46,510 POPULAR BEING DEVELOPED THROUGH 2451 01:42:46,510 --> 01:42:50,247 A LOT OF OTHER INFECTIONS AND 2452 01:42:50,247 --> 01:42:51,315 OTHER THINGS LAST BE SEVERAL 2453 01:42:51,315 --> 01:42:52,716 MONTHS AND CLOSE TO A YEAR HAVE 2454 01:42:52,716 --> 01:42:54,818 BEEN IN THE PIPELINE FOR OTHER 2455 01:42:54,818 --> 01:42:58,656 INFECTIONS, THESE COULD EITHER 2456 01:42:58,656 --> 01:43:03,060 TARGET NEUTRALIZE HSE OR ANOTHER 2457 01:43:03,060 --> 01:43:04,495 NOVEL STRATEGY TO SUPPRESS 2458 01:43:04,495 --> 01:43:05,996 ACTIVATION, ANOTHER TECHNOLOGY 2459 01:43:05,996 --> 01:43:10,601 SUCH AS ADDING GENE EDITING OR 2460 01:43:10,601 --> 01:43:14,171 CRSPR CAS, OR MEGAN NUCLEACES 2461 01:43:14,171 --> 01:43:16,273 CAN BE TARGETED TO SUPPRESS 2462 01:43:16,273 --> 01:43:16,874 REACTIVATION AND WE'RE 2463 01:43:16,874 --> 01:43:18,475 ENTHUSIASTIC TO SEE WHAT OTHER 2464 01:43:18,475 --> 01:43:20,911 KIND OF OTHER NOX FAMILY 2465 01:43:20,911 --> 01:43:21,645 ACTIVATORLE TARGETING STRATEGIES 2466 01:43:21,645 --> 01:43:22,913 INVESTIGATORS WILL COME UP WITH. 2467 01:43:22,913 --> 01:43:26,050 SO THIS LIST IS NOT EXHAUSTIVE. 2468 01:43:26,050 --> 01:43:28,018 I WOULD LIKE TO THANK OUR 2469 01:43:28,018 --> 01:43:30,721 COUNCIL MEMBERS DR. STEPHANIE 2470 01:43:30,721 --> 01:43:35,259 TAYLOR DR. MARY ESTES WHO ARE 2471 01:43:35,259 --> 01:43:37,461 SUPPORTIVE OF THERE INITIATIVE 2472 01:43:37,461 --> 01:43:38,429 AND THEIR THOUGHTFUL COMMENTS. 2473 01:43:38,429 --> 01:43:40,397 THEY WERE SUPPORT OF OF HOW MANY 2474 01:43:40,397 --> 01:43:41,532 DIFFERENT MECHANISMS AND THIS 2475 01:43:41,532 --> 01:43:43,867 WAS BROAD LOOKINGA THE A LOT OF 2476 01:43:43,867 --> 01:43:44,868 DIFFERENT APPROACHES FOR 2477 01:43:44,868 --> 01:43:45,202 THERAPEUTICS. 2478 01:43:45,202 --> 01:43:46,203 THERE ARE A COUPLE QUESTIONS 2479 01:43:46,203 --> 01:43:48,872 THAT CAME UP DURING OUR CALLS, 2480 01:43:48,872 --> 01:43:52,943 THE FIRST WAS WHAT IS REALISTIC 2481 01:43:52,943 --> 01:43:53,978 FREQUENCY FOR MONOCLONAL 2482 01:43:53,978 --> 01:43:55,546 ANTIBODY THERAPY BASED ON WHAT 2483 01:43:55,546 --> 01:43:57,147 IS IN DEVELOPMENT FOR OTHER 2484 01:43:57,147 --> 01:44:00,617 INFECTIONS AND A FEW EXAMPLES, 2485 01:44:00,617 --> 01:44:02,152 COVID-19 HAS MONOCLONALS THAT 2486 01:44:02,152 --> 01:44:04,688 ARE CURRENTLY LASTING 6 MONTHS, 2487 01:44:04,688 --> 01:44:06,090 THERE ARE NUMEROUS CANDIDATES IN 2488 01:44:06,090 --> 01:44:09,460 THE HIV FIELD, LASTING 3-6 2489 01:44:09,460 --> 01:44:10,861 MONTHS AND ZIKA VIRUS HAS A 2490 01:44:10,861 --> 01:44:13,030 CANDIDATE THAT WILL PROJECT TO 2491 01:44:13,030 --> 01:44:15,632 LAST UP TO 9 MONTHS, SO WE THINK 2492 01:44:15,632 --> 01:44:16,467 THAT SOMETHING AALONG THOSE 2493 01:44:16,467 --> 01:44:18,936 LINES CAN BE ATTAINABLE FOR HSV 2494 01:44:18,936 --> 01:44:19,169 AS WELL. 2495 01:44:19,169 --> 01:44:20,571 AND THE OTHER QUESTION WOULD BE 2496 01:44:20,571 --> 01:44:22,539 WHAT WOULD BE THE ANTICIPATED 2497 01:44:22,539 --> 01:44:24,508 MAXIMUM BUDGET FOR THE BI PHASIC 2498 01:44:24,508 --> 01:44:24,742 AWARD. 2499 01:44:24,742 --> 01:44:27,044 SO FOR THE R21 PORTION, THE 2500 01:44:27,044 --> 01:44:29,713 DIRECT COST WOULD BE 275,000 2501 01:44:29,713 --> 01:44:34,351 OVER 2 YEARS, AND FOR THE R33, 2502 01:44:34,351 --> 01:44:35,619 THE PROJECTS THAT MEET THEIR 2503 01:44:35,619 --> 01:44:37,021 MILESTONES AND MAKE THAT 2504 01:44:37,021 --> 01:44:40,024 TRANSITION WOULD THEN BE AWARDED 2505 01:44:40,024 --> 01:44:42,526 300,000 ANNUALLY FOR 3 YEARS. 2506 01:44:42,526 --> 01:44:50,901 AND WITH THAT I WILL BE HAPPY TO 2507 01:44:50,901 --> 01:44:51,735 TAKE ANY QUESTIONS. 2508 01:44:51,735 --> 01:44:58,675 RIGHT ON TIME. 2509 01:44:58,675 --> 01:45:00,044 >> THANK YOU KRISTI. 2510 01:45:00,044 --> 01:45:10,521 ANY QUESTIONS OR COMMENTS IN 2511 01:45:10,988 --> 01:45:11,588 OKAY, THANK YOU. 2512 01:45:11,588 --> 01:45:16,593 SO WE DO NEED EVERYBODY'S VOTES 2513 01:45:16,593 --> 01:45:19,029 AND ADDITIONAL COMMENTS, WELL, 2514 01:45:19,029 --> 01:45:21,565 IT'S NEW, WHERE DO YOU VOTE, I 2515 01:45:21,565 --> 01:45:22,966 THINK IT'S--IT'S IN THE 2516 01:45:22,966 --> 01:45:23,801 ELECTRONIC COUNCIL BOOK BUT IF 2517 01:45:23,801 --> 01:45:25,569 YOU NEED HELP THIS WOULD BE THE 2518 01:45:25,569 --> 01:45:34,945 TIME TO ASK FOR IT. 2519 01:45:34,945 --> 01:45:45,489 CAN EVERYBODY FIND THE PLACE TO 2520 01:45:46,657 --> 01:45:47,224 RECORD YOUR--LINDA BLACKENSDADT, 2521 01:45:47,224 --> 01:45:57,701 IS IT CRYSTAL CLEAR IN OKAY, 2522 01:46:45,649 --> 01:46:45,916 GOOD. 2523 01:46:45,916 --> 01:46:47,885 OUR HELPERS HAVE ARRIVED BUT 2524 01:46:47,885 --> 01:46:49,987 EXCEPT FOR RECORKING THE VOTES, 2525 01:46:49,987 --> 01:46:57,728 I THINK OUR MEETING CAN 2526 01:46:57,728 --> 01:47:08,138 CONCLUDE, PEOPLE CAN ...